Document:

Second Amended and Restated Investor Rights Agreement

 Exhibit 4.3 
 JAZZ PHARMACEUTICALS, INC. 
 SECOND AMENDED AND
RESTATED 
 INVESTOR RIGHTS AGREEMENT 
 June 24, 2005 

 JAZZ PHARMACEUTICALS, INC. 
 SECOND AMENDED AND RESTATED 
 INVESTOR
RIGHTS AGREEMENT 
 THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is made as of
June 24, 2005, by and among Jazz Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the holders of Common Stock, Preferred Stock and/or warrants to purchase the Series BB Preferred Stock of the Company
listed on the attached Exhibit A (collectively, the “Investors”). 
 RECITALS 
 A. The Company has issued to certain of the Investors warrants, dated as of the date hereof (the “Series BB Warrants”), to
purchase in the aggregate 8,695,652 shares of the Company’s Series BB Preferred Stock (the “Series BB Preferred Stock”), pursuant to a Senior Secured Note and Warrant Purchase Agreement, dated June 24, 2005, by and
among the Company and certain of the Investors (the “Note and Warrant Purchase Agreement”). 
 B. The Company and
certain of the Investors have previously entered into an Amended and Restated Investor Rights Agreement dated February 18, 2004 (the “Prior Agreement”) in connection with the sale by the Company of the Company’s
Series B Preferred Stock and Series B Prime (“Series B/P”) Preferred Stock. 
 C. In connection with
the purchase and sale of the Series BB Warrants pursuant to the Note and Warrant Purchase Agreement, the Company and Investors desire (i) to provide for certain rights of the Investors and (ii) to supersede and replace the Prior Agreement
with this Agreement. 
 NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 
 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 1.1 “Affiliate” shall mean, with respect to any Person, a Person directly or indirectly controlling, controlled by, or under
common control with, such Person provided, however, that, except for purposes of Section 14.2, no Series BB Holder shall be considered an Affiliate of any other Person except to the extent, and only to the extent, that such Series
BB Holder holds Convertible Securities (or shares of Common Stock issued upon conversion thereof) other than Series BB Preferred Stock (or shares of Common Stock issued upon conversion thereof). 
 1.2 “Change of Control” means (i) a sale of all or substantially all of the assets of the Company to a Person that is
neither an Initial B/P Holder nor an Affiliate of 

 
an Initial B/P Holder, or to a Group that does not include an Initial B/P Holder or an Affiliate of an Initial B/P Holder, or a sale of all or substantially
all of the assets of the Company to a Person in which the stockholders of the Company immediately prior to such transaction do not control more than 50% of the voting power immediately following the transaction; (ii) a transaction or series of
related transactions by the Company (other than transaction(s) determined by the Board of Directors to be primarily for cash financing purposes) or by any stockholder or stockholders of the Company resulting in more than 50% of the voting power of
the Company being held by a Person that is neither an Initial B/P Holder nor an Affiliate of an Initial B/P Holder, or by a Group that does not include an Initial B/P Holder or an Affiliate of an Initial B/P Holder; (iii) a merger or
consolidation of the Company with or into a Person that is neither an Initial B/P Holder nor an Affiliate of an Initial B/P Holder, or with or into a Group that does not include an Initial B/P Holder or an Affiliate of an Initial B/P Holder, if and
only if, after such merger or consolidation, directors of the Company immediately prior to such merger or consolidation do not constitute a majority of the directors of the surviving entity or its parent. 
 1.3 “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. 
 1.4 “Control” shall have the meaning given such term under Rule 405 of the Securities Act of 1933,
as amended (the “Securities Act”). 
 1.5 “Convertible Securities” shall mean the shares of Series A
Preferred Stock, Series B Preferred Stock, Series B/P Preferred Stock and Series BB Preferred Stock held from time to time by the Investors and their permitted assigns. 
 1.6 “Defaulting Investor” shall have the meaning given to such term in the Stock Purchase Agreement, dated January 27, 2004 between the Company and certain Investors (as the same may be
amended from time to time in accordance with the terms thereof, the “Purchase Agreement”). 
 1.7
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 
 1.8 “Form S-1”
shall mean Form S-1 issued by the Commission or any comparable or successor form or forms then in effect. 
 1.9 “Form
S-3” shall mean Form S-3 issued by the Commission or any comparable or successor form or forms then in effect. 
 1.10
“Group” means two or more Persons acting together as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of or voting securities of the Company. 
  

 2 

 1.11 “Holder” shall mean any holder of outstanding Registrable Securities which
have not been sold to the public, but only if such holder is one of the Investors or an assignee or transferee of registration rights as permitted by Section 14. 
 1.12 “Initial B/P Holder” shall mean a Person that holds any shares of Series B/P Preferred as of the date the first share of Series B/P Preferred is issued. 
 1.13 “KKR” shall mean Kohlberg Kravis Roberts & Co., L.P. and its Affiliates. 
 1.14 “Managers” shall mean Samuel R. Saks, Bruce C. Cozadd, Robert M. Myers, Matthew K. Fust, Carol A. Gamble and Janne L.T.
Wissel. 
 1.15 “Material Adverse Event” shall mean any change, event or effect that is materially adverse to the
general affairs, business, operations, assets, prospects, condition (financial or otherwise) or results of operations of the Company and its subsidiaries taken as a whole. 
 1.16 “New Securities” shall mean any capital stock of the Company, whether authorized or not, and any rights, options, or
warrants to purchase said capital stock, any securities or instruments containing equity-like features (including without limitation stock appreciation rights and phantom stock), and securities of any type whatsoever that are, or may become,
convertible into or exercisable for said capital stock; provided, however, that “New Securities” does not include (a) the Convertible Securities outstanding as of the date hereof or issued or issuable pursuant to the Purchase
Agreement or the Company’s Common Stock issuable upon conversion of the Convertible Securities or the Company’s Series B Preferred Stock issuable upon conversion of the Series B/P Preferred Stock; (b) Common Stock or options to
purchase Common Stock issued to the Company’s officers, directors, employees, consultants, and advisors pursuant to a stock option plan of the Company or other agreement or arrangement approved by the Company’s Board of Directors;
(c) securities issued as a dividend or distribution with respect to the Convertible Securities; (d) securities issued in connection with equipment leasing, real estate, bank financing or similar transactions approved by the Company’s
Board of Directors; (e) securities issued pursuant to the acquisition of a product or technology, the acquisition of another corporation or entity by consolidation, corporate reorganization, or merger, or purchase of all or substantially all of
the assets or capital stock of such corporation or entity, each as approved by the Company’s Board of Directors; (f) securities issued in connection with the exercise of warrants, notes or other rights to acquire securities of the Company
(excluding the options described in subsection (b) of this Section 1.16) approved by the Board of Directors; (g) securities issued without consideration pursuant to stock dividends, subdivisions, recapitalizations, stock splits or
other similar transactions approved by the Company’s Board of Directors; (h) non-convertible debt securities issued in connection with the Banc of America Debt (as defined in the Purchase Agreement); and (i) any other 

  

 3 

 
securities issued with the approval of the Company’s Board of Directors in connection with the settlement of any suit, action, claim, proceeding or
investigation to which the Company is a party. 
 1.17 “Person” means an individual, partnership, corporation,
limited liability company, limited partnership, business trust, joint stock company, trust, unincorporated association, joint venture, governmental authority or other entity of whatever nature. 
 1.18 The term “Preferred Stock” shall mean the Series A Preferred Stock, Series B Preferred Stock, Series B/P Preferred Stock and
Series BB Preferred Stock of the Company. 
 1.19 The terms “Register”, “Registered”, and
“Registration” refer to a registration effected by preparing and filing a registration statement on Form S-1, S-2 or S-3 in compliance with the Securities Act (“Registration Statement”), and the
declaration or ordering of the effectiveness of such Registration Statement. 
 1.20 “Registrable Securities” shall
mean (i) any Common Stock now owned or hereafter acquired by a Manager, (ii) the Common Stock issued or issuable upon conversion of the Convertible Securities, and (iii) any Common Stock issued (or issuable upon conversion or exercise
of any warrant, right or other security which is issued) upon stock dividends, subdivisions, stock splits, recapitalization, merger or other distributions with respect to, or in exchange for, or in replacement of, such securities identified in
clauses (i) and (ii) and this clause (iii), excluding, however, (iv) any Registrable Securities previously sold to the public and (v) any Registrable Securities sold by a person in a transaction in which its rights under this
Agreement are not assigned. 
 1.21 “Registration Expenses” shall mean (a) all expenses incurred by the Company
or its subsidiaries in complying with Sections 5, 6 or 7 of this Agreement, including, without limitation, all federal and state registration, qualification, and filing fees, printing expenses, fees and disbursements of counsel for the Company, blue
sky fees and expenses, and the expense of any regular or special audits incident to or required by any such registration, and (b) the expenses of one special counsel for all Holders (if different from counsel to the Company) up to $45,000 and
one special counsel for all Managers (if different from counsel to the Company) up to $45,000. 
 1.22 “Securities
Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 1.23 “Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the sale of Registrable
Securities pursuant to this Agreement, and all fees and disbursements of counsel to the Holders and the Managers that are not included in Registration Expenses. 
  

 4 

 1.24 “Series BB Holder” means a holder of Series BB Warrants or Series BB
Preferred Stock (or shares of Common Stock issued upon conversion thereof). 
 1.25 “Trigger Persons” shall mean
Samuel Saks and Bruce Cozadd. 
 2. Financial Statements and Reports to Stockholders. 
 2.1 Annual and Quarterly Statements. For so long as an Investor and its Affiliates hold at least 500,000 shares of Convertible Securities
or Common Stock issued upon conversion thereof (as adjusted for combinations, consolidations, subdivisions, stock splits and the like with respect to such shares), the Company shall deliver to such Investor: 
 (a) as soon as practicable after the end of each fiscal year of the Company and in any event within 90 days thereafter, a consolidated balance sheet of
the Company as of the end of such year and consolidated statements of income, stockholders’ equity and cash flow for such year, which year-end financial reports shall be in reasonable detail and, prepared in accordance with generally accepted
accounting principles and, commencing with the year-end financial reports for 2004, shall be audited and certified by an independent public accounting firm of nationally recognized standing selected by the Company; and 
 (b) as soon as practicable after the end of each quarter of any fiscal year, and in any event within 45 days thereafter, a consolidated balance sheet of
the Company as of the end of each such quarter, and a consolidated statement of income and a consolidated statement of cash flows of the Company for such quarter and for the current fiscal year to date, prepared in accordance with generally accepted
accounting principles (except for required footnotes and year-end adjustments). 
 2.2 Monthly Statements; Annual Budget. For
so long as an Investor and its Affiliates hold at least 1% of the outstanding shares of Convertible Securities (including, for purposes of calculating the numerator and denominator, Common Stock issued upon conversion thereof), the Company will
deliver to such Investor: 
 (a) within 30 days of the end of each month, a consolidated balance sheet of the Company as of the end of each
such month, and a consolidated statement of income and a consolidated statement of cash flows of the Company for such month and for the current fiscal year to date; and 
 (b) by the beginning of the Company’s fiscal year, an operating budget and plan (the “Plan”) respecting the next fiscal year. 
  

 5 

 2.3 Inspection. The Company shall permit each Investor that together with its Affiliates
holds at least 500,000 shares of Convertible Securities (including Common Stock issued upon conversion thereof, and as adjusted for combinations, consolidations, subdivisions, stock splits and the like with respect to any such shares), at such
Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances, and accounts with its officers, all at such reasonable times as may be
requested by each such Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.3 to provide any information which it reasonably considers to be a trade secret or confidential information. 
 2.4 Confidentiality. Each Investor agrees that it will keep confidential and will not use (except in connection with the evaluation or
monitoring of its investment or its representative’s service on the Board of Directors of the Company), disclose or divulge for a period of three years after receipt any information regarding the Company and its business which such Investor may
obtain from the Company pursuant to this Section 2, and which the Company has marked or otherwise specifically identified to the Investor as being confidential either orally or in writing, unless such information is known, or until such
information becomes known, to the public through no fault of such Investor or its agents, or unless the Board of Directors, Chief Executive Officer, President or General Counsel of the Company gives his or her written consent to the Investor’s
release of such information, except that no such written consent shall be required (and the Investor shall be free to release such information) if such information is to be provided to the Investor’s counsel or accountant, or to an officer,
director, general partner, limited partner, stockholder, investment counselor or advisor of an Investor or such Investor’s Affiliate, or employee of an Investor or such Investor’s Affiliate with a need to know such information; provided
that any such counsel, accountant, officer, director, general partner, limited partner, stockholder, investment counselor or advisor, or employee is subject to confidentiality obligations no less restrictive in any material respects than the
provisions of this Section 2.4. Notwithstanding the foregoing, this Section 2.4 shall not apply (a) to information which an Investor learns from a third party with the right to make such disclosure, provided such Investor complies
with the restrictions imposed by the third party, (b) to information which is in an Investor’s possession prior to the time of disclosure by the Company and not acquired by such Investor under a confidentiality obligation, (c) to the
extent (after requesting and pursuing confidential treatment to the extent reasonably possible) an Investor is required to disclose such information by law or a governmental regulatory authority, (d) to the extent (after requesting and pursuing
confidential treatment to the extent reasonably possible) an Investor is required to disclose such information by court order, (e) to general and summary information disclosed to an Investor’s or such Investor’s Affiliates’
general partners, limited partners, members, and/or stockholders in such Investor’s or such Affiliates’ periodic reporting to such parties or to an Investor’s or such Investor’s Affiliates’ prospective investors in such
Investor’s or such Affiliates’ marketing activities, in a manner consistent with the custom 

  

 6 

 
and practice of the private venture capital and/or private equity industries, provided that such Investor or such Affiliate advise such parties that the
information disclosed is confidential, and provided further that the information disclosed does not include any proprietary information of the Company, and (f) to an Investor’s disclosure of the fact that such Investor has made an
investment in the Company, the amount and general nature thereof, the identity of such Investor’s co-investors in the Company if previously disclosed by the Company or such co-investor, and to such Investor’s disclosure of the general
business and goals of the Company. 
 3. Right of First Refusal. 
 3.1 Right of First Refusal on New Securities. The Company hereby grants to each Investor owning Convertible Securities (or Common Stock
issued upon conversion thereof) the right of first refusal to purchase up to its Pro Rata Share (as defined below) of New Securities which the Company may, from time to time, propose to issue. Such Investors may purchase said New Securities on the
same terms and at the same price at which the Company proposes to sell the New Securities. The “Pro Rata Share” of each Investor, for purposes of this right of first refusal, is the ratio of (i) the total number of
shares of Common Stock issued or issuable upon conversion of outstanding Convertible Securities held by such Investor to (ii) the total number of shares of Common Stock (including any shares of Common Stock into which outstanding shares of the
Convertible Securities are convertible) and Common Stock issuable pursuant to warrants, rights or options outstanding immediately prior to the issuance of the New Securities. 
 3.2 Notice. In the event the Company proposes to undertake an issuance of New Securities, it shall give to each eligible Investor notice
(the “Notice”) of its intention, describing the type of New Securities, the price, the terms upon which the Company proposes to issue the same, the number of shares which such Investor is entitled to purchase pursuant to
Section 3.1, and a statement that each Investor shall have 15 business days to respond to such Notice. Each such Investor shall have 15 business days from the date of receipt of the Notice to agree to purchase any or all of its Pro Rata Share
of the New Securities for the price and upon the terms specified in the Notice by giving notice to the Company and stating therein the number of New Securities it wishes to purchase, including, if so desired, any over-allotment of New Securities it
wishes to purchase in the event any other Investor elects to purchase less than its full Pro Rata Share, and forwarding payment for the number of New Securities (up to its Pro Rata Share) it has elected to purchase. In the event any such Investor
elects to purchase less than its full Pro Rata Share of New Securities, the remaining balance of New Securities shall be allotted and sold to those Investors who have exercised their options to purchase their full Pro Rata Share within the 15
business day period specified in this Section 3.2 and have indicated in their notices to the Company that they desire to purchase overalloted New Securities. If there are two or more such Investors that elect to purchase 

  

 7 

 
a total number of New Securities in excess of the number available, the remaining balance of New Securities shall be allocated to such Investors on a pro
rata basis based on the total number of shares of Common Stock issued or issuable upon conversion of Convertible Securities held by such Investors electing to purchase an amount of New Securities in excess of their Pro Rata Share. Upon notice from
the Company to Investors who elected to purchase additional New Securities that additional New Securities were allotted to such Investors, such Investors shall forward payment for the New Securities allotted to them within 15 business days of the
Company’s request for payment. 
 3.3 Sale of New Securities. In the event an Investor fails to exercise in full its right
of first refusal within the period of time specified in Section 3.2 or the eligible Investors do not exercise their right of first refusal with respect to all of the New Securities to be sold as specified in the Notice, the Company shall have
120 days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within 60 days after the date of such agreement) to sell the New Securities respecting which such
Investor’s rights were not exercised, at a price and upon terms no more favorable to the purchaser thereof than specified in the Notice. In the event the Company has not sold or entered into an agreement to sell the New Securities within such
120 day period (or sold and issued New Securities within 60 days from the date of the agreement), the Company shall not thereafter issue or sell any New Securities without first offering such securities to such Investor in the manner provided above.

 3.4 Waiver of Right of First Refusal. The right of first refusal granted under this Section 3 may be waived with
respect to any particular sale of New Securities as to all eligible Investors by the Investors (excluding Defaulting Investors) holding at least 60% of the Convertible Securities purchased by the Investors (excluding Defaulting Investors) (or an
equivalent number of shares consisting of Registrable Securities issued upon conversion of the Convertible Securities or a combination of such Registrable Securities and such Convertible Securities). Any such waiver shall not apply to any subsequent
sale of New Securities. 
 4. Termination of Covenants. The covenants of the Company set forth in Sections 2.1, 2.2, 2.3 and 3
shall terminate and be of no further force or effect with respect to all Investors upon the earliest to occur of (a) immediately prior to the closing of a firm commitment underwritten public offering pursuant to an effective registration
statement under the Securities Act, covering the offer and sale of the Company’s Common Stock to the public, (b) such time as the Company has a class of equity securities registered under the Exchange Act, and (c) a Change of Control,
and such covenants shall terminate as to any Investor as of the date such Investor no longer holds any shares of Registrable Securities. 
 5. Demand for Initial Public Offering. Subject to the terms of this Agreement, in the event that (i) the Company has not consummated an initial public offering pursuant 

  

 8 

 
to an effective Registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock for the account of the Company to the
public by the fifth anniversary of the date on which the first share of Series B Preferred Stock was sold by the Company (the “Fifth Anniversary”), (ii) the Company receives after the Fifth Anniversary from Managers
holding a majority of Registrable Securities and Convertible Securities then held by all Managers a notice requesting that the Company effect a Registration with respect to shares of Common Stock of the Company on Form S-1, and (iii) such
notice is approved by (A) if both Trigger Persons are then employed by the Company, both Trigger Persons, or (B) if only one of the Trigger Persons is then employed by the Company, the Trigger Person who is then employed by the Company, or
(C) if neither Trigger Person is then employed by the Company, the then current Chief Executive Officer of the Company, then the Company shall as soon as practicable, and in any event, within 90 days from receipt of such notice, use its
reasonable best efforts to effect a primary Registration of shares of Common Stock of the Company, provided that the anticipated aggregate price to the public of the shares covered by such Registration would not be less than $60,000,000 (before
deduction for underwriters commissions and expenses) and the anticipated per share price of such shares would be not less than $4.09 per share (appropriately adjusted for combinations, consolidations, subdivisions, recapitalizations, stock splits or
other similar transaction). The Company shall select the underwriter for the offering, subject to the approval of Managers holding a majority of the Registrable Securities then held by those Managers requesting the Registration under this
Section 5. 
 6. Other Demand Registrations. 
 6.1 Requests for Registration on Form Other Than Form S-3. 
 (a) Subject to the terms of this Agreement, in the event that the Company shall receive from a Holder or Holders (not including any Managers) of at least 40% of the Registrable Securities (or a lesser percentage of
such shares if the anticipated aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000) at any time after six months after the effective date of the Registration Statement with respect to the
Company’s initial public offering of shares of Common Stock, a notice requesting that the Company effect any Registration with respect to at least 20% of the then outstanding shares of Registrable Securities (or a lesser percentage of such
shares if the anticipated aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000) on a form other than Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all
other Holders and (ii) as soon as practicable, and in any event, within 90 days from receipt of notice from the Holders requesting Registration, use reasonable best efforts to effect Registration of the Registrable Securities specified in such
request, together with any Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company. So long as the Company is a 

  

 9 

 
registrant qualified to use Form S-3, the Company shall not be obligated to take any action to effect any such registration pursuant to this
Section 6.1(a) after the Company has effected one such Registration pursuant to this Section 6.1(a) and such Registration has been declared effective; provided, however, that the demand registration under this
Section 6.1(a) shall be in addition to the demand registration provided for under Section 6.1(b). 
 (b) Subject to the terms of
this Agreement, in the event that the Company shall receive from a Holder who originally committed to purchase (and did not default in any purchase) at least 50,000,000 shares of Series B Preferred Stock and/or Series B/P Preferred Stock
(appropriately adjusted for combinations, consolidations, subdivisions, recapitalizations, stock splits and the like with respect to such shares) at any time after six months after the effective date of the Registration Statement with respect to the
Company’s initial public offering of shares of Common Stock, a notice requesting that the Company effect any Registration with respect to at least 20% of the then outstanding shares of Registrable Securities (or a lesser percentage of such
shares if the anticipated aggregate price to the public of such shares, net of Selling Expenses, would not be less than $25,000,000) on a form other than Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all
other Holders and (ii) as soon as practicable, and in any event, within 90 days from receipt of notice from the Holder requesting Registration, use reasonable best efforts to effect Registration of the Registrable Securities specified in such
request, together with any Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company. So long as the Company is a registrant qualified to use Form S-3, the Company
shall not be obligated to take any action to effect any such registration pursuant to this Section 6.1(b) after the Company has effected one such Registration pursuant to this Section 6.1(b) and such Registration has been declared
effective; provided, however, that the demand registration under this Section 6.1(b) shall be in addition to the demand registration provided for under Section 6.1(a). 
 (c) Notwithstanding anything to the contrary in Sections 6.1(a) and 6.1(b), the right of Managers to participate in demand registrations shall be
limited as follows: No Manager may sell a number of shares in a registered offering under Section 6.1(a) or 6.1(b) that exceeds X; where X equals the number of Registrable Securities held by such Manager times the greater of Y or Z; Y equals
the number of shares requested to be sold by KKR divided by the total number of shares of Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other than Managers) divided by the total number of
shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (v) of Section 1.20) held by such Holders (other than Managers). This paragraph (c) shall terminate and be of no
force and effect from such time, if any, as KKR ceases to own either Convertible Securities or Registrable Securities. 
  

 10 

 6.2 Request for Registration on Form S-3. 
 (a) If a Holder or Holders (not including any Managers) of at least 20% of the outstanding shares of Registrable Securities requests that the Company
file a Registration Statement on Form S-3 for an offering of shares of Registrable Securities, the anticipated aggregate price to the public of which, net of Selling Expenses, would not be less than $25,000,000, and the Company is a registrant
qualified to use Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders and (ii) as soon as practicable, use reasonable best efforts to effect a Registration of the Registrable Securities on
such form, together with the Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company; provided, however, that the Company shall not be required to
effect more than two Registrations pursuant to Section 6.2 in any 12 month period. All of the provisions of Section 6.5 shall be applicable to each Registration initiated under this Section 6.2. 
 (b) For each $40,000,000 in original issue price of Registrable Securities purchased by a Holder (a “Principal Holder”), such
Principal Holder may request that the Company file a Registration Statement on Form S-3 for an offering of shares of Registrable Securities, and provided that the anticipated aggregate price to the public of such shares, net of Selling Expenses,
would not be less than $25,000,000 and the Company is a registrant qualified to use Form S-3, the Company shall (i) promptly give notice of the proposed Registration to all other Holders and (ii) as soon as practicable, use reasonable best
efforts to effect a Registration of the Registrable Securities on such form, together with the Registrable Securities of any Holder joining in such request as are specified in a notice given within 20 days after notice from the Company;
provided, however, that the Company shall not be required to effect more than two Registrations pursuant to Section 6.2 in any 12 month period. A Principal Holder shall have the right to demand one Registration under this
Section 6.2(b) for each $40,000,000 in original issue price of Registrable Securities purchased by such Holder. All of the provisions of Section 6.5 shall be applicable to each Registration initiated under this Section 6.2.

 (c) Notwithstanding anything to the contrary in Sections 6.2(a) and 6.2(b), the right of Managers to participate in demand registrations
shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 6.2(a) or 6.2(b) that exceeds X; where X equals the number of Registrable Securities held by such Manager times the greater of Y or Z; Y
equals the number of shares requested to be sold by KKR divided by the total number of shares of Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other than Managers) divided by the total
number of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (v) of Section 1.20) held by all Holders (other than Managers). This paragraph (c) shall terminate and
be of no force and effect from such time, if any, as KKR ceases to own Convertible Securities or Registrable Securities. 
  

 11 

 6.3 Right of Deferral. 
 (a) Notwithstanding the foregoing, the Company shall not be obligated to file a Registration Statement pursuant to Section 6: 
 (i) if the Company, within ten days of the receipt of the request from Holders, gives notice of its bona fide intention to effect the filing of a
Registration Statement with the Commission subject to Section 7 hereof within 60 days of receipt of such request (other than to a Registration of securities in a Rule 145 transaction or with respect to an employee benefit plan), provided that
the Company is actively employing all reasonable best efforts to cause such Registration Statement to become effective; 
 (ii) within
120 days immediately following the effective date of any Registration Statement pertaining to the securities of the Company (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan); or

 (b) Notwithstanding the foregoing, the Company shall not be obligated to file a Registration Statement pursuant to Section 5 or 6 if
the Company shall furnish to the requesting Holders a certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its
stockholders for a Registration Statement to be filed in the near future, then the Company’s obligation to use all reasonable best efforts to file a Registration Statement shall be deferred for a period not to exceed (i) six months with
respect to a demand pursuant to Section 5, and (ii) 120 days with respect to a demand pursuant to Section 6, from the receipt of the request to file such registration by such Holders; provided, however, that the Company shall not
exercise the deferral rights contained in these Sections 6.3(a)(i) and 6.3(b) more than once in any 12-month period. 
 6.4
Registration of Other Securities in Demand Registration. Any Registration Statement filed pursuant to the request of the Holders under this Section 6 may, subject to the provisions of Section 6.5, include securities of the
Company other than Registrable Securities. 
 6.5 Underwriting in Demand Registration. 
 (a) Notice of Underwriting. If the Holders intend to distribute the Registrable Securities covered by their request made pursuant to this
Section 6 by means of an underwriting, they shall so advise the Company as a part of their request, and the Company shall include such information in the notice referred to in Sections 6.1 and 6.2. 

  

 12 

 
The right of any Holder to Registration pursuant to Section 6 shall be conditioned upon such Holder’s agreement to participate in such underwriting
and the inclusion of such Holder’s eligible Registrable Securities in the underwriting. 
 (b) Selection of Underwriter in Demand
Registration. If a Registration requested pursuant to Section 6.1 or 6.2 is to be underwritten, the Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting
agreement and related agreements with the representative (“Underwriter’s Representative”) of the underwriter or underwriters selected for such underwriting by the Holders of a majority of the Registrable Securities being
registered by the Holders and reasonably acceptable to the Company. 
 (c) Marketing Limitation in Demand Registration. If the
Underwriter’s Representative advises the Holders in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of
the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, then the number of shares of Registrable Securities that may be included in the Registration and underwriting
shall be allocated among all Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities held by such Holders at the time of filing the Registration Statement. No Registrable Securities or other securities
excluded from the underwriting by reason of this Section 6.5(c) shall be included in such Registration Statement. 
 (d) Right of
Withdrawal in Demand Registration. If any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by notice to the Company, the Underwriter’s Representative and the
Holders requesting Registration delivered at least ten days prior to the effective date of the Registration Statement. The securities so withdrawn shall also be withdrawn from the Registration Statement. 
 7. Piggyback Registration. 
 7.1 Notice of Piggyback Registration and Inclusion of Registrable Securities; Special Limitation for Managers. 
 (a) Subject to the terms of this Agreement, if the Company decides to Register any of its Common Stock on a form that would be suitable for a registration of Registrable Securities, whether pursuant to a demand
registration contemplated by this Agreement or otherwise, the Company will: (i) promptly give each Holder notice thereof (which shall include a list of the jurisdictions in which the Company intends to attempt to qualify such securities under
the applicable Blue Sky or other state securities laws) and (ii) subject to Section 7.2, include in such Registration (and any related qualification under Blue Sky laws or other compliance), and in any underwriting involved therein, all
the Registrable Securities specified in a notice delivered to the Company by any Holder within 20 days after delivery of such notice from the Company. 
  

 13 

 (b) Notwithstanding anything to the contrary in Section 7.1(a), the right of Managers to
participate in demand registrations shall be limited as follows: No Manager may sell a number of shares in a registered offering under Section 7.1 that exceeds X; where X equals the number of Registrable Securities held by such Manager times
the greater of Y or Z; Y equals the number of shares requested to be sold by KKR divided by the total number of shares of Registrable Securities held by KKR; and Z equals the number of shares requested to be sold by all Holders (other than Managers)
divided by the total number of shares of Registrable Securities (including for this purpose shares that would be Registrable Securities but for clause (v) of Section 1.20) held by all Holders (other than the Managers). This paragraph
(c) shall terminate and be of no force and effect from such time, if any, as KKR ceases to own Convertible Securities or Registrable Securities. 
 7.2 Underwriting in Piggyback Registration. 
 (a) Notice of Underwriting in Piggyback
Registration. If the Registration of which the Company gives notice is for a Registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the notice given pursuant to Section 7.1. In such
event, the right of any Holder to Registration shall be conditioned upon such underwriting and the inclusion of such Registrable Securities in such underwriting to the extent provided in this Section 7. All Holders proposing to distribute their
securities through such underwriting shall (together with the Company) enter into an underwriting agreement and related agreements with the Underwriter’s Representative for such offering. The Holders shall have no right to participate in the
selection of the underwriters for an offering pursuant to this Section 7. 
 (b) Marketing Limitation in Piggyback
Registration. If the Underwriter’s Representative advises the Holders seeking registration of Registrable Securities pursuant to this Section 7 in writing that market factors (including, without limitation, the aggregate number of
shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, the
Underwriter’s Representative (subject to the allocation priority set forth in Section 7.2(c)) may: 
 (i) in the case of the
Company’s initial Registered public offering, exclude some or all of the Registrable Securities from such registration and underwriting; and 
 (ii) in the case of any Registered public offering subsequent to the initial public offering, limit the number of shares of Registrable Securities to be included in such Registration and underwriting to not less than 30% of the securities
included in such Registration. 
  

 14 

 (c) Allocation of Shares in Piggyback Registration. If the Underwriter’s
Representative limits the number of shares to be included in a Registration pursuant to Section 7.2(b), the number of shares to be included in such Registration shall be allocated among all Holders, in proportion, as nearly as practicable, to
the respective amounts of Registrable Securities which such Holders hold at the time of filing the Registration Statement. No Registrable Securities or other securities excluded from the underwriting by reason of this Section 7.2(c) shall be
included in the Registration Statement. 
 (d) Withdrawal in Piggyback Registration. If any Holder disapproves of the terms of
any such underwriting, such person may elect to withdraw therefrom by notice to the Company and the Underwriter’s Representative delivered at least ten days prior to the effective date of the Registration Statement. Any Registrable Securities
or other securities excluded or withdrawn from such underwriting shall be withdrawn from such Registration. 
 8. Expenses of
Registration. All Registration Expenses incurred in connection with Registrations pursuant to Section 5, 6.1, 6.2 and 7, shall be borne by the Company. All Registration Expenses incurred in connection with any other Registration,
qualification, or compliance, shall be apportioned among the Company and the Holders of the securities so registered on the basis of the number of shares so registered. Notwithstanding the above, the Company shall not be required to pay for any
expenses of any Registration proceeding begun pursuant to Section 6 if the Registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (which Holders shall bear such
expenses), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one Registration pursuant to Section 6; provided, however, that if at the time of such withdrawal, the Holders have learned of a Material
Adverse Event not known to the Holders at the time of their request, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 6. All Selling Expenses shall be borne by the holders of
the securities Registered pro rata on the basis of the number of shares Registered. 
 9. Termination of Registration Rights.
The rights to cause the Company to register securities granted under Sections 6 and 7 of this Agreement and to receive notices pursuant to Section 7 of this Agreement shall terminate, with respect to each Holder, on the earlier of (i) the
twelfth anniversary of the date that the first share of Series B Preferred Stock is sold and issued by the Company, and (ii) with respect to each Holder if such Holder is eligible to sell all of such Holder’s Registrable Securities under
Rule 144 of the Securities Act (excluding Rule 144(k) thereunder) within any three month period without volume limitations. 
  

 15 

 10. Registration Procedures and Obligations. Whenever required under this Agreement to
effect any Registration of securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the
Commission a Registration Statement with respect to such securities and use its reasonable best efforts to cause such Registration Statement to become effective, and, in the case of a Registration pursuant to Section 6 or Section 7, upon
the request of the sellers of a majority of the Registrable Securities registered thereunder, keep such Registration Statement effective for up to two years. 
 (b) Furnish to each seller of Registrable Securities a copy of any information contained in the Registration Statement about such seller for the purpose of allowing the seller to verify the information. 
 (c) Prepare and file as expeditiously as reasonably practicable with the Commission such amendments and supplements to such Registration Statement and
the prospectus used in connection with such Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement. 
 (d) Furnish to the sellers of Registrable Securities such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
 (e) Use its reasonable best efforts to register and qualify the Registrable Securities covered by such Registration Statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the sellers of Registrable Securities, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business
in any jurisdiction where it is not so qualified or to file a general consent to service of process in any such states or jurisdictions, and provided further that in the event any jurisdiction in which the securities shall be qualified imposes a
non-waivable requirement that expenses incurred in connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable pro rata by selling stockholders. 
 (f) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement and related agreements, in
usual and customary form, with the managing underwriter of such offering. Each seller of Registrable Securities participating in such underwriting shall also enter into and perform its obligations under such an agreement and related agreements.

  

 16 

 (g) Promptly notify each seller of Registrable Securities covered by such Registration Statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 
 (h) Provide a transfer agent and registrar for all securities registered pursuant to such Registration Statement and a CUSIP number for all such
securities, in each case not later than the effective date of such registration. 
 (i) Furnish, at the request of any Holder requesting
Registration of Registrable Securities pursuant to this Agreement, on the date that such Registrable Securities are delivered for sale in connection with a Registration pursuant to this Agreement, (i) an opinion, dated such date, of the counsel
representing the Company for the purposes of such Registration, in form and substance as is customarily given to underwriters (with an information copy provided to each Holder selling Registrable Securities) in an underwritten public offering, and
(ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering,
addressed to the underwriters (with an information copy provided to each holder of Registrable Securities). 
 (j) Use all reasonable best
efforts to list the securities covered by such Registration Statement with NASDAQ or any securities exchange on which the Common Stock of the Company is then listed, or NASDAQ or such securities exchange as shall be selected by the Company.

 (k) Notify each seller of Registrable Securities under such Registration Statement of (i) the effectiveness of such Registration
Statement, (ii) the filing of any post-effective amendments to such Registration Statement, or (iii) the filing of a supplement to such Registration Statement. 
 (l) Make available for inspection upon reasonable notice during the Company’s regular business hours by each seller of Registrable Securities, any underwriter participating in any distribution pursuant to such
Registration Statement, and any attorney, accountant or other agent retained by such seller or underwriter, all material financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers,
directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such Registration Statement. Each seller of Registrable Securities agrees to use the same degree
of care as such seller uses to protect its own confidential information, but in no event less than reasonable care, to keep confidential 

  

 17 

 
any information furnished to it by the Company pursuant to this Subsection 10(l) for a period of 3 years (so long as such information is not in the public
domain); provided, however, such seller’s obligation to keep information confidential under this Subsection 10(l) shall not apply (a) to information which such seller learns from a third party with the right to make such disclosure,
provided the seller complies with the restrictions imposed by the third party, (b) to information which is in seller’s possession prior to the time of disclosure by the Company and not acquired by seller under a confidentiality obligation,
(c) to the extent (after requesting and pursuing confidential treatment to the extent reasonably possible) the seller is required to disclose such information by law or a governmental regulatory authority, (d) to the extent (after
requesting and pursuing confidential treatment to the extent reasonably possible) seller is required to disclose such information by court order, and (e) to information disclosed to any partner, subsidiary, parent, legal counsel or advisor of
such seller for the purpose of evaluating or monitoring its investment in the Company. Notwithstanding anything herein to the contrary, any party to this Agreement (and any employee, representative, or other agent of any party to this
Agreement) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are
provided to it relating to such tax treatment and tax structure. 
 (m) Cause the senior executive officers of the Company to participate in
the customary “road show” presentations that may be reasonably requested by the Holders or the managing underwriter in any underwritten offering and otherwise to facilitate, cooperate with, and participate in each underwritten offering.

 (n) Cooperate with each seller of Registrable Securities and each underwriter or agent, if any, participating in the disposition of such
Registrable Securities and their respective counsel in connection with any filings required to be made with the National Association of Securities Dealers, Inc. 
 11. Information Furnished by Holder. It shall be a condition precedent of the Company’s obligations under Sections 6 and 7 of this Agreement that each Holder holding Registrable Securities included
in any Registration furnish to the Company such information regarding such Holder and the distribution proposed by such Holder(s) as the Company may reasonably request. 
 12. Indemnification. 
 12.1 Company’s Indemnification of Holders. To the
extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors, and constituent partners and members, legal counsel for the Holders, and each person controlling such Holder, with respect to which
Registration, qualification, or compliance of Registrable Securities has been effected pursuant to this Agreement, and each underwriter, if any, and each person who controls any underwriter against all claims, 

  

 18 

 
losses, damages, liabilities, or actions in respect thereof (collectively, “Damages”) to the extent such Damages arise out of or are
based upon any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such Registration, qualification, or compliance, or are
based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Company of any rule or regulation promulgated under the
Securities Act applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration, qualification, or compliance; and the Company will reimburse each such Holder, each such underwriter, and
each person who controls any such Holder or underwriter, for any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action; provided, however, that the indemnity
contained in this Section 12.1 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the consent of the Company (which consent shall not unreasonably be withheld or delayed); and provided, further,
that the Company will not be liable (i) in any such case to the extent that any such Damages arise out of or are based upon any untrue statement or omission based upon written information furnished to the Company by such Holder, underwriter, or
controlling person and stated to be for use in connection with the offering of securities of the Company or (ii) in the case of a sale directly by a Holder of Registrable Securities (including a sale of such Registrable Securities through any
underwriter retained by such Holder engaging in a distribution solely on behalf of such Holder), if such untrue statement or alleged untrue statement or omission or alleged omission was contained in a preliminary prospectus and corrected in a final
or amended prospectus, and such Holder failed to deliver a copy of the final or amended prospectus at or prior to the confirmation of the sale of the Registrable Securities to the person asserting any such loss, claim, damage, liability or action in
any case in which such delivery is required by the Securities Act. 
 12.2 Holder’s Indemnification of Company. To the
extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such Registration, qualification or, compliance is being effected pursuant to this Agreement, indemnify and hold
harmless the Company, each of its directors and officers, each legal counsel and independent accountant of the Company, each underwriter, if any, of the Company’s securities covered by such a Registration Statement, each person who controls the
Company or such underwriter within the meaning of the Securities Act, and each other seller of Registrable Securities and each of its officers, directors, and constituent partners, and each person controlling such other seller, against all Damages
arising out of or based upon any untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, prospectus, offering circular, or other document, or any omission (or alleged omission) to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by such Holder of any rule or 

  

 19 

 
regulation promulgated under the Securities Act applicable to such Holder and relating to action or inaction required of such Holder in connection with any
such Registration, qualification, or compliance, and will reimburse the Company, such other sellers of Registrable Securities, such directors, officers, partners, persons, law and accounting firms, underwriters or control persons for any legal and
any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or
omission (or alleged omission) is made in such Registration Statement, prospectus, offering circular, or other document in reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically
for use in connection with the offering of securities of the Company, provided, however, that the indemnity contained in this Section 12.2 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the
consent of such Holder (which consent shall not be unreasonably withheld or delayed); and provided, further, that each Holder’s liability under this Section 12.2 shall not exceed such Holder’s net proceeds from the offering of
securities made in connection with such Registration. 
 12.3 Indemnification Procedure. Promptly after receipt by an
indemnified party under this Section 12 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 12, notify the indemnifying
party in writing of the commencement thereof and generally summarize such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled
to select counsel for the defense of such claim with the approval of any parties entitled to indemnification, which approval shall not be unreasonably withheld or delayed; provided further, however, that if either party reasonably determines that
there may be a conflict between the position of the Company and the Investors in conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 12, then counsel for such party shall be
entitled to conduct the defense to the extent reasonably determined by such counsel to be necessary to protect the interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to
the ability of the indemnifying party to defend such action, shall relieve such indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this Section 12, but the omission so to notify the indemnifying
party will not relieve such party of any liability that such party may have to any indemnified party otherwise than under this Section 12. 
 12.4 Contribution. If the indemnification provided for in this Section 12 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any Damages referred to therein, then the
indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or 

  

 20 

 
payable by such indemnified party as a result of such Damages in such proportion as is appropriate to reflect the relative fault of the indemnifying party on
the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such Damages as well as any other relevant equitable considerations; provided, however, that in no event shall any
contribution by a Holder under this Section 12.4 exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by such Holder. The relative fault of the indemnifying party and of the indemnified party
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party
and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
 12.5 Conflicts. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are
in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 12.6 Survival of
Obligations. The obligations of the Company and Holders under this Section 12 shall survive the completion of any offering of Registrable Securities in a Registration Statement under this Agreement or otherwise. 
 13. Limitations on Registration Rights Granted to Other Securities. From and after the date of this Agreement, so long as at least
10,000,000 shares of the Convertible Securities (including shares of Common Stock issued upon conversion thereof and as adjusted for combinations, consolidations, subdivisions, stock splits and the like with respect to such shares) remain issued and
outstanding, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company providing for the granting to such holder of (a) any Registration rights or (b) any information rights that
are superior to or on parity with the information rights granted to the Holders under this Agreement, except that, with the consent of the Holders (excluding Defaulting Investors) holding at least 55% of the Registrable Securities then held by the
Holders (excluding Defaulting Investors), additional persons may be added as parties to this Agreement with regard to any or all securities of the Company held by them. Any such additional parties shall execute a counterpart of this Agreement, and
upon execution by such additional parties and by the Company, shall be considered a Holder for all purposes of this Agreement and any Common Stock held by them or issued or issuable upon conversion of any securities held by them, and any Common
Stock issued (or issuable upon conversion or exercise of any warrant, right or other security which is issued) upon stock dividends, subdivisions, stock splits, recapitalization, merger or other distributions with respect to, or in exchange for, or
in replacement of, such securities identified in this clause, excluding, however, any securities previously sold to the public and any securities sold by a person in a transaction in which its rights under this 

  

 21 

 
Agreement are not assigned, shall be considered Registrable Securities. The additional parties and the additional Registrable Securities shall be identified
in an amendment to Exhibit A hereto. 
 14. Transferability. 
 14.1 Limitations on Transferability. Each Investor covenants that in no event will it dispose of any of the Convertible Securities or
Registrable Securities (other than pursuant to Rule 144 promulgated by Commission under the Securities Act (“Rule 144”) or other exemption from registration, or except in connection with an Investor’s exercise
of its Registration rights under this Agreement) unless and until (a) the Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the circumstances surrounding the proposed
disposition, and (b) if reasonably requested by the Company, the Investor shall have furnished the Company with an opinion of counsel reasonably satisfactory in form and substance to the Company and the Company’s counsel to the effect that
(x) such disposition will not require registration under the Securities Act and (y) appropriate action necessary for compliance with the Securities Act and any applicable state, local, or foreign law has been taken. Notwithstanding the
limitations set forth in the foregoing sentence, if the Investor is a partnership or limited liability company it may transfer the Convertible Securities or Registrable Securities to its constituent partners or members or its Affiliates, or a
retired partner or member of such partnership or limited liability company who retires after the date hereof, or to the estate of any such partner or member or retired partner or retired member or transfer by gift, will, or intestate succession to
any such partner’s or member’s spouse, domestic partner, lineal descendants or ancestors without the necessity of registration or opinion of counsel if the transferee agrees in writing to be subject to the terms of the Transactional
Agreements, as applicable, to the same extent if such transferee were an Investor; provided, however, that Investor hereby covenants not to effect such transfer if such transfer either would invalidate the securities laws exemptions
pursuant to which the Convertible Securities or Registrable Securities were originally offered and sold or would itself require registration and/or qualification under the Securities Act or applicable state securities laws. Notwithstanding the
foregoing, an Investor who is a Manager shall not dispose of any Convertible Securities or Registrable Securities in contravention of the Transactional Agreements (as defined herein). Each certificate evidencing the Convertible Securities or
Registrable Securities transferred as provided above shall bear the appropriate restrictive legend set forth in Section 5.1 of the Purchase Agreement, except that such certificate shall not bear such legend if the transfer was made in
compliance with Rule 144 or if the opinion of counsel referred to above is to the further effect that such legend is not required in order to establish compliance with any provisions of the Securities Act. 
 14.2 Transfer of Rights. The rights to information under Sections 2, the right of first refusal under Section 3 and the right to cause
the Company to Register 

  

 22 

 
securities granted by the Company to the Holders under Sections 6 and 7 of this Agreement may be assigned by any Investor or its Affiliates to a transferee
or assignee of any Convertible Securities or Registrable Securities not sold to the public acquiring the lesser of (a) at least 50% of the Registrable Securities and Convertible Securities then held by such Investor or its Affiliates with
respect to the first transfer by such Investor or its Affiliates to a non-Affiliate, 100% of the Registrable Securities and Convertible Securities then held by such Investor or its Affiliates with respect to any subsequent transfer by such Investor
or its Affiliates to a non-Affiliate, or 100% of the Registrable Securities and Convertible Securities held by a transferee or assignee of a Holder to a non-Affiliate of such transferee or assignee, and (b) at least 2,000,000 shares (or such
lesser number of shares as would be held by an Investor who is not a Defaulting Investor, who has a Total Capital Commitment of $2,727,200 as defined in the Purchase Agreement, and who has not sold any shares acquired under the Purchase Agreement)
of the Convertible Securities or Registrable Securities (as adjusted for combinations, consolidations, subdivisions, stock splits and the like with respect to such shares) to a non-Affiliate; provided, however, that (i) the Company must receive
notice prior to the time of said transfer, stating the name and address of said transferee or assignee and identifying the securities with respect to which such rights are being assigned, (ii) the Board of Directors must consent to the
assignment, which consent shall not be unreasonably withheld, and (iii) such transferee or assignee must agree in writing to be bound by the terms and conditions of this Agreement. Notwithstanding the limitation set forth in the foregoing
sentence respecting the minimum number of shares which must be transferred, any Holder which is a corporation, partnership or limited liability company may transfer such Holder’s rights to information under Section 2, right of first
refusal under Section 3 and Registration rights under Sections 6 and 7 to such Holder’s Affiliates, as the case may be, without restriction as to the number or percentage of shares acquired by any such Affiliates. 
 15. Market Standoff. Each Holder hereby agrees that, if so requested by the Company and the Underwriter’s Representative (if any),
such Holder shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of any Registrable Securities or other securities of the Company (“Market Standoff”) without the
prior written consent of the Company and the Underwriter’s Representative for such period of time (a) not to exceed 180 days following the effective date of a Registration Statement of the Company filed under the Securities Act in the case
of the Company’s initial public offering or (b) commencing with the date the Company provides notice to the Holders of a proposed follow-on offering pursuant to Section 7.1 (including Registrations initiated pursuant to
Section 6) and ending 90 days after the effective date of the Registration Statement or, in the event of a shelf registration, the date of the prospectus for such follow-on offering, as may be requested by the Underwriter’s Representative;
provided, however, that a Holder shall not be required to agree to a Market Standoff for a period of time that commences less than 30 days after the expiration of another period of time during which the Holder has agreed to a Market 

  

 23 

 
Standoff. The obligations of the Holders under this Section 15 shall be conditioned upon similar agreements being in effect with each other stockholder
who is an officer, or director or, with respect only to the Company’s initial public offering, greater than 1% stockholder of the Company prior to such initial public offering. 
 16. Conversion of Preferred Stock. The Registration rights of the Holders of the Registrable Securities set forth in this Agreement are
conditioned upon the conversion of the Registrable Securities with respect to which registration is sought into Common Stock immediately prior to the closing of the offering of such Registrable Securities pursuant to an effective Registration
Statement. 
 17. Reports Under the Exchange Act. With a view to making available to the Holders the benefits of Rule 144
promulgated under the Securities Act and any other rule or regulation of the Commission that may at any time permit a Holder to sell securities of the Company to the public without Registration or pursuant to a registration on Form S-3, the Company
agrees, for as long as a Holder holds Registrable Securities, to: 
 (a) make and keep public information available, as those terms are
understood and defined in Rule 144, at all times after the effective date of the first Registration Statement filed by the Company for the offering of its securities to the public; 
 (b) take such action as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as
soon as practicable after the end of the fiscal year in which the first Registration Statement filed by the Company for the offering of its securities to the general public is declared effective; 
 (c) file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act;

 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities, promptly upon request (i) a written statement by
the Company that it has complied with the reporting requirements of Rule 144 (at any time after 90 days after the effective date of the first Registration Statement filed by the Company), the Securities Act, and the Exchange Act (at any time after
it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of
the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the Commission which permits the selling of any such
securities without Registration or pursuant to such form; and 
  

 24 

 (e) at any time, at the request of any Holder of Registrable Securities, make available to such Holder
and to any prospective transferee of such Registrable Securities the information concerning the Company described in Rule 144A(d)(4) under the Securities Act. 
 18. Covenants. 
 18.1 Confidentiality Agreements. Unless otherwise determined by the
unanimous vote of the Board of Directors, the Company shall require all future officers, directors, and employees of the Company to execute and deliver an Employee Confidential Information and Inventions Agreement in substantially the form of
Exhibit 18.1. 
 18.2 Market Stand-off Agreements. The Company shall cause all future purchasers of, and all future
holders of options to purchase, shares of the Company’s capital stock to execute and deliver an agreement providing for a lockup or market standoff commitment similar to the Market Standoff set forth in Section 15. 
 18.3 Stock Plans. The Company will not sell shares of stock or grant options to employees, advisors, officers, and directors of, and
consultants to, the Company except pursuant to a stock option plan or such other arrangements, contracts or plans which have been approved by the Board of Directors. Following the date on which the first share of Series B Preferred Stock was sold by
the Company, except as may otherwise be determined by the Board of Directors in any particular instance, any options or shares granted or issued by the Company shall be subject to a four-year vesting or repurchase schedule, and options granted by
the Company shall have an exercise price equal to the fair market value of the Company’s Common Stock at the time of grant as determined by the Board of Directors. 
 18.4 Special Covenants. Without first obtaining the affirmative vote or written consent of Investors holding a majority of the then outstanding Convertible Securities (including Common Stock issued upon
conversion thereof), the Company shall not take any action that: 
 (a) results in the issuance of any equity securities by a subsidiary of
the Company that holds or is intended to hold assets of at least $25,000,000 to any person or business entity other than the Company or any of its wholly-owned subsidiaries (other than director qualifying shares); 
 (b) results in the sale, transfer, or other encumbrance of assets of the Company or any subsidiary with a value of $15,000,000 or more; or 

(c) provides for the incurrence of more than $15,000,000 of indebtedness, in the aggregate, by the Company or its subsidiaries. 
  

 25 

 18.5 Employment Agreements. The Company will not waive any rights under the Employment
Agreements without the consent of the Board of Directors. 
 18.6 Conversion Ratio. The Company will not split, divide or
combine either the Company’s Series B Preferred Stock, Series B/P Preferred Stock or Series BB Preferred Stock without splitting, dividing or combining, in the same manner and to the same extent, the other such series of Preferred Stock.

 18.7 Termination of Covenants. Sections 18.1, 18.2,18.3, 18.4, 18.5 and 18.6 shall be effective as of the date hereof and
shall continue in effect until and shall terminate upon the earliest to occur of (a) the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, covering the offer and
sale of the Company’s Common Stock to the public (b) such time as the Company has a class of equity securities registered under the Exchange Act, and (c) a Change of Control. 
 19. Miscellaneous. 
 19.1
Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of California excluding those laws that direct the application of the laws of another jurisdiction. 
 19.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 19.3 Headings. The headings of the Sections of this Agreement are for
convenience and shall not by themselves determine the interpretation of this Agreement. 
 19.4 Notices. All notices required
or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, or if
not, then on the next business day; (iii) one day after deposit with a nationally (or internationally) recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices to the Company shall be sent to
the Company’s principal place of business. All notices to other parties to this Agreement shall be sent to the address as set forth on the signature page or at such other address as such party may designate by ten days advance notice to the
other parties. 
 19.5 Amendment and Waiver of Agreement. Except as otherwise provided herein, any provision of this Agreement
may be amended or waived only by a written instrument signed by the Company and persons (excluding Defaulting Investors) holding at least 60% of the Registrable Securities then held by such persons (excluding Defaulting Investors); provided,
however, that (a) Section 5 and 19.5(a) may not be 

  

 26 

 
amended or waived without the consent of Managers holding a majority of Registrable Securities then held by all Managers, and (b) Sections 6.1(b),
6.2(b) and 19.5(b) may not be amended or waived without the consent of all Holders who have demand rights under subsections 6.1(b) and 6.2(b). In addition, this Agreement may not be amended to increase any material financial obligations of any
Investor hereunder without the prior written consent of such Investor. Any waiver, amendment, modification or termination of any provision of this Agreement shall be binding on all parties hereto and their respective successors and permitted
assigns. 
 19.6 Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to
be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable
provision had never been contained herein. 
 19.7 Entire Agreement; Successors and Assigns. This Agreement and the
Transactional Agreements (as defined below) constitute the entire agreement between the parties regarding the subject matter hereof and thereof and supersede and replace any and all prior negotiations, correspondence, understandings and agreements,
including without limitation the Prior Agreement, between the parties regarding the subject matter hereof and thereof. For purposes of this Agreement, the “Transactional Agreements” shall mean the Purchase Agreement and the
Second Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith among the Company and other parties identified therein, the Second Amended and Restated Voting Agreement of even date herewith among the Company and the
parties identified therein, and the Employment Agreements dated as of February 18, 2004 between the Company and each of the Executives named in Section 6.10 of the Purchase Agreement, each as may be amended in accordance with its terms.
Subject to the exceptions specifically set forth in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective executors, administrators, heirs, successor, and permitted assigns of the
parties. 
 19.8 Aggregation. All outstanding shares of capital stock of the Company held or acquired by an Affiliate of a
Person shall be aggregated together with all other shares of capital stock held by such Person for the purpose of determining the availability of any rights under this Agreement. 
 19.9 Cumulative Remedies. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other
right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not
prevent the concurrent assertion or employment of any other right or remedy. 
  

 27 

 19.10 Specific Performance. The parties hereto hereby declare that it is impossible to
measure in money the damages that will accrue to a party hereto or to their heirs, personal representatives, or assigns by reason of a failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be
specifically enforceable. If any party hereto or his heirs, personal representatives, or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby
waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 
 19.11 Accession; Amendment of Exhibit. Any person that becomes an Investor as defined in the Purchase Agreement or a registered holder of a
Series BB Warrant shall become a party to this Agreement by executing and delivering to the Company a counterpart signature pages to this Agreement and shall thereupon be deemed an “Investor” for all purposes of this Agreement. The number
of shares of Convertible Securities, Registrable Securities owned by each Investor, and the number of shares (if any) of Series BB Preferred Stock subject to Series BB Warrants held by each Investor, as of the date hereof is set forth on Exhibit
A, which exhibit may be amended from time to time by the Company upon notice to the Investors to reflect changes in the number of shares of Convertible Securities or Registrable Securities owned by the Investors; provided, however, that no such
notice shall be required upon the exercise of the Series BB Warrants by any of the Investors; provided further, however, that the failure to so amend Exhibit A shall have no effect on the rights of the Investors under this Agreement.

 [SIGNATURE PAGES FOLLOW] 
  

 28 

					
	Investors:	 	KKR JP LLC
			
		 	By:	 	 /s/ Mike Michelson

		 	Name:	 	Mike Michelson
		 	Title:	 	Member
		 	Address:	 	 9 West 57th Street, 42nd Floor
 New York, NY 10019

		
		 	KKR JP III LLC
			
		 	By:	 	 /s/ Mike Michelson

		 	Name:	 	Mike Michelson
		 	Title:	 	Member
		 	Address:	 	 9 West 57th Street, 42nd Floor
 New York, NY 10019

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

			
	Investors:	  	THOMA CRESSEY FUND VII, L.P.
		
		  	By
		
		  	 TC Partners VII, LP
 Its General Partner
 By

		
		  	 Thoma Cressey Equity Partners Inc.
 Its General
Partner

		  	By
		
		  	 /s/ Lee M. Mitchell

		  	 Lee M. Mitchell
 Vice President

		
		  	THOMA CRESSEY FRIENDS FUND VII, L.P.
		
		  	By
		
		  	 TC Partners VII, LP
 Its General Partner
 By

		
		  	Thoma Cressey Equity Partners Inc.
		  	Its General Partner
		  	By
		
		  	 /s/ Lee M. Mitchell

		  	Lee M. Mitchell
		  	Vice President

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	CCG INVESTMENT FUND, L.P.
			
		 	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its:	 	Authorized Representative
			
		 	By:	 	 /s/ Ken Diekroeger

		 	Its:	 	Managing Director
		 	Address:	 	 c/o Golden Gate Capital
 One Embarcadero
Center
 33rd Floor
 San Francisco, CA 94111

		
		 	CCG AV, LLC-SERIES C
			
		 	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its:	 	Authorized Representative
			
		 	By:	 	 /s/ Ken Diekroeger

		 	Its:	 	Managing Director
		 	Address:	 	 c/o Golden Gate Capital
 One Embarcadero
Center
 33rd Floor
 San Francisco, CA 94111

		
		 	CCG ASSOCIATES-QP, LLC
			
		 	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its:	 	Authorized Representative
			
		 	By:	 	 /s/ Ken Diekroeger

		 	Its:	 	Managing Director
		 	Address:	 	 c/o Golden Gate Capital
 One Embarcadero
Center
 33rd Floor
 San Francisco, CA 94111

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	CCG INVESTMENT FUND-AI, LP
			
		 	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its:	 	Authorized Representative
			
		 	By:	 	 /s/ Ken Diekroeger

		 	Its:	 	Managing Director
		 	Address:	 	 c/o Golden Gate Capital
 One Embarcadero
Center
 33rd Floor
 San Francisco, CA 94111

		
		 	CCG ASSOCIATES-AI, LLC
			
		 	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its:	 	Authorized Representative
			
		 	By:	 	 /s/ Ken Diekroeger

		 	Its:	 	Managing Director
		 	Address:	 	 c/o Golden Gate Capital
 One Embarcadero
Center
 33rd Floor
 San Francisco, CA 94111

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	CCG AV, LLC-SERIES A
			
		 	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its:	 	Authorized Representative
			
		 	By:	 	 /s/ Ken Diekroeger

		 	Its:	 	Managing Director
		 	Address:	 	 c/o Golden Gate Capital
 One Embarcadero
Center
 33rd Floor
 San Francisco, CA 94111

		
		 	CCG CI, LLC
			
		 	By:	 	Golden Gate Capital Management, L.L.C.
		 	Its:	 	Authorized Representative
			
		 	By:	 	 /s/ Ken Diekroeger

		 	Its:	 	Managing Director
		 	Address:	 	 c/o Golden Gate Capital
 One Embarcadero
Center
 33rd Floor
 San Francisco, CA 94111

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	  	JAZZ INVESTORS, L.L.C.
			
		  	By:	  	 Beecken Petty & Company, L.L.C.
 its
Manager

			
		  	By:	  	 /s/ Kenneth W. O’Keefe

		  		  	 Kenneth W. O’Keefe,
 its Managing
Director

		  	Address:	  	 c/o Beecken Petty & Company
 Healthcare Equity
Partners
 200 W. Madison Street
 Suite 1910
 Chicago, IL 60606

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

											
	Investors:	 		 		 	LEHMAN BROTHERS HEALTHCARE
		 		 		 		 	VENTURE CAPITAL L.P.
						
		 		 		 		 	By:	 	 Lehman Brothers HealthCare Venture
 Capital Associates
L.P., its General Partner

						
		 		 		 		 	By:	 	LB I Group Inc., its General Partner
						
		 		 		 		 	By:	 	 /s/ Steven Berkenfeld

		 		 		 		 		 	Steven Berkenfeld
		 		 		 		 		 	Senior Vice President
		 		 		 		 	Address:	 	399 Park Avenue
		 		 		 		 		 	 New York, NY 10022
 Attn: Fred
Steinberg

					
		 		 		 		 	LEHMAN BROTHERS P.A. LLC
						
		 		 		 		 	By:	 	 /s/ Steven Berkenfeld

		 		 		 		 		 	 Steven Berkenfeld
 Senior Vice
President

		 		 		 		 	Address:	 	399 Park Avenue
		 		 		 		 		 	 New York, NY 10022
 Attn: Fred
Steinberg

					
		 		 		 		 	 LEHMAN BROTHERS PARTNERSHIP
 ACCOUNT 2000/2001, L.P.

						
		 		 		 		 	By:	 	LB I Group Inc., its General Partner
						
		 		 		 		 	By:	 	 /s/ Steven Berkenfeld

		 		 		 		 		 	 Steven Berkenfeld
 Senior Vice
President

		 		 		 		 	Address:	 	399 Park Avenue
		 		 		 		 		 	 New York, NY 10022
 Attn: Fred
Steinberg

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

									
	Investors:	 		 	 LEHMAN BROTHERS OFFSHORE
 PARTNERSHIP ACCOUNT 2000/2001, L.P.

					
	 	 	 	 	 	 	By:	 	 Lehman Brothers Offshore Partners Ltd.,
 its General
Partner

					
		 		 		 	By:	 	 /s/ Steven Berkenfeld

		 		 		 		 	Steven Berkenfeld
		 		 		 		 	Vice President
		 		 		 	Address:	 	399 Park Avenue
		 		 		 		 	 New York, NY 10022
 Attn: Fred
Steinberg

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	PROSPECT VENTURE PARTNERS II, L.P.
			
		 	By:	 	 Prospect Management Co. II, LLC,
 its General
Partner

			
		 		 	 /s/ Dave Markland, attorney-in-fact

		 		 	 James Tananbaum
 Managing Member

		 	Address:	 	 435 Tasso Street, Suite 200
 Palo Alto, CA
94301

		
		 	PROSPECT ASSOCIATES II, L.P.
			
		 	By:	 	 Prospect Management Co. II, LLC,
 its General
Partner

			
		 		 	 /s/ Dave Markland, attorney-in-fact

		 		 	 James Tananbaum
 Managing Member

		 	Address:	 	 435 Tasso Street, Suite 200
 Palo Alto, CA
94301

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	VERSANT VENTURE CAPITAL II, L.P.
			
		 	By:	 	 Versant Ventures II, L.L.C.
 its General
Partner

			
		 	By:	 	 /s/ Samuel D. Colella

		 		 	 Samuel D. Colella
 Managing
Director

		 	Address:	 	 3000 Sand Hill Road
 Building 4, Suite 210

Menlo Park, CA 94025

		
		 	VERSANT SIDE FUND II, L.P.
			
		 	By:	 	 Versant Ventures II, L.L.C.
 its General
Partner

			
		 	By:	 	 /s/ Samuel D. Colella

		 		 	 Samuel D. Colella
 Managing
Director

		 	Address:	 	 3000 Sand Hill Road
 Building 4, Suite 210

Menlo Park, CA 94025

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	VERSANT AFFILIATES FUND II-A, L.P.
			
		 	By:	 	 Versant Ventures II, L.L.C.
 its General
Partner

			
		 	By:	 	 /s/ Samuel D. Colella

		 		 	 Samuel D. Colella
 Managing Director

		 	Address:	 	 3000 Sand Hill Road
 Building 4, Suite 210
 Menlo Park, CA 94025

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	BVCF IV, L.P.
			
		 	By:	 	 Adams Street Partners, LLC,
 its General
Partner

			
		 	By:	 	 /s/ Terry Gould

		 		 	 Terry Gould
 Partner

		 	Address:	 	 One North Wacker Drive
 Suite 2200
 Chicago, IL 60606

		
		 	ADAMS STREET V, L.P.
			
		 	By:	 	 Adams Street Partners, LLC,
 its General
Partner

			
		 	By:	 	 /s/ Terry Gould

		 		 	 Terry Gould
 Partner

		 	Address:	 	 One North Wacker Drive
 Suite 2200
 Chicago, IL 60606

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	CARDINAL FUND I, L.P.
			
		 	By:	 	Cardinal Management I, L.P., General Partner
		 	By:	 	Cardinal MGP, L.L.C., General Partner
			
		 	By:	 	 /s/ John H. Fant

		 	Name:	 	John H. Fant
		 	Title:	 	Vice President
		 	Address:	 	 201 Main Street, Suite 2415
 Fort Worth, TX
76102
 Attn: Ray Pinson

		
		 	FW JAZZ PHARMA INVESTORS, L.P.
		 	By:	 	Group VI, 31, L.L.C., General Partner
			
		 	By:	 	 /s/ John H. Fant

		 	Name:	 	John H. Fant
		 	Title:	 	Vice President
		 	Address:	 	 201 Main Street, Suite 3100
 Fort Worth, TX
76102
 Attn: John H. Fant

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	EGS PRIVATE HEALTHCARE
		 	PARTNERSHIP II, L.P.
			
		 	By:	 	 EGS Private Healthcare Investments, L.L.C.,
 its
General Partner

			
		 	By:	 	 /s/ Abhijeet Lele

		 		 	 Abhijeet Lele,
 Member of Board of
Managers

		 	Address:	 	 105 Rowayton Ave.
 Rowayton, CT
06853

		
		 	 EGS PRIVATE HEALTHCARE
 INVESTORS
II, L.P.

			
		 	By:	 	 EGS Private Healthcare Investments, L.L.C.,
 its
General Partner

			
		 	By:	 	 /s/ Abhijeet Lele

		 		 	Abhijeet Lele,
		 		 	Member of Board of Managers
		 	Address:	 	 105 Rowayton Ave.
 Rowayton, CT
06853

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	 EGS PRIVATE HEALTHCARE
 CANADIAN
PARTNERS, L.P.

			
		 	By:	 	 EGS Private Healthcare Investments, L.L.C.,
 its
General Partner,

			
		 	By:	 	 /s/ Abhijeet Lele

		 		 	 Abhijeet Lele,
 Member of Board of
Managers

		 	Address:	 	 105 Rowayton Ave.
 Rowayton, CT
06853

		
		 	 EGS PRIVATE HEALTHCARE
 PRESIDENTS
FUND, L.P.

			
		 	By:	 	 EGS Private Healthcare Investments, L.L.C.,
 its
General Partner

			
		 	By:	 	 /s/ Abhijeet Lele

		 		 	Abhijeet Lele,
		 		 	Member of Board of Managers
		 	Address:	 	 105 Rowayton Ave.
 Rowayton, CT
06853

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Dated: June 24, 2005	 		 	 /s/ Samuel Saks
 Samuel
Saks

			
	Dated: June 24, 2005	 		 	 /s/ Bruce Cozadd
 Bruce
Cozadd

			
	Dated: June 24, 2005	 		 	 /s/ Robert Myers
 Robert
Myers

			
	Dated: June 24, 2005	 		 	 /s/ Janne Wissel
 Janne
Wissel

			
	Dated: June 24, 2005	 		 	 /s/ Matthew K. Fust
 Matthew K.
Fust

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	WAUD CAPITAL PARTNERS, L.P.
			
		 	By:	 	Waud Capital Partners, L.L.C.
		 	Its:	 	General Partner
			
		 	By:	 	 /s/ Reeve B. Waud

		 		 	 Reeve B. Waud
 Managing Partner

		 	Address:	 	 560 Oakwood Avenue, Suite 203
 Lake Forest, IL
60045

		
		 	WAUD CAPITAL AFFILIATES, L.L.C.
			
		 	By:	 	 /s/ Reeve B. Waud

		 		 	 Reeve B. Waud
 Managing Member

		 	Address:	 	 560 Oakwood Avenue, Suite 203
 Lake Forest, IL
60045

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	DEEP COVE MEZZANINE, LLC
			
		 	By:	 	 /s/ Reeve B. Waud

		 		 	 Reeve B. Waud
 Manager

		 	Address:	 	 560 Oakwood Avenue, Suite 203
 Lake Forest, IL
60045

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	LERNER ENTERPRISES, L.P.
			
		 	By:	 	Oak Hill Advisors, L.P.
		 		 	 as advisor and attorney-in-fact to
 Lerner Enterprises, L.P. (OHP account)

			
		 	By:	 	 /s/ Glenn K. August

		 	Name:	 	Glenn K. August
		 	Title:	 	President

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

					
	Investors:	 	OAK HILL CREDIT ALPHA FUND, LP
			
		 	By:	 	 Oak Hill Credit Alpha GenPar, L.P.,
 Its General
Partner

			
		 	By:	 	 Oak Hill Credit Alpha MGP, LLC,
 Its General
Partner

			
		 	By:	 	 /s/ Glenn K. August

		 	Name:	 	Glenn K. August
		 	Title:	 	Managing Member

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

									
	Investors:	 		 	LB I GROUP INC.
					
		 		 		 	By:	 	 /s/ Jeffrey A. Ferrell

		 		 		 	Name:	 	Jeffrey A. Ferrell
		 		 		 	Title:	 	Vice President
				
		 		 		 	 With Notices to:
  
 Lehman Brothers
 399 Park Avenue
 9th Floor
 New York, NY 10022
 Attn: Jeffrey A. Ferrell
 Fax: 646-758-5022

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

									
	Investors:	 		 	KKR TRS HOLDINGS, INC.
					
		 		 		 	By:	 	 /s/ Barbara J. S. McKee

		 		 		 	Name:	 	Barbara J. S. McKee
		 		 		 	Title:	 	Authorized Signatory
				
		 		 		 	With Notices to:
				
		 		 		 	KKR Financial Corp.
		 		 		 	4 Embarcadero Center, Suite 2050
		 		 		 	San Francisco, CA 94111
		 		 		 	Attn: Barbara J.S. McKee
		 		 		 	Fax: 415-391-3077

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

									
	Investors:	 		 	GENERAL ELECTRIC PENSION TRUST
					
		 		 		 	By:	 	 GE Asset Management Incorporated
 its Investment
Manager

					
		 		 		 	By:	 	 /s/ Michael M. Pastore

		 		 		 	Name:	 	Michael M. Pastore, Vice President
				
		 		 		 	 With Notices to:
  
 General Electric Pension Trust
 c/o GE Asset Management
Incorporated
 3001 Summer Street
 P.O. Box 7900
 Stamford, CT 06904-7900
 Fax: 203 326-7903
 Attention: Daniel L. Furman

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

  

									
	Company:	 		 	JAZZ PHARMACEUTICALS, INC.
		 		 		 	a Delaware Corporation
					
		 		 		 	By:	 	 /s/ Carol A. Gamble

		 		 		 		 	Carol A. Gamble
		 		 		 		 	Senior Vice President and General Counsel

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT 

 Exhibit A 
 SCHEDULE OF INVESTORS 
  

			
	 Name and Address
	  	 Securities

	 KKR JP LLC
 9 W. 57th Street, 42nd Floor
 New York, NY 10019
	  	94,932,531 shares of Series B/P Preferred Stock
		
	 KKR JP III LLC
 9 W. 57th Street, 42nd Floor
 New York, NY 10019
	  	403,344 shares of Series B/P Preferred Stock
		
	 Thoma Cressey Fund VII, L.P.
 Sears Tower, 92nd Floor
 233 South Wacker Drive
 Chicago, IL 60606
	  	21,662,348 shares of Series B Preferred Stock
		
	 Thoma Cressey Friends Fund VII, L.P.
 Sears Tower, 92nd Floor
 233 South Wacker Drive
 Chicago, IL 60606
	  	338,237 shares of Series B Preferred Stock
		
	 CCG Investment Fund, LP
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	9,521,349 shares of Series B Preferred Stock
		
	 CCG AV, LLC-Series C
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	480,987 shares of Series B Preferred Stock
		
	 CCG Associates-QP, LLC
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	523,132 shares of Series B Preferred Stock
		
	 CCG Investment Fund-AI, LP
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	127,553 shares of Series B Preferred Stock

			
	 Name and Address
	  	 Securities

	 CCG AV, LLC-Series A
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	127,260 shares of Series B Preferred Stock
		
	 CCG CI, LLC
 c/o Golden Gate Capital
 One Embarcadero Center, 33rd Floor
 San Francisco, CA 94111
	  	220,006 shares of Series B Preferred Stock
		
	 Jazz Investors, LLC
 c/o Beecken Petty & Company Healthcare Equity Partners
 200 W. Madison Street, Suite 1910
 Chicago, IL 60606
	  	14,667,057 shares of Series B Preferred Stock
		
	 Lehman Brothers HealthCare Venture Capital L.P.
 399 Park Avenue
 New York, NY 10022
 Attention: Fred Steinberg
	  	1,833,382 shares of Series B Preferred Stock
		
	 Lehman Brothers P. A. L.L.C.
 399 Park Avenue
 New York, NY 10022
 Attention: Fred Steinberg
	  	3,509,093 shares of Series B Preferred Stock
		
	 Lehman Brothers Partnership Account 2000/2001, L.P.
 399 Park Avenue
 New York, NY 10022
 Attention: Fred Steinberg
	  	1,581,017 shares of Series B Preferred Stock
		
	 Lehman Brothers Offshore Partnership Account 2000/2001, L.P.
 399 Park Avenue
 New York, NY 10022
 Attention: Fred Steinberg
	  	410,036 shares of Series B Preferred Stock
		
	 Prospect Venture Partners II, L.P.
 435 Tasso Street, Suite 200
 Palo Alto, CA 94301
	  	 7,313,625 shares of Series A Preferred Stock
 6,139,997
shares of Series B Preferred Stock

  

 2 

			
	 Name and Address
	  	 Securities

	 Prospect Associates II, L.P.
 435 Tasso Street, Suite 200
 Palo Alto, CA 94301
	  	111,375 shares of Series A Preferred Stock 93,502 shares of Series B Preferred Stock
		
	 Versant Venture Capital II, L.P.
 3000 Sand Hill Road
 Building 4, Suite 210
 Menlo Park, CA 94025
	  	7,223,361 shares of Series A Preferred Stock 6,064,216 shares of Series B Preferred Stock
		
	 Versant Side Fund II, L.P.
 3000 Sand Hill Road
 Building 4, Suite 210
 Menlo Park, CA 94025
	  	64,559 shares of Series A Preferred Stock 54,200 shares of Series B Preferred Stock
		
	 Versant Affiliates Fund II-A, L.P.
 3000 Sand Hill Road
 Building 4, Suite 210
 Menlo Park, CA 94025
	  	137,080 shares of Series A Preferred Stock 115,083 shares of Series B Preferred Stock
		
	 BVCF IV, L.P.
 One North Wacker Drive, Suite 2200
 Chicago, IL 60606
	  	2,200,058 shares of Series B Preferred Stock
		
	 Adams Street V, L.P.
 One North Wacker Drive, Suite 2200
 Chicago, IL 60606
	  	2,200,058 shares of Series B Preferred Stock
		
	 Cardinal Fund I, L.P.
 201 Main Street, Suite 2415
 Fort Worth, TX 76102
 Attention: Ray Pinson
	  	 2,933,411 shares of Series B Preferred Stock
 Warrant to
Purchase 86,957 shares of Series BB Preferred Stock

		
	 FW Jazz Pharma Investors, L.P.
 201 Main Street, Suite 3100
 Fort Worth, TX 76102
 Attention: John H. Fant
	  	 1,466,706 shares of Series B Preferred Stock
 Warrant to
Purchase 43,478 shares of Series BB Preferred Stock

		
	 EGS Private Healthcare Partnership II, L.P.
 105 Rowayton Ave.
 Rowayton, CT 06853
	  	2,222,679 shares of Series B Preferred Stock

  

 3 

			
	 Name and Address
	  	 Securities

	 EGS Private Healthcare Investors II, L.P.
 105 Rowayton Ave.
 Rowayton, CT 06853
	  	350,540 shares of Series B Preferred Stock
		
	 EGS Private Healthcare Canadian Partners, L.P.
 105 Rowayton Ave.
 Rowayton, CT 06853
	  	334,462 shares of Series B Preferred Stock
		
	 EGS Private Healthcare Presidents Fund, L.P.
 105 Rowayton Ave.
 Rowayton, CT 06853
	  	25,730 shares of Series B Preferred Stock
		
	 Samuel R. Saks
	  	2,640,000 shares of Common Stock 150,000 shares of Series A Preferred Stock 733,352 shares of Series B Preferred Stock
		
	 Bruce C. Cozadd
	  	1,980,000 shares of Common Stock 733,352 shares of Series B Preferred Stock
		
	 Robert M. Myers
	  	 1,047,500 shares of Common Stock
 513,347 shares of
Series B Preferred Stock

		
	 Janne L.T. Wissel
	  	 330,000 shares of Common Stock
 733,352 shares of Series
B Preferred Stock

		
	 Matthew K. Fust
	  	 330,000 shares of Common Stock
 220,005 shares of Series
B Preferred Stock

		
	 Carol A. Gamble
	  	300,000 shares of Common Stock
		
	 Waud Capital Partners, L.P.
 560 Oakwood Avenue, Suite 203
 Lake Forest, IL 60045
	  	5,280,141 shares of Series B Preferred Stock

  

 4 

			
	 Name and Address
	  	 Securities

	 Waud Capital Affiliates, L.L.C.
 560 Oakwood Avenue, Suite 203
 Lake Forest, IL 60045
	  	586,682 shares of Series B Preferred Stock
		
	 Deep Cove Mezzanine, LLC
 560 Oakwood Ave, Suite 203
 Lake Forest, IL 60045
	  	Warrants to purchase 543,478 shares of Series BB Preferred Stock
		
	 Lerner Enterprises, LLP
 c/o Oak Hill Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY 10022
	  	Warrants to purchase 71,630 shares of Series BB Preferred Stock
		
	 LB I Group Inc.
 c/o Lehman Brothers
 399 Park Avenue, 9th Floor
 New York, NY 10022
	  	Warrants to purchase 3,369,566 shares of Series BB Preferred Stock
		
	 KKR TRS Holdings, Inc.
 c/o KKR Financial Corp.
 4 Embarcadero Center, Suite 2050
 San Francisco, CA 94111
	  	Warrants to purchase 2,717,391 shares of Series BB Preferred Stock
		
	 General Electric Pension Trust
 c/o GE Asset Management Incorporated
 3001 Summer Road
 P.O. Box 7900
 Stamford, CT 06904-7900
	  	Warrants to purchase 869,565 shares of Series BB Preferred Stock
		
	 Coast DL Funding LLC
 c/o Oak Hill Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY 10022
	  	Warrants to purchase 443,804 shares of Series BB Preferred Stock
		
	 Oak Hill Credit Opportunities Financing, Ltd.
 c/o Oak Hill Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY 10022
	  	Warrants to purchase 294,348 shares of Series BB Preferred Stock

  

 5 

			
	 Name and Address
	  	 Securities

	 Oak Hill Credit Alpha Finance I (Offshore), Ltd.
 c/o Oak Hill Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY 10022
	  	Warrants to purchase 193,152 shares of Series BB Preferred Stock
		
	 Oak Hill Credit Alpha Finance I, LLC
 c/o Oak Hill Advisors LP
 65 East 55th Street, 32nd Floor
 New York, NY 10022
	  	Warrants to purchase 62,283 shares of Series BB Preferred Stock

  

 6 

 Exhibit 18.1 
 JAZZ PHARMACEUTICALS, INC. 
 EMPLOYEE CONFIDENTIAL
INFORMATION AND 
 INVENTIONS AGREEMENT 
 In partial consideration and as a condition of my employment or continued employment with Jazz Pharmaceuticals, Inc., a Delaware corporation (which together with any parent, subsidiary, affiliate, or successor is
hereinafter referred to as the “Company”), and effective as of the date that my employment with the Company first commenced (or, if earlier, the date on which I began my discussions with the Company concerning my employment
by the Company), I hereby agree as follows: 
 1. Noncompetition; At-Will Employment. During my employment with the Company, I
will perform for the Company such duties as it may designate from time to time and will devote my best efforts to the business of the Company and will not, without the prior written approval of an officer of the Company if I am not an executive
officer of the Company or the Board of Directors of the Company if I am an executive officer of the Company, directly or indirectly participate in or assist any business which is a current or potential supplier, customer, or competitor of the
Company. I agree that unless specifically provided in another writing signed by me and an officer of the Company, my employment by the Company is not for a definite period of time. Rather, my employment relationship with the Company is one of
employment at will and my continued employment is not obligatory by either myself or the Company. Nothing in this Agreement is intended to create any employment relationship or arrangement other than “at will” employment. 
 2. Nonsolicitation. During the term of my employment by the Company, and for twelve months thereafter, I shall not directly or indirectly,
without the prior written consent of the Company, solicit, recruit, encourage or induce any employees, directors, consultants, contractors or subcontractors of the Company to leave the employ of the Company, either on my own behalf or on behalf of
any other person or entity. 
 3. Confidentiality Obligation. I will hold all Confidential Information in confidence and will
not disclose, use, copy, publish, summarize, or remove from the premises of the Company any Confidential Information, except (a) as necessary to carry out my assigned responsibilities as a Company employee, and (b) upon and after
termination of my employment, only as specifically authorized in writing by an officer of the Company. “Confidential Information” is all information related to any aspect of the business of the Company which is either
information not known by actual or potential competitors of the Company or is proprietary information of the Company, whether of a technical nature or otherwise. Confidential Information includes inventions, disclosures, processes, compounds,
biological materials, gene sequences, systems, methods, formulae, devices, patents, patent applications, trademarks, intellectual properties, instruments, materials, products, patterns, compilations, programs, techniques, sequences, designs, 

 
research or development activities and plans, specifications, computer programs, source codes, costs of production, prices and other financial data, volume
of sales, promotional methods, marketing plans, lists of names or classes of customers, or personnel, lists of suppliers, business plans, business opportunities, financial statements, financial models, or financial projections. 
 4. Information of Others. I will safeguard and keep confidential the proprietary information of customers, vendors, consultants, and other
parties with which the Company does business to the same extent as if it were Company Confidential Information. I will not, during my employment with the Company or otherwise, use or disclose to the Company any confidential, trade secret, or other
proprietary information or material of any previous employer or other person, and I will not bring onto the Company’s premises any unpublished document or any other property belonging to any former employer or third party without the written
consent of that former employer or third party. 
 5. Company Property. All papers, records, data, notes, drawings, files,
documents, samples, devices, products, equipment, computer files, databases and other materials, including copies and in whatever form, relating to the business of the Company that I possess or create as a result of my Company employment, whether or
not confidential, are the sole and exclusive property of the Company. In the event of the termination of my employment, I will promptly deliver all such materials to the Company and will sign and deliver to the Company the “Termination
Certificate” attached hereto as Exhibit A. 
 6. Ownership of Inventions. All inventions, ideas, designs,
developments, techniques, processes, improvements, schematics, formulas, compounds, compilations, methods, sequences, algorithms, trade secrets, works of authorship, and related know-how which result from work performed by me, alone or with others,
on behalf of the Company or from access to the Company Confidential Information or property whether or not patentable, copyrightable, or qualified for other protection as proprietary information or works (collectively
“Inventions”) shall be the property of the Company, and, to the extent permitted by law, shall be “works made for hire.” I hereby assign and agree to assign to the Company or its designee, without further
consideration, my entire right, title, and interest in and to all Inventions, other than those described in Paragraph 7 of this Agreement, including all rights to obtain, register, perfect, and enforce patents, copyrights, trademark rights and other
intellectual property protection for Inventions. I will disclose promptly and in writing to the individual designated by the Company or to my immediate supervisor all Inventions which I have made or reduced to practice. During my employment and for
four years after, I will assist the Company (at its expense) in every proper way to obtain and enforce patents, copyrights, trademarks and other forms of intellectual property protection on Inventions in any and all countries, including the
disclosure to the Company of all pertinent information and data with 

  

 2 

 
respect thereto, the execution of applications, specifications, assignments, recordations and all other instruments which the Company shall deem necessary in
order to apply for, claim, obtain, maintain and transfer such rights and in order to assign and convey to the Company, its successors, assigns and nominees, the sole and exclusive rights, title and interest in and to such Inventions, and any
patents, copyrights, trademarks or other intellectual property rights relating thereto. 
 7. Excluded Inventions. Attached
hereto as Exhibit B is a list of all inventions, improvements, and original works of authorship which I desire to exclude from this Agreement, each of which has been made or reduced to practice by me prior to the commencement of my employment
by the Company. I understand that this Agreement requires disclosure, but not assignment, of any invention that qualifies under Section 2870 of the California Labor Code, a copy of which is attached hereto as Exhibit C. 
 8. Invention Records; Patent Applications. I agree to create and maintain, and to make available to the Company’s legal counsel,
adequate and current written records of all inventions and original works of authorship made by me (alone or with others) during the term of my employment with the company. Such records will be kept in the form of notes, sketches, drawings or other
appropriate format. All such records will be available to the company at all times, and will be the sole property of the Company. If the Company files an original United States patent application covering any invention of which I am a named
inventor, I will receive an inventor’s fee of $100. If the Company is unable, because of my mental or physical incapacity or for any other reason to secure my signature to apply for or to pursue any patent applications or copyright or trademark
registrations covering any inventions or original works of authorship assigned to the company hereunder, I hereby irrevocably appoint the Company and its authorized officers and agents as my agent and attorney-in-fact to act for me and on my behalf
to execute and further the prosecution and issuance of letters patent and copyright and trademark registrations thereon, with the same legal effect as if I had executed them. 
 9. Prior Contracts. I represent that there are no other contracts to assign inventions that are now in existence between any other person
or entity and me. I further represent that I have no other employments, consultancies, or undertakings which would restrict and impair my performance of this Agreement. 
 10. Agreements with the United States Government and Other Third Parties. I acknowledge that the Company from time to time may have agreements with other persons or with the United States Government or
agencies thereof which impose obligations or restrictions on the Company regarding Inventions made during the course of work under such agreements or regarding the confidential nature of such work. I agree to be bound by all such obligations or
restrictions and to take all action necessary to discharge the obligations of the Company thereunder. 
  

 3 

 11. Miscellaneous. 
 (a) Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of
California excluding those laws that direct the application of the laws of another jurisdiction. 
 (b)
Enforcement. If any provision of this Agreement shall be determined to be invalid or unenforceable for any reason, it shall be adjusted rather than voided, if possible, in order to achieve the intent of the parties to the extent
possible. In any event, all other provisions of this Agreement, shall be deemed valid, and enforceable to the full extent possible. 
 (c) Injunctive Relief; Consent to Jurisdiction. I acknowledge and agree that damages will not be an adequate remedy in the event of a breach of any of my obligations under this Agreement. I therefore agree that the Company
shall be entitled (without limitation of any other rights or remedies otherwise available to the Company and without the necessity of posting a bond) to obtain an injunction from any court of competent jurisdiction prohibiting the continuance or
recurrence of any breach of this Agreement. I hereby submit myself to the jurisdiction and venue of the courts of the State of California for purposes of any such action. I further agree that service upon me in any such action or proceeding may be
made by first class mail, certified or registered, to my address as last appearing on the records of the Company. 
 (d)
Attorneys’ Fees. If any party seeks to enforce its rights under this Agreement by legal proceedings or otherwise, the non-prevailing party shall pay all costs and expenses of the prevailing party. 
 (e) Waiver. The waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a
waiver of any subsequent breach of the same or any other provision hereof. 
 (f) Binding Effect. This Agreement
shall be binding upon and shall inure to the benefit of the successors, executors, administrators, heirs, representatives, and assigns of the parties. 
 (g) Survival. The provisions of this Agreement shall survive the termination of my employment and the assignment of this Agreement by the Company to any successor in interest or other assignee.

 (h) Headings. The Section headings herein are intended for reference and shall not by themselves determine
the construction or interpretation of this Agreement. 
  

 4 

 (i) Severability. In case any provision of this Agreement shall be invalid,
illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 
 (j) Entire Agreement; Modifications. This Employee Confidential Information and Inventions Agreement contains the entire agreement between the Company and the undersigned employee concerning the subject
matter hereof and supersedes any and all prior and contemporaneous negotiations, correspondence, understandings, and agreements, whether oral or written, respecting that subject matter. All modifications to this Agreement must be in writing and
signed by the party against whom enforcement of such modification is sought. 
 [Signature Page Follows] 
  

 5 

 IN WITNESS WHEREOF, I have executed this Employee Confidential Information and Inventions Agreement as of
the ___ day of _____, 2007. 
  

			
	 
	Employee Signature
	
	 
	Type/Print Employee’s Name
		
	Address:	 	  
		 	  
		 	  
		
	Fax Number:	 	  
		
	E-mail:	 	  

 RECEIPT ACKNOWLEDGED: 
  

			
	JAZZ PHARMACEUTICALS, INC.
		
	By:	 	  
		
	Title:	 	  

  

 EXHIBIT A 
 TERMINATION CERTIFICATION 
 This is to certify that I do not have in my possession, nor have I failed
to return, any papers, records, data, notes, drawings, files, documents, computer files, databases, samples, devices, products, equipment, designs, computer programs, and other materials, including reproductions of any of the aforementioned items,
belonging to Jazz Pharmaceuticals, Inc., its subsidiaries, affiliates, successors, or assigns (together, the “Company”). 
 I further certify that I have complied with all the terms of the Company’s Employee Confidential Information and Inventions Agreement signed by me, including the reporting of any Inventions (as defined therein) conceived or made by me
(solely or jointly with others) covered by that agreement. 
 I further agree that, in compliance with the Employee Confidential Information
and Inventions Agreement, I will hold in confidence and will not disclose, use, copy, publish, or summarize any Confidential Information (as defined in the Employee Confidential Information and Inventions Agreement) of the Company or of any of its
customers, vendors, consultants, and other parties with which it does business. 
  

			
		
	Date:	 	  

  

	
	
	   
	Employee’s Signature
	
	   
	Type/Print Employee’s Name

 EXHIBIT B 
 EXCLUDED INVENTIONS, IMPROVEMENTS, AND ORIGINAL WORKS OF 
 AUTHORSHIP 
 (please mark N/A and initial if not applicable) 
  

					
	Title	  	Date	  	 Identifying Number
 Or Brief Description

  

 EXHIBIT C 
 California Labor Code 
 § 2870. Application of provision providing that employee shall assign or
offer to assign rights in invention to employer. 
  

	(a)	Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not
apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either: 

  

	 	(1)	Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the
employer. 

  

	 	(2)	Result from any work performed by the employee for the employer. 

  

	(b)	To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision
(a), the provision is against the public policy of this state and is unenforceable. 

 Added Stats 1979 ch 1001 § 1; Amended Stats 1986 ch
346 § 1.Senior Secured Note and Warrant Purchase Agreement

 Exhibit 4.4 
 TWIST MERGER SUB, INC. 
 $80,000,000 

15% Senior Secured Notes due June 24, 2011 
 GUARANTEED AND ACCOMPANIED WITH WARRANTS ISSUED BY 
 JAZZ PHARMACEUTICALS, INC. 
  

 SENIOR SECURED NOTE AND WARRANT PURCHASE
AGREEMENT 
  

 Dated as of June 24, 2005 

 Table of Contents 
  

					
	 	  	Page
	 SECTION 1.
	 	Authorization, Sale and Issuance of Notes and Warrants	  	2
			
	 Section 1.1
	 	Authorization	  	2
	 Section 1.2
	 	Sale and Purchase of the Notes and Warrants	  	2
	 Section 1.3
	 	Closing	  	3
	 Section 1.4
	 	Payment Terms of the Notes	  	3
			
	 SECTION 2.
	 	Company Guaranty	  	3
			
	 Section 2.1
	 	Background	  	3
	 Section 2.2
	 	Company Guaranty	  	3
	 Section 2.3
	 	No Fraudulent Conveyance	  	4
	 Section 2.4
	 	Unconditional Guaranty	  	4
	 Section 2.5
	 	Waiver	  	5
	 Section 2.6
	 	Authorization	  	5
	 Section 2.7
	 	Responsibility	  	5
	 Section 2.8
	 	Consent	  	6
	 Section 2.9
	 	Transfer	  	6
	 Section 2.10
	 	Continuation	  	6
	 Section 2.11
	 	Subrogation	  	6
	 Section 2.12
	 	Subordination	  	6
			
	 SECTION 3.
	 	Security Interests	  	7
			
	 Section 3.1
	 	Grant of Security Interests	  	7
	 Section 3.2
	 	Perfection of Security Interests	  	7
	 Section 3.3
	 	Possession of Collateral and Related Matters	  	8
	 Section 3.4
	 	Continuing Security Interest; Termination	  	8
			
	 SECTION 4.
	 	Conditions to Closing	  	9
			
	 Section 4.1
	 	Consummation of the Merger	  	9
	 Section 4.2
	 	Closing Deliveries	  	9
	 Section 4.3
	 	Additional Equity Financing	  	9
	 Section 4.4
	 	Security Interests; Indebtedness; Waivers and Consents	  	9
	 Section 4.5
	 	Fees and Expenses	  	10
	 Section 4.6
	 	Representations and Warranties	  	10
	 Section 4.7
	 	Performance; No Default	  	10
	 Section 4.8
	 	No Material Adverse Effect	  	10
			
	 SECTION 5.
	 	Representations and Warranties of the Company and the Borrower	  	11
			
	 Section 5.1
	 	Organization; Power and Authority	  	11
	 Section 5.2
	 	Authorization, Etc	  	11
	 Section 5.3
	 	Disclosure	  	11
	 Section 5.4
	 	Capitalization; Subsidiaries	  	11
	 Section 5.5
	 	Financial Statements	  	13
	 Section 5.6
	 	Compliance with Laws, Other Instruments, Etc	  	13

  

 i 

					
	 Section 5.7
	 	Governmental Authorizations, Etc	  	13
	 Section 5.8
	 	Litigation; Observance of Agreements, Statutes and Orders	  	13
	 Section 5.9
	 	Taxes	  	14
	 Section 5.10
	 	Title to Property; Leases	  	14
	 Section 5.11
	 	Intellectual Property, Licenses, Permits, Etc	  	14
	 Section 5.12
	 	Compliance with ERISA	  	15
	 Section 5.13
	 	Private Offering by the Company	  	15
	 Section 5.14
	 	Use of Proceeds	  	16
	 Section 5.15
	 	Existing Indebtedness; Future Liens	  	16
	 Section 5.16
	 	Foreign Assets Control Regulations, Etc	  	16
	 Section 5.17
	 	Status under Certain Statutes	  	16
	 Section 5.18
	 	Environmental Matters	  	17
	 Section 5.19
	 	Names	  	17
	 Section 5.20
	 	Locations; FEIN	  	17
	 Section 5.21
	 	Solvency	  	17
	 Section 5.22
	 	Status of Security Interest	  	18
			
	 SECTION 6.
	 	Representations of the Purchasers	  	18
			
	 Section 6.1
	 	Representations to the Borrower and the Company	  	18
	 Section 6.2
	 	Exculpation of the Purchasers	  	20
			
	 SECTION 7.
	 	Information as to the Company	  	20
			
	 Section 7.1
	 	Financial and Business Information	  	20
	 Section 7.2
	 	Officer’s Certificate	  	22
	 Section 7.3
	 	Inspection	  	22
	 Section 7.4
	 	Executive Management Access	  	23
			
	 SECTION 8.
	 	Prepayment of the Notes	  	23
			
	 Section 8.1
	 	Required Prepayments	  	23
	 Section 8.2
	 	Optional Prepayments with Make-Whole Amount	  	24
	 Section 8.3
	 	Maturity, Surrender, Etc	  	24
			
	 SECTION 9.
	 	Affirmative Covenants	  	24
			
	 Section 9.1
	 	Compliance with Law	  	24
	 Section 9.2
	 	Insurance	  	25
	 Section 9.3
	 	Maintenance of Properties	  	25
	 Section 9.4
	 	Payment of Taxes and Claims	  	25
	 Section 9.5
	 	Corporate Existence, Etc	  	25
	 Section 9.6
	 	Minimum Cash Balance	  	26
	 Section 9.7
	 	Subsidiary Documentation	  	26
	 Section 9.8
	 	Perfection and Maintenance of Security Interests	  	27
	 Section 9.9
	 	Collateral Locations	  	27
			
	 SECTION 10.
	 	Negative Covenants	  	27
			
	 Section 10.1
	 	Limitations on Indebtedness	  	27
	 Section 10.2
	 	Mergers, Consolidations and Dispositions	  	30
	 Section 10.3
	 	Limitation on Liens	  	31

  

 ii 

					
	 Section 10.4
	 	Restricted Payments	  	31
	 Section 10.5
	 	Subsidiaries, Acquisitions and Investments	  	32
	 Section 10.6
	 	Transactions with Affiliates	  	32
	 Section 10.7
	 	Corporate Documents	  	32
			
	 SECTION 11.
	 	Events of Default	  	33
			
	 SECTION 12.
	 	Remedies on Default, Etc	  	35
			
	 Section 12.1
	 	Acceleration	  	35
	 Section 12.2
	 	Other Remedies	  	36
	 Section 12.3
	 	Certain Remedies as to Collateral	  	36
	 Section 12.4
	 	Appointment of Attorney-in-Fact	  	36
	 Section 12.5
	 	Limitation on Duty of the Collateral Agent with Respect to Collateral	  	37
	 Section 12.6
	 	Application of Proceeds	  	37
	 Section 12.7
	 	License of Intellectual Property	  	37
	 Section 12.8
	 	No Waivers or Election of Remedies, Expenses, Etc	  	38
			
	 SECTION 13.
	 	Registration; Transfer; Substitution of Notes	  	38
			
	 Section 13.1
	 	Registration of Notes	  	38
	 Section 13.2
	 	Transfer of Notes	  	38
	 Section 13.3
	 	Replacement of Notes	  	39
	 Section 13.4
	 	Securitization	  	39
			
	 SECTION 14.
	 	Payments on Notes	  	39
			
	 Section 14.1
	 	Place of Payment	  	39
	 Section 14.2
	 	Home Office Payment	  	39
			
	 SECTION 15.
	 	Expenses, Etc	  	40
			
	 Section 15.1
	 	Fees; Transaction Expenses	  	40
	 Section 15.2
	 	Survival	  	40
			
	 SECTION 16.
	 	Survival of Representations and Warranties; Entire Agreement	  	40
			
	 SECTION 17.
	 	Amendment and Waiver	  	41
			
	 Section 17.1
	 	Requirements	  	41
	 Section 17.2
	 	Solicitation of Holders of Notes	  	41
	 Section 17.3
	 	Binding Effect, Etc	  	41
	 Section 17.4
	 	Notes Held by Company, Etc	  	42
			
	 SECTION 18.
	 	Notices	  	42
			
	 SECTION 19.
	 	Reproduction of Documents	  	42
			
	 SECTION 20.
	 	Confidential Information	  	43
			
	 SECTION 21.
	 	The Collateral Agent	  	44
			
	 Section 21.1
	 	Appointment; Nature of Relationship	  	44
	 Section 21.2
	 	Powers	  	44
	 Section 21.3
	 	General Immunity	  	44
	 Section 21.4
	 	No Responsibility for Loans, Creditworthiness, Collateral, Recitals, Etc	  	44

  

 iii 

					
	 Section 21.5
	  	Action on Instructions of Purchasers	  	45
	 Section 21.6
	  	Employment of Collateral Agents and Counsel	  	45
	 Section 21.7
	  	Reliance on Documents; Counsel	  	45
	 Section 21.8
	  	The Collateral Agent’s Reimbursement and Indemnification	  	45
	 Section 21.9
	  	Rights as a Purchaser	  	46
	 Section 21.10
	  	Successor Collateral Agent	  	46
	 Section 21.11
	  	Collateral Documents	  	46
			
	 SECTION 22.
	  	Miscellaneous	  	47
			
	 Section 22.1
	  	Successors and Assigns	  	47
	 Section 22.2
	  	Payments Due on Non-Business Days	  	47
	 Section 22.3
	  	Headings	  	47
	 Section 22.4
	  	Severability	  	47
	 Section 22.5
	  	Construction	  	48
	 Section 22.6
	  	Counterparts	  	48
	 Section 22.7
	  	Governing Law	  	48
	 Section 22.8
	  	Waiver of Jury Trial	  	48
	 Section 22.9
	  	Indemnity	  	48

  

 iv 

			
	SCHEDULE A	 	—  Information Relating To Purchasers
		
	SCHEDULE B	 	—  Defined Terms
		
	EXHIBIT A	 	—  Form of 15% Senior Secured Note due June 24, 2011
		
	EXHIBIT B	 	—  Form of Warrant to Purchase Series BB Preferred Stock
		
	EXHIBIT 4.2	 	—  List of Closing Deliverables

  

 v 

 Dated as of June 24, 2005 
 TO EACH PURCHASER LISTED ON THE ATTACHED 
     SCHEDULE A WHO IS A SIGNATORY HERETO (COLLECTIVELY WITH
THEIR RESPECTIVE 
     SUCCESSORS AND ASSIGNS,
THE “PURCHASERS”): 
 Ladies and Gentlemen: 
 THIS SENIOR SECURED NOTE AND WARRANT PURCHASE
AGREEMENT (this “Agreement”) is hereby entered into by and among the Purchasers, JAZZ PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and
TWIST MERGER SUB, INC., a Delaware corporation (the “Borrower”), with reference to the following: 
  

	 	A.	The Company has informed the Purchasers that the Company intends to acquire Orphan Medical, Inc., a Delaware corporation (“Orphan Medical”), by way of the merger
(the “Merger”) of the Borrower, a wholly-owned subsidiary of the Company, with and into Orphan Medical, with Orphan Medical becoming the surviving corporation, all pursuant to that certain Agreement and Plan of Merger by and among
Orphan Medical, the Company and the Borrower, dated April 18, 2005, as amended (the “Merger Agreement”). 

  

	 	B.	The Purchasers have agreed, subject to the terms and conditions hereof, to furnish debt financing to the Borrower by way of the purchase of the Borrower’s senior secured notes
in order to provide the Company with a portion of the necessary cash required to consummate the Merger and pay for transaction costs associated therewith. 

  

	 	C.	Under the terms of the Merger Agreement, all of the properties, rights, privileges, powers and franchises of Orphan Medical shall vest in and all of the debts, liabilities and
duties (including the obligations and duties of the Borrower hereunder) shall be assumed by the Surviving Corporation (as defined in the Merger Agreement). 

  

	 	D.	Certain capitalized terms used in this Agreement are defined in Schedule B; references to a “Schedule” or an “Exhibit” are, unless otherwise
specified, to a Schedule or an Exhibit attached to this Agreement. All references to the Borrower in this Agreement shall be deemed to include the Borrower both before and after taking into account the effect of the Merger such that the
Borrower shall mean and include the Surviving Corporation (as defined in the Merger Agreement) and any reference to a Subsidiary of the Company shall mean and include the Borrower and any Subsidiary of the Borrower. 

  

 1 

 NOW THEREFORE, the Purchasers, the Company and the Borrower hereby agree as
follows: 
 SECTION 1. AUTHORIZATION, SALE AND ISSUANCE OF NOTES
AND WARRANTS. 
 Section 1.1 Authorization 
 (a) The Borrower has authorized the issue and sale of $80,000,000 aggregate principal amount of its 15% Senior Secured Notes (the
“Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13 of this Agreement) due June 24, 2011. The Notes shall be substantially in the form set forth on
Exhibit A. 
 (b) The Company has further authorized the issuance and sale to each Purchaser of Warrants (the
“Warrants”, such term to include any such warrants issued in substitution therefor pursuant to the terms thereof) to purchase Series BB Preferred Stock, par value $0.0001 per share, of the Company (“BB Preferred”),
each substantially in the form set forth in Exhibit B. 
 Section 1.2 Sale and Purchase of the Notes and Warrants. Subject
to the terms and conditions of this Agreement, at the Closing provided in Section 1.3: 
 (a) The Borrower hereby
agrees to issue and sell to each Purchaser and each Purchaser agrees to purchase from the Company on the date of the Closing, a Note in the aggregate principal amount set forth opposite such Purchaser’s name on Schedule A attached hereto
at a purchase price of 100% of the aggregate principal amount of such Note. Each Purchaser’s obligation hereunder is several and not joint with the other Purchasers’ obligations such that no Purchaser shall have any obligation or liability
to any Person for the performance or nonperformance by any other Purchaser hereunder. 
 (b) As further consideration for the
purchase of the Notes by the Purchasers pursuant to Section 1.2(a), and with the Company’s express acknowledgement of its direct and indirect benefit received in connection with such financial accommodations, the Company agrees to
issue and deliver to each Purchaser, at the Closing, a Warrant to purchase that number of shares of the BB Preferred set forth opposite such Purchaser’s name on Schedule A attached hereto. 
 (c) The Borrower, the Company and each Purchaser hereby acknowledge and agree that the Note and Warrant issued in accordance with this
Agreement constitute an “investment unit” for the purposes of Section 1273(c)(2)(A) of the Code. In accordance with Sections 1273(c)(2)(A) and 1273(b)(2) of the Code, the issue price of the investment unit is 100% of the aggregate
principal amount of the Note set forth opposite each such Purchaser’s name on Schedule A. Allocating that issue price between the Note and Warrant based on their relative fair market values, as required by Section 1273(c)(2)(B) of
the Code and Treasury Regulation Section 1.1273-2(h)(1), results in (i) the Note having an issue price of 93.30% of the aggregate principal amount of such Note and (ii) the Warrant having a purchase price of 6.70% of the aggregate
principal amount of such Note. The Borrower, the Company and each Purchaser agrees to prepare their respective federal income tax returns in a manner consistent with the foregoing agreement. 
  

 2 

 Section 1.3 Closing. The sale and issuance of the Notes and Warrants shall occur at a closing
(the “Closing”) at the offices of the Company, 3180 Porter Drive, Palo Alto, California 94304 at 10:00 a.m. local time on June 24, 2005 or on such other Business Day thereafter as may be agreed upon by the Company and the
Purchasers. At the Closing: 
 (a) The Borrower will deliver to or at the direction of each Purchaser a Note to be purchased
thereby in the form of a single Note dated the date of the Closing and registered in such Purchaser’s name, against delivery by such Purchaser to the Borrower or its order of immediately available funds in the amount of the purchase price
therefor by wire transfer to the account of the Paying Agent (as defined in the Merger Agreement), held in the name and for the benefit of the Borrower, identified in writing by the Company prior to the Closing. 
 (b) The Company will deliver to or at the direction of each Purchaser a Warrant dated the date of the Closing and registered in the name
of such Purchaser, and evidencing the right of such Purchaser to purchase that number of shares of the Company’s BB Preferred set forth opposite such Purchaser’s name on Schedule A. 
 Section 1.4 Payment Terms of the Notes. The Notes shall bear interest, in the amounts and payable at the times set forth therein, and shall
be due and payable in full on the maturity date set forth therein or as otherwise provided for under this Agreement without defense, set off or counterclaim of any sort. All payments required to be made under the Notes shall be made in the manner
and to the account of each Purchaser as set forth in the Notes. 
 SECTION 2. COMPANY GUARANTY. 
 Section 2.1 Background. The Company hereby acknowledges and affirms that, as the sole beneficial owner of all of the capital stock of the
Borrower, it will directly or indirectly receive certain benefits from the credit accommodations provided for under this Agreement and is therefore willing to guaranty the prompt payment and performance of the Obligations of the Borrower, on the
terms set forth in this Section 2. 
 Section 2.2 Company Guaranty. For value received and in consideration for the
Purchasers’ execution of this Agreement and the purchase of the Notes, the Company unconditionally guarantees (a) the full and prompt payment when due, whether at maturity or earlier, by reason of acceleration or otherwise, and at all
times thereafter, of all of the indebtedness and obligations of every kind and nature of the Borrower to each Purchaser, or any permitted assignee of any Purchaser, pursuant to the terms of this Agreement and the other Related Documents, howsoever
created, arising or evidenced, whether direct or indirect, absolute or contingent, joint or several, now or hereafter existing, or due or to become due, and howsoever owned, held or acquired by such Purchaser, whether through discount, premium,
purchase, direct loan or as collateral or otherwise, and whether principal, interest, fees, costs, expenses or otherwise (including without limitation any interest, Make-Whole Amount, fees or expenses accruing following the commencement of any
insolvency, receivership, reorganization or bankruptcy case or proceeding relating to the Borrower, whether or not a claim for post-petition interest, Make-Whole Amount, fees or expenses is allowed in such case or proceeding); and (b) the
prompt, full and faithful discharge by the Borrower of each and every term, 

  

 3 

 
condition, agreement, representation and warranty now or hereafter made by the Borrower to the Purchasers under this Agreement and the other Related
Documents (all such indebtedness and obligations listed in (a) and (b) of this sentence being hereinafter referred to as the “Obligations”). The Company further agrees to pay all reasonable out-of-pocket costs and
expenses, including, without limitation, all court costs and reasonable attorneys’ fees paid or incurred by any Purchaser in collecting all or any part of the Obligations from, or in prosecuting or defending any action against, the Company. All
amounts payable by the Company under this Section 2 shall be payable upon demand and shall be made in lawful money of the United States, in immediately available funds. 
 Section 2.3 No Fraudulent Conveyance. It is intended that the Company’s guaranty under this Section 2 (the “Company
Guaranty”), and any Liens granted by the Company to secure the Company Guaranty, do not constitute a “Fraudulent Conveyance” (as hereinafter defined). Consequently, the Company agrees that if the Company Guaranty, or any Liens
securing the Company Guaranty, would, but for the application of this sentence, constitute a Fraudulent Conveyance, the Company Guaranty and each such Lien shall be valid and enforceable only to the maximum extent that would not cause the Company
Guaranty or such Lien to constitute a Fraudulent Conveyance, and the Company Guaranty or the other Related Documents providing for such Lien shall automatically be deemed to have been amended accordingly at all relevant times. For purposes hereof,
“Fraudulent Conveyance” means a fraudulent conveyance under Section 548 of the Bankruptcy Code or a fraudulent conveyance or fraudulent transfer under the provisions of any applicable fraudulent conveyance or fraudulent
transfer law or similar law of any state, nation or other governmental unit, as in effect from time to time. 
 Section 2.4
Unconditional Guaranty. The Company hereby agrees that its obligations under the Company Guaranty shall be unconditional, irrespective of (i) the validity or enforceability of the Obligations or any part thereof, or of any Notes, Related
Documents or other document evidencing all or any part of the Obligations, (ii) the absence of any attempt to collect from the Borrower or any other guarantor of all or any part of the Obligations or other action to enforce the same,
(iii) the waiver or consent by any Purchaser with respect to any provision of any instrument evidencing the Obligations, or any part thereof, or any other agreement heretofore, now or hereafter executed by the Borrower or any other guarantor of
all or any part of the Obligations, and delivered to such Purchaser, (iv) failure by any Purchaser or the Collateral Agent to take any steps to perfect and maintain its security interest in, or to preserve its rights to, any security or
collateral for the Obligations or any guaranty, (v) the existence or nonexistence of any defenses which may be available to the Borrower or any other guarantor of all or any part of the Obligations, (vi) the institution of any proceeding
under Chapter 11 of Title 11 of the United States Code (11 U.S.C. § 101 et seq.), as amended (the “Bankruptcy Code”), or any similar proceeding, by or against the Borrower or any other guarantor, or any Purchaser’s
election in any such proceeding of the application of Section 1111(b)(2) of the Bankruptcy Code, (vii) any borrowing or grant of a security interest by the Borrower, as debtor-in-possession, under Section 364 of the Bankruptcy Code
(or use of cash collateral under Section 363 of the Bankruptcy Code), (viii) the disallowance, under Section 502 of the Bankruptcy Code, of all or any portion of the Purchasers’ claim(s) for repayment of the Obligations, or
(ix) any other circumstance which might otherwise constitute a legal or equitable discharge or defense of a guarantor other than the indefeasible payment in full of all Obligations. 
  

 4 

 Section 2.5 Waiver. The Company hereby waives diligence, presentment, demand of payment,
filing of claims with a court in the event of receivership or bankruptcy of the Borrower or other guarantors, protest or notice with respect to the Obligations and all demands whatsoever, and covenants that the Company Guaranty will not be
discharged, except by complete and indefeasible payment and performance of the Obligations. The Company further waives notice of (i) acceptance of the Company Guaranty, (ii) the existence or incurring from time to time of any Obligations
guarantied hereunder, and (iii) the existence of any Default or Event of Default, the making of demand, nonpayment, or the taking of any action by any Purchaser or the Collateral Agent, under this Agreement or any of the other Related
Documents. At any time that the Notes become due and payable, whether by maturity or acceleration, any holder of a Note may, in its sole election (regardless of whether the liability of Borrower or any other guarantor of all or any part of the
Obligations has matured or may then be enforced), proceed directly and at once, without notice, against the Company to collect and recover the full amount or any portion of the Obligations, without first proceeding against the Borrower or any other
guarantor, or against any security or collateral for the Obligations. The Company agrees that the Company Guaranty constitutes a guarantee of payment when due and not of collection. 
 Section 2.6 Authorization. The Purchasers and the Collateral Agent are hereby authorized, without notice or demand and without affecting the
liability of the Company hereunder, at any time and from time to time to (i) renew, extend, accelerate or otherwise change the time for payment of, or other terms relating to, the Obligations or otherwise modify, amend or change the terms of
this Agreement, any Note or any other Related Document (subject to the terms hereof and thereof), now or hereafter executed by the Borrower, the Company or any other guarantor and delivered to any of the Purchasers; (ii) accept partial payments
on the Obligations; (iii) take and hold security or collateral for the payment of the Obligations guaranteed hereby, or for the payment of the Company Guaranty, or for the payment of any other guaranties of the Obligations, and exchange,
enforce, waive and release any such security or collateral; (iv) apply such security or collateral and direct the order or manner of sale or other disposition thereof as in its discretion it may determine; and (v) settle, release,
compromise, collect or otherwise liquidate the Obligations and any security or collateral therefor in any manner, without affecting or impairing the obligations of the Company hereunder. 
 Section 2.7 Responsibility. The Company hereby assumes responsibility for keeping itself informed of the financial condition of the Borrower
and any and all endorsers and/or other guarantors of any instrument or document evidencing all or any part of the Obligations and of all other circumstances bearing upon the risk of nonpayment of the Obligations or any part thereof, and the Company
hereby agrees that neither the Purchasers nor the Collateral Agent shall have any duty to advise the Company of information known to any Purchaser or the Collateral Agent regarding such condition or any such circumstances or to undertake any
investigation. If any of the Purchasers or the Collateral Agent, each in their respective discretion, undertakes at any time or from time to time to provide any such information to the Company, such Purchaser or the Collateral Agent, as applicable,
shall be under no obligation to update any such information or to provide any such information to the Company on any subsequent occasion. The Company further acknowledges that the Company has examined or had the opportunity to examine this Agreement
and the other Related Documents, and waives any defense which may exist resulting from the Company’s failure to receive or examine at any time this Agreement or the other Related Documents. 
  

 5 

 Section 2.8 Consent. The Company consents and agrees that none of the Purchasers or the
Collateral Agent shall be under any obligation to marshal any assets in favor of the Company or against or in payment of any or all of the Obligations. The Company further agrees that, to the extent that the Borrower, the Company or any other Person
makes a payment or payments to the Purchasers, or any Purchaser receives any proceeds of collateral, which payment or payments or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside and/or required to
be repaid to the Borrower, its estates, trustees, receivers or any other Person, including, without limitation, the Company, under any bankruptcy law, state or federal law, common law or equitable theory, then to the extent of such payment or
repayment, the Obligations or the part thereof which has been paid, reduced or satisfied by such amount, and the Company’s obligations hereunder with respect to such portion of the Obligations, shall be reinstated and continued in full force
and effect as of the date such initial payment, reduction or satisfaction occurred. 
 Section 2.9 Transfer. Subject to the
provisions of Section 13, any Purchaser may sell or assign the Obligations or any part thereof, or grant participations therein, pursuant to the terms of this Agreement and in any such event, each and every immediate or remote assignee
or holder of, or participant in, all or any of the Obligations shall have the right to enforce the Company Guaranty, by suit or otherwise, for the benefit of such assignee, holder or participant, as fully as if herein by name specifically given such
right, but each Purchaser shall have an unimpaired right, prior and superior to that of any such assignee, holder or participant, to enforce the Company Guaranty for the benefit of such Purchaser, as to any part of the Obligations retained by such
Purchaser. 
 Section 2.10 Continuation. The Company Guaranty shall continue in full force and effect (and may not be revoked or
terminated), and the Purchasers shall be entitled to purchase the Notes on the faith hereof, until such time as all of the Obligations have been indefeasibly paid and satisfied in full. 
 Section 2.11 Subrogation. Any and all rights of any nature of the Company to subrogation, contribution, reimbursement or indemnity and any
right of the Company to recourse to any assets or property of, or payment from, the Borrower or any other guarantor of all or any part of the Obligations as a result of any payments made or to be made hereunder for any reason, are hereby
unconditionally waived by the Company, and the Company shall not at any time exercise any of such rights unless and until all of the Obligations have been indefeasibly paid and satisfied in full. Any payments received by the Company in violation of
this Section 2.11 shall be held in trust for, and immediately remitted to, the Purchasers. 
 Section 2.12 Subordination.
The payment of any and all of indebtedness, liabilities and obligations of Borrower to the Company of every kind or nature, whether joint or several, due or to become due, absolute or contingent, now existing or hereafter arising, and whether
principal, interest, fees, costs, expenses or otherwise (collectively, the “Subordinated Debt”), is expressly subordinated to the Obligations. So long as an Event of Default exists, no payment of any kind (by voluntary payment,
prepayment, acceleration, setoff or otherwise) of any portion of the Subordinated Debt may be made by Borrower or received or accepted by the Company at any time. Until such time as the Obligations have been indefeasibly paid and satisfied in full,
the Company will not (i) obtain any Lien on any property of the Borrower to secure the 

  

 6 

 
Subordinated Debt, or (ii) commence any lawsuit, action or proceeding of any kind against the Borrower to recover all or any part of the Subordinated
Debt. Any payments received by the Company in violation of this Section 2.12 shall be held in trust for and immediately remitted to the Purchasers. 
 SECTION 3. SECURITY INTERESTS. 
 Section 3.1 Grant of Security Interests. To secure the
full and prompt payment and performance of the Obligations and the Company Guaranty, including all renewals, extensions, restructurings and refinancings of any or all of the foregoing, each of the Borrower and the Company hereby grants to the
Collateral Agent, for the benefit of the holders of the Notes, a continuing Lien in and to all right, title and interest of Borrower and the Company in the following property, respectively, of the Borrower and the Company, whether now owned or
existing or hereafter acquired thereby or arising and regardless of where located, including the products and proceeds thereof (all being collectively referred to as the “Collateral”): 
  

							
		 	i)	 	Accounts;	  	
		 	 ii)
	 	Deposit Accounts (as defined in the UCC);
		 	 iii)
	 	Documents of Title;	  	
		 	 iv)
	 	Equipment;	  	
		 	 v)
	 	General Intangibles;	  	
		 	 vi)
	 	Inventory;	  	
		 	 vii)
	 	Investment Property; and	  	
		 	 viii)
	 	Other Collateral;	  	

 provided, however, that notwithstanding any of the other provisions set forth in this
Section 3, this Agreement shall not constitute a grant of a security interest in (a) any ownership interests of any Foreign Subsidiary or (b) any property to the extent that such grant of a security interest is prohibited by
any requirements of law of a Governmental Authority, requires a consent not obtained of any Governmental Authority pursuant to such requirement of law or is prohibited by, or constitutes a breach or default under or results in the termination of or
requires any consent not obtained under, any contract, license, agreement, instrument or other document evidencing or giving rise to such property or any applicable shareholder or similar agreement, except to the extent that such requirement of law
or the term in such contract, license, agreement, instrument or other document or shareholder or similar agreement providing for such prohibition, breach, default or termination or requiring such consent is ineffective under applicable law.

 Section 3.2 Perfection of Security Interests. Each of the Borrower and the Company hereby authorizes the Collateral Agent to
prepare and file such financing statements or amendments thereof (including financing statements and amendments thereof describing the Collateral as “all assets” or “all personal property” or words to that effect) as the
Collateral Agent or the Purchasers may from time to time deem necessary or appropriate in order to perfect and maintain the security interests granted hereunder in accordance with the UCC or the Uniform Commercial Code of any applicable
jurisdiction. Each of the Borrower and the Company shall, at the Collateral Agent’s request, at any time and from time to time, execute and deliver to the Collateral Agent within ten (10) Business Days of such request, such documents and
other agreements and instruments (and pay the cost of filing or recording the same in all public offices 

  

 7 

 
deemed reasonably necessary or desirable by the Collateral Agent or the Purchasers) and do such other acts and things as the Collateral Agent may deem
necessary or desirable in order to establish and maintain a valid, attached and perfected security interest in the Collateral in favor of the Collateral Agent for the benefit of the Purchasers (free and clear of all other liens, claims and rights of
third parties whatsoever, whether voluntarily or involuntarily created, except as otherwise permitted by Section 10.3) to secure payment of the Obligations, and in order to facilitate the collection of the Collateral. Each of the
Borrower and the Company irrevocably hereby makes, constitutes and appoints the Collateral Agent (and all Persons designated by the Collateral Agent for that purpose) as the Borrower’s and the Company’s respective true and lawful attorney
and agent-in-fact to file such financing statements and other similar documents, agreements and instruments as may be necessary to preserve and perfect the Collateral Agent’s security interest in the Collateral. Each of the Borrower and the
Company acknowledges and agrees that the Collateral is intended to encompass all assets and property of Borrower and the Company (subject to the terms and conditions of this Agreement) and if at any time Borrower or the Company acquires any interest
in any assets or property a security interest in which cannot be perfected by the filing of a financing statement in the appropriate jurisdiction or any assets or property a security interest in which can be perfected by the filing of a financing
statement in the appropriate jurisdiction but that are not covered by the security interest grant set forth above (e.g., commercial tort claims, it being certified by Borrower or the Company that it has no interest in any commercial tort claims as
of the Closing), then the Borrower or the Company, as appropriate, will, if reasonably requested by the Collateral Agent, cause such assets or property to become part of the Collateral and take such reasonable steps as the Collateral Agent or the
Purchasers may require in accordance with this Section 3.2. Each of the Borrower and the Company hereby agree to give the Collateral Agent prompt notice of any commercial tort claim filed by the Company or any of its subsidiaries.

 Section 3.3 Possession of Collateral and Related Matters. Until an Event of Default has occurred and is continuing, both of
the Borrower and the Company shall have the right, except as otherwise provided in this Agreement, to (a) sell or lease any of their Inventory normally held thereby for any such purpose, (b) use and consume any raw materials, work in
process or other materials normally held thereby for such purpose and (c) dispose of any assets to the extent permitted under Section 10.2. If any Inventory is in the possession or control of any warehouseman or the Company’s
or the Borrower’s, as applicable, agents or processors, then the Borrower or the Company, as applicable, shall, upon the Collateral Agent’s request, notify such warehouseman, agent or processor of the Collateral Agent’s security
interest in such Inventory and, upon the Collateral Agent’s request, instruct them to hold all such Inventory for the Collateral Agent’s account and subject to the Collateral Agent’s instructions. 
 Section 3.4 Continuing Security Interest; Termination. 
 (a) This Section 3 creates a continuing security interest in the Collateral and shall (i) remain in full force and effect
until the payment or satisfaction in full of the Obligations (other than any contingent indemnity obligations), (ii) be binding upon the Borrower and the Company, and their respective successors and assigns and (iii) except to the extent
that the rights of any transferor or assignor are limited by the terms of this Agreement, inure, together with the rights and remedies of the Collateral Agent, to the benefit of the Collateral Agent and the holders of Notes. The Borrower’s and
the Company’s successors and assigns shall include, without limitation, a receiver, trustee or debtor-in possession thereof or therefor. 
  

 8 

 (b) Upon the payment in full in cash of the Obligations (other than any contingent
indemnity obligations), the security interests granted pursuant to this Section 3 shall terminate and all rights to the Collateral shall revert to the Borrower and the Company, as applicable. Upon any such termination of the security
interests hereunder, the Borrower and the Company shall each be entitled to the return, upon its request and at its expense, of such of the Collateral held by the Collateral Agent as shall not have been sold or otherwise applied pursuant to the
terms hereof and the Collateral Agent will, at the Borrower’s and the Company’s expense, execute and deliver to the Borrower or the Company, as applicable such other documents as they shall reasonably request to evidence such termination.
In connection with any transfers, sales or other dispositions of assets permitted under this Agreement or any other release of Collateral that may be required in connection with any other action which is permitted by this Agreement, the Collateral
Agent will release and terminate the Liens granted under this Agreement with respect to such assets. 
 SECTION 4. CONDITIONS
TO CLOSING. 
 Each Purchaser’s obligation to purchase and pay for the Notes to be sold thereto at the
Closing is subject to the fulfillment to such Purchaser’s reasonable satisfaction, prior to or at the Closing, of the following conditions: 
 Section 4.1 Consummation of the Merger. All conditions necessary to consummate the Merger under the Merger Agreement shall have been satisfied or waived (provided that if such waiver is material it shall have been in a manner
approved by the Purchasers), the parties to the Merger Agreement shall be prepared to consummate the Merger on the date of the Closing simultaneously with the purchase of the Notes, and each Purchaser shall have received evidence of the foregoing
reasonably satisfactory to it. 
 Section 4.2 Closing Deliveries. The Purchasers shall have received, in form and substance
reasonably satisfactory to the Purchasers, all documents, instruments, agreements, opinions and certificates identified on Exhibit 4.2. 
 Section 4.3 Additional Equity Financing. The Company shall have received during the period from April 18, 2005, up and including the date of the Closing, at least $99,999,998 (a) in gross investment proceeds by way of
the issuance of additional shares of Series B Preferred Stock of the Company or (b) in cash proceeds from specific product development financing arrangements and each Purchaser shall have received evidence of the foregoing reasonably
satisfactory to it 
 Section 4.4 Security Interests; Indebtedness; Waivers and Consents. 
 (a) The Purchasers shall have received the results of recent lien, tax lien, judgment and litigation searches in each relevant
jurisdiction with respect to the Company and the Borrower (including, for the avoidance of doubt, as to Orphan Medical prior to the Merger) and their respective Subsidiaries, and such searches shall reveal no 

  

 9 

 
Liens other than Permitted Liens or Liens that are being discharged on or prior to the consummation of the Closing pursuant to documentation reasonably
satisfactory to the Purchasers. 
 (b) All outstanding Indebtedness of the Company and the Borrower (including, for the
avoidance of doubt, Indebtedness of Orphan Medical prior to the Merger) and their respective Subsidiaries, other than Permitted Indebtedness, shall have been paid in full or otherwise discharged, all documents evidencing such Indebtedness shall have
been terminated and be of no further force and effect, in each case pursuant to documentation reasonably satisfactory to the Purchasers, and each Purchaser shall have received evidence of the foregoing reasonably satisfactory to it. 
 (c) All waivers, approvals or consents of Governmental Authorities or other third parties as may be required by law or under contract to
consummate the Merger and the transactions contemplated by this Agreement (including any necessary stockholder agreements, consents or waivers required in connection with the issuance of the Warrants) shall have been obtained (except as otherwise
permitted by the Merger Agreement) and each Purchaser shall have received evidence of the foregoing reasonably satisfactory to it. 
 Section 4.5 Fees and Expenses. The Company or the Borrower shall have paid the fees, expenses and other amounts payable to KKR Financial Corp. and LB I Group Inc., or on their behalf, upon the Closing as provided pursuant to the
Commitment Letter (including the Term Sheet attached thereto, the “Commitment Letter”) dated April 18, 2005 delivered by KKR Financial Corp. and LB I Group Inc. and agreed and accepted by the Company, such fees and expenses to
include reimbursement of legal counsel to the Purchasers as provided under the Commitment Letter. 
 Section 4.6 Representations and
Warranties. At the time of the Closing both before and after taking into account the effect of the Merger, the representations and warranties of the Company and the Borrower in this Agreement and the Related Agreements, which are qualified by
their terms as to Materiality, shall be correct and all other representations and warranties of the Company and the Borrower in this Agreement and the Related Agreements shall be correct in all material respects. 
 Section 4.7 Performance; No Default. Each of the Company and the Borrower shall have performed and complied with all agreements and
conditions contained in this Agreement required to be performed or complied with by it prior to or at the Closing, and after giving effect to the issue and sale of the Notes (and the application of the proceeds thereof as contemplated by
Schedule 5.14), the issue of the Warrants and the consummation of the Merger, no Default or Event of Default shall have occurred and be continuing. 
 Section 4.8 No Material Adverse Effect. Nothing has occurred since April 18, 2005, which could reasonably be expected to have a Material Adverse Effect (solely for this purpose, as such term is
defined in the Merger Agreement). 
  

 10 

 SECTION 5. REPRESENTATIONS AND WARRANTIES OF
THE COMPANY AND THE BORROWER. 
 Each of the Company and the
Borrower represents and warrants, jointly and severally, to the Purchasers that, as of the date hereof and at the Closing, both before and after giving effect to the Merger: 
 Section 5.1 Organization; Power and Authority. Each Credit Party is a corporation duly organized, validly existing and in good standing under
the laws of its jurisdiction of incorporation, and is duly qualified as a foreign corporation and is in good standing in each jurisdiction in which such qualification is required by law, other than those jurisdictions as to which the failure to be
so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Each Credit Party has the corporate power and authority to own or hold under lease the properties it purports to
own or hold under lease, to transact the business it transacts and proposes to transact, to execute and deliver this Agreement and/or the other Related Documents to which it is a party, and to perform the provisions hereof and thereof. 

Section 5.2 Authorization, Etc. This Agreement and the other Related Documents, and in the case of the Borrower, the borrowing under the
Notes, have been duly authorized by all necessary corporate action on the part of each Credit Party signatory thereto, and this Agreement and such other Related Documents each constitutes, and upon execution and delivery thereof, will constitute, a
legal, valid and binding obligation of the each such Credit Party, as applicable, enforceable against such Credit Party, respectively, in accordance with its terms, except as such enforceability may be limited by (a) applicable bankruptcy,
insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and (b) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity
or at law). 
 Section 5.3 Disclosure. This Agreement, the documents, certificates or other writings delivered to the Purchasers
by or on behalf of the Company and the Borrower in connection with the transactions contemplated hereby and the financial statements listed in Schedule 5.5, taken as a whole, do not contain any untrue statement of a material fact or omit
to state any fact necessary to make the statements therein not materially misleading in light of the circumstances under which they were made. Since December 31, 2004, there has been no change in the financial condition, operations, business or
properties of the Company, the Borrower and any of their respective Subsidiaries, taken as a whole, except changes that individually or in the aggregate would not reasonably be expected to have a Material Adverse Effect. There is no fact known to
the Company or the Borrower that would reasonably be expected to have a Material Adverse Effect that has not been set forth herein or in the other documents, certificates and other writings delivered to the Purchasers by or on behalf of the Company
or the Borrower specifically for use in connection with the transactions contemplated hereby. 
 Section 5.4 Capitalization;
Subsidiaries. 
 (a) The authorized capital stock of the Company consists of: 
  

 11 

 (i) 308,236,575 shares of Preferred Stock, with a par value of $0.0001, of which
(A) 15,000,000 shares are designated as Series A Preferred Stock, all of which are issued and outstanding, (B) 189,205,047 shares are designated as Series B Preferred Stock, 52,801,406 of which are issued and outstanding,
(C) 95,335,876 shares are designated as Series B Prime Preferred Stock, 57,201,526 of which are issued and outstanding, and (D) 8,695,652 shares are designated as Series BB Preferred Stock, none of which are issued and outstanding and all
of which are reserved for issuance upon the exercise of all the Warrants issued pursuant to and under this Agreement. All issued and outstanding shares of Preferred Stock have been duly and validly issued and are fully paid and nonassessable.

 (ii) 252,716,057 shares of Common Stock, of which 6,839,171 shares have been duly and validly issued and are fully paid and
nonassessable. 
 (iii) The Company has reserved: (A) 189,205,047 shares of its Series B Preferred Stock and 95,335,876
shares of it Series B Prime Preferred Stock for issuance pursuant to the terms of the Preferred Stock Purchase Agreement of the Company dated as of January 27, 2004; (B) 8,695,652 shares of its Series BB Preferred Stock for issuance upon
the exercise of the Warrants; (C) 197,900,699 shares of Common Stock upon conversion of its Preferred Stock; (D) 23,517,858 shares of Common Stock for issuance under the Company’s 2003 Equity Incentive Plan, of which 395,000 shares
have been issued upon the exercise of options. Options to purchase 14,760,445 shares of Common Stock have been granted under the Company’s 2003 Equity Incentive Plan. Except for the Warrants (as defined herein), as provided for under that
certain Second Amended and Restated Investor Rights Agreement dated as of June 24, 2005 by and among the Company, the investors in the Company’s Series A Preferred Stock, Series B Preferred Stock and Series B Prime Preferred Stock, the
holders of the Warrants and certain holders of Common Stock and as otherwise set forth above, there are no outstanding rights of first refusal, preemptive rights, phantom stock, stock appreciation rights or other rights, warrants, options,
conversion privileges, subscriptions, or other rights or agreements, either directly or indirectly, to purchase or otherwise acquire or issue any equity securities of the Company. 
 (b) The Company has no direct Subsidiaries other than the Borrower. Schedule 5.4 includes a complete and correct list of the
authorized and issued and outstanding capital stock of the Borrower both before and after giving effect to the Merger. All of the outstanding shares of capital stock of the Borrower are validly issued and outstanding and fully paid and nonassessable
and all such shares are owned by the Company free and clear of all Liens other than Permitted Liens. There are no outstanding commitments or other obligations of the Borrower to issue, and no options, warrants or other rights of any Person to
acquire, any shares of any class of capital stock or other equity interests of the Borrower. 
 (c) After giving effect to the
Merger, the Borrower has no Subsidiaries other than Orphan Medical Europe Limited, a company formed under the laws of England and 

  

 12 

 
Wales (“Orphan Sub”). Schedule 5.4 includes a complete and correct list of the authorized and issued and outstanding share
capital of Orphan Sub. All of the outstanding share capital of Orphan Sub has been validly issued and outstanding and fully paid and nonassessable and all such share capital is owned by the Borrower free and clear of all Liens other than Permitted
Liens. There are no outstanding commitments or other obligations of Orphan Sub to issue, and no options, warrants or other rights of any Person to acquire, any share capital or other equity interests of Orphan Sub. Orphan Sub does not have and never
had any assets, employees or ongoing business operations. 
 Section 5.5 Financial Statements. The Company has delivered to each
Purchaser copies of the financial statements of the Company and its Subsidiaries listed on Schedule 5.5. All of said financial statements (including in each case the related schedules and notes) fairly present in all material respects
the consolidated financial position of the Company and its Subsidiaries as of the respective dates specified in such financial statements and the consolidated results of their operations and cash flows for the respective periods so specified and
have been prepared in accordance with GAAP consistently applied throughout the periods involved except as set forth in the notes thereto (subject, in the case of any interim financial statements, to normal year-end adjustments). 
 Section 5.6 Compliance with Laws, Other Instruments, Etc. The execution, delivery and performance by each Credit Party of the Related
Documents to which each such Credit Party is a party, including the Notes, in the case of the Borrower, and the Warrants, in the case of the Company, will not violate, contravene, result in any breach of, or constitute a default under, or result in
the creation of any Lien (other than Liens permitted by Section 10.3) in respect of any property of such Credit Party under, (a) any indenture, mortgage, deed of trust, loan, purchase or credit agreement, lease, corporate charter or
by-laws, or any other agreement or instrument to which any Credit Party is bound or by which any Credit Party or any of their respective properties may be bound or affected, (b) any of the terms, conditions or provisions of any order, judgment,
decree, or ruling of any court, arbitrator or Governmental Authority applicable to any Credit Party or (c) any statute or other rule or regulation of any Governmental Authority applicable to any Credit Party, in each case, except to the extent
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 5.7 Governmental
Authorizations, Etc. Except as disclosed in Schedule 5.7, no consent, approval or authorization of, or registration, filing or declaration with, any Governmental Authority is required in connection with the execution, delivery or
performance by each Credit Party of the Related Documents to which each such Credit Party is a party, including the Notes, in the case of the Borrower, and the Warrants, in the case of the Company. 
 Section 5.8 Litigation; Observance of Agreements, Statutes and Orders. 
 (a) Except as disclosed in Schedule 5.8, there are no actions, suits or proceedings pending or, to the knowledge of the
Company or the Borrower, threatened against or affecting any Credit Party or the property of any Credit Party in any court or before any arbitrator of any kind or before or by any Governmental Authority that, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect. 
  

 13 

 (b) No Credit Party is in default under any term of any agreement or instrument to which
it is a party or by which it is bound, or any order, judgment, decree or ruling of any court, arbitrator or Governmental Authority or is in violation of any applicable law, ordinance, rule or regulation (including without limitation Environmental
Laws) of any Governmental Authority, which default or violation, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 
 Section 5.9 Taxes. Each Credit Party has filed all tax returns that are required to have been filed by it in any jurisdiction, and has paid all taxes shown to be due and payable on such returns and all
other taxes and assessments levied upon it or its properties, assets, income or franchises, to the extent such taxes and assessments have become due and payable and before they have become delinquent, except for any taxes and assessments
(a) the amount of which is not individually or in the aggregate Material or (b) the amount, applicability or validity of which is currently being contested in good faith by appropriate proceedings and with respect to which such Credit
Party has established adequate reserves in accordance with GAAP. The charges, accruals and reserves on the books of the Borrower and the Company and their Subsidiaries in respect of Federal, state or other taxes for all fiscal periods are adequate.
Except as disclosed in Schedule 5.9, the Federal income tax liabilities of the Borrower, the Company and their respective Subsidiaries have been determined and paid for all fiscal years up to and including the fiscal year ended
December 31, 2004. 
 Section 5.10 Title to Property; Leases. The Credit Parties have good and sufficient title to their
respective properties that individually or in the aggregate are Material, including all such properties reflected in the most recent audited balance sheets referred to in Section 5.5 or purported to have been acquired by the Credit
Parties after said date (except as sold or otherwise disposed of in the ordinary course of business), in each case free and clear of Liens prohibited by this Agreement. All leases entered into by a Credit Party that individually or in the aggregate
are Material are valid and subsisting and are in full force and effect in all material respects. 
 Section 5.11 Intellectual
Property, Licenses, Permits, Etc. 
 (a) Schedule 5.11 sets forth all of the Credit Parties’ patents and
patent applications, in-bound patent licenses, trademarks and trademark applications, in-bound trademark licenses, copyrights and copyright applications and in-bound copyright licenses, including the description thereof, the name of the registered
owner, the jurisdiction of such registration and the registration number (collectively, the “IP Rights”). 
 (b) Except as disclosed in Schedule 5.11, to the Knowledge of the Company: 
 (i) the Company and its
Subsidiaries own or possess the IP Rights, without known conflict with the rights of others; 
 (ii) no Product of the Company
or its Subsidiaries infringes in any Material respect any license, patent, copyright, service mark, trademark, trade name or other intellectual property right owned by any other Person; and 
  

 14 

 (iii) there is no Material violation by any Person of any right of the Company or any of
its Subsidiaries with respect to any IP Rights. 
 Section 5.12 Compliance with ERISA. 
 (a) The Company and each ERISA Affiliate have operated and administered each Plan in compliance with all applicable laws except for such
instances of noncompliance as have not resulted in and could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any ERISA Affiliate has incurred any liability pursuant to Title I or IV of ERISA or the penalty
or excise tax provisions of the Code relating to employee benefit plans (as defined in Section 3 of ERISA), and no event, transaction or condition has occurred or exists that could reasonably be expected to result in the incurrence of any such
liability by the Company or any ERISA Affiliate, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate, in either case pursuant to Title I or IV of ERISA or to such penalty or excise tax
provisions or to Section 401(a)(29) or 412 of the Code, other than such liabilities or Liens as would not reasonably be expected to be, individually or in the aggregate, Material. 
 (b) The present value of the aggregate benefit liabilities under each of the Plans (other than Multiemployer Plans), determined as of the
end of such Plan’s most recently ended plan year on the basis of the actuarial assumptions specified for funding purposes in such Plan’s most recent actuarial valuation report, did not exceed the aggregate current value of the assets of
such Plan allocable to such benefit liabilities. The term “benefit liabilities” has the meaning specified in Section 4001 of ERISA and the terms “current value” and “present value” have the meaning specified in
Section 3 of ERISA. 
 (c) The Company and its ERISA Affiliates have not incurred withdrawal liabilities (and are not
subject to contingent withdrawal liabilities) under Section 4201 or 4204 of ERISA in respect of Multiemployer Plans that remain unsatisfied or that, individually or in the aggregate, would reasonably be expected to be Material. 
 (d) The expected post-retirement benefit obligation (determined as of the last day of the Company’s most recently ended fiscal year
in accordance with Financial Accounting Standards Board Statement No. 106, without regard to liabilities attributable to continuation coverage mandated by Section 4980B of the Code) of the Company and its Subsidiaries is not Material.

 (e) Assuming that the representations and warranties of the Purchasers set forth in Section 6.1(e) are true and
correct, the execution and delivery of this Agreement and the issuance and sale of the Notes hereunder will not involve any transaction that is subject to the prohibitions of Section 406 of ERISA or in connection with which a tax could be
imposed pursuant to Section 4975(c)(l)(A)-(D) of the Code. 
 Section 5.13 Private Offering by the Company. Assuming
that the representations and warranties of the Purchasers set forth in Section 6 are true and correct, the offering, issuance and 

  

 15 

 
delivery of the Notes, the Warrants and the shares of capital stock issuable upon the exercise of the Warrants (collectively, the
“Securities”) are exempt from the registration requirements of the Securities Act and the rules and regulations thereunder, and, except for the federal and state filings set forth in Schedule 5.7, it is not necessary to make
or obtain any filings, registrations, qualifications, notifications or consents or approvals of or with any Governmental Authority in connection therewith. 
 Section 5.14 Use of Proceeds. The Borrower will apply the proceeds of the sale of the Notes to consummate the Merger and pay for transactions costs incurred in connection therewith. No Credit Party is
engaged principally or as one of its activities, in the business of extending credit for the purpose of “purchasing” or “carrying” any “margin stock” as such terms are defined in Regulation U of the Federal Reserve
Board as now and from time to time hereafter in effect. Other than in connection with the Merger, none of the proceeds of the Notes will be used, directly or indirectly, for the purpose of purchasing or carrying any margin stock or for any other
purpose which might cause any of the Notes under this Agreement to be considered a “Purpose credit” within the meaning of Regulations T, U, or X of the Board of Governors of the Federal Reserve Board. 
 Section 5.15 Existing Indebtedness; Future Liens. 
 (a) Except as described therein, Schedule 5.15 sets forth a complete and correct list of all outstanding Indebtedness of each
Credit Party as of the date of Closing. No Credit Party is in default and no waiver of default is currently in effect, in the payment of any principal or interest on any Indebtedness of such Credit Party and no event or condition exists with respect
to any Indebtedness of such Credit Party that would permit (or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such Indebtedness to become due and payable before its stated maturity or before its regularly
scheduled dates of payment. 
 (b) Except as disclosed in Schedule 5.15, no Credit Party has agreed or consented
to cause or permit in the future (upon the happening of a contingency or otherwise) any of its property, whether now owned or hereafter acquired, to be subject to a Lien other than Permitted Liens. 
 Section 5.16 Foreign Assets Control Regulations, Etc. Neither the sale of the Notes by the Borrower hereunder nor its use of the proceeds
thereof will violate the Trading with the Enemy Act, as amended, or any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order
relating thereto. Without limiting the foregoing, neither the Company nor any of its Subsidiaries (a) is or will become a blocked person described in Section 1 of Executive Order 13224 of September 23, 2001 Blocking Property and
Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism (66 Fed. Reg. 49049 (2001)) or (b) engages or will engage in any dealings or transactions, or be otherwise associated, with any such person.

 Section 5.17 Status under Certain Statutes. No Credit Party is an “investment company” registered or required to be
registered subject to regulation under the Investment Company Act of 1940, as amended, or is subject to regulation under the Public Utility Holding Company Act of 1935, as amended, or the Federal Power Act, as amended. 
  

 16 

 Section 5.18 Environmental Matters. Except as otherwise disclosed in Schedule 5.18:

 (a) the Company has no Knowledge of any claim, has received no notice of any claim, and no proceeding has been instituted
raising any claim against any Credit Party or any real properties now or formerly owned, leased or operated thereby, alleging any damage to the environment or violation of any Environmental Laws, except, in each case, such as would not reasonably be
expected to result in a Material Adverse Effect; 
 (b) the Company has no knowledge of any facts which would give rise to any
claim, public or private, of violation of Environmental Laws or damage to the environment emanating from, occurring on or in any way related to real properties now or formerly owned, leased or operated by any Credit Party or to other assets or their
use, except, in each case, such as would not reasonably be expected to result in a Material Adverse Effect; 
 (c) no Credit
Party has stored any Hazardous Materials on real properties now or formerly owned, leased or operated by any of them or has disposed of any Hazardous Materials in a manner contrary to any Environmental Laws in each case in any manner that would
reasonably be expected to result in a Material Adverse Effect; and 
 (d) all buildings on all real properties now owned,
leased or operated by any Credit Party are in compliance with applicable Environmental Laws, except where failure to comply could not reasonably be expected to result in a Material Adverse Effect. 
 Section 5.19 Names. Schedule 5.19 sets forth all names, trade names, fictitious names and business names under which each Credit Party
currently conducts its business or has at any time during the past five years conducted business. 
 Section 5.20 Locations;
FEIN. Schedule 5.20 sets forth the state of organization of each Credit Party, location of each Credit Party’s chief executive office and principal place of business, the location of all other offices of the Credit Parties, and all
Collateral locations other than (a) locations of Inventory which has been delivered to clinical research organizations in connection with such Credit Party’s clinical research or to physicians as a sample, in each case, in the ordinary
course of such Credit Party’s business, or (b) locations of Equipment being used by employees and consultants of any Credit Party in the ordinary course of business. Each Credit Party’s federal employer identification number and
entity identification number in its respective state of incorporation is set forth on Schedule 5.20. 
 Section 5.21
Solvency. At the Closing, both before and after giving effect to the Merger and the transactions contemplated by this Agreement and the other Related Documents, and, as of the date of this Agreement, each Credit Party: (a) owns assets the
fair saleable value of which are (i) greater than the total amount of its liabilities (including contingent liabilities) and (ii) greater than the amount that will be required to pay its probable liabilities as they mature; (b) has
capital that is not unreasonably small in relation to its businesses as presently conducted or any contemplated or undertaken transaction; and (c) does not intend to incur and does not believe that it will incur debts beyond its ability to pay
such debts as they become due. 
  

 17 

 Section 5.22 Status of Security Interest. This Agreement creates in favor of the Collateral
Agent a legal, valid and enforceable security interest in the Collateral. When financing statements setting forth the Collateral and naming the Collateral Agent as the secured party and the Borrower and the Company, as the debtor, respectively, have
been filed with the Secretary of State of the State of Delaware against each of the Borrower and the Company, the Collateral Agent will have a fully perfected first priority Lien on, and security interest in, the Collateral in which a security
interest may be perfected by such filing, subject only to Permitted Liens. 
 SECTION 6. REPRESENTATIONS OF THE
PURCHASERS. 
 Section 6.1 Representations to the Borrower and the Company. Each Purchaser represents and warrants
to the Borrower and the Company, severally and not jointly, with respect to its purchase of the Notes and Warrants as follows: 
 (a) Purchaser is purchasing the Note and Warrant for investment for Purchaser’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act.
Purchaser is an “accredited investor” as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and, in any case, has such knowledge and experience in financial and business matters as to be capable of evaluating the
merits and risks of investing in the Securities. Purchaser has not been formed for the purpose of investing in the Securities. 
 (b) Purchaser understands that the Note and Warrant that Purchaser is purchasing have not been registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide
nature of Purchaser’s investment intent as expressed herein. 
 (c) Purchaser further acknowledges and understands that
the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available and the Securities may be imprinted with a legend indicating such restrictions on the
transferability thereof. 
 (d) Purchaser understands that the Securities are presently characterized as “restricted
securities” under the federal securities laws inasmuch as they are being acquired from the Company and the Borrower in a transaction not involving a public offering and that under such laws and applicable regulations, such securities may be
resold without registration under the Securities Act only in certain limited circumstances. In this connection, Purchaser represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed
thereby and by the Securities Act. 
 (e) Purchaser represents that at least one of the following statements is an accurate
representation as to each source of funds (a “Source”) to be used by such Purchaser to pay the purchase price of the Notes to be purchased by such Purchaser hereunder: 
  

 18 

 (i) if such Purchaser is an insurance company, the Source does not include assets
allocated to any separate account maintained by you in which any employee benefit plan (or its related trust) has any interest, other than a separate account that is maintained solely in connection with your fixed contractual obligations under which
the amounts payable, or credited, to such plan and to any participant or beneficiary of such plan (including any annuitant) are not affected in any manner by the investment performance of the separate account; or 
 (ii) the Source is either (i) an insurance company pooled separate account, within the meaning of Prohibited Transaction Exemption
(“PTE”) 90-1 (issued January 29, 1990), or (ii) a bank collective investment fund, within the meaning of the PTE 91-38 (issued July 12, 1991) and, except as Purchaser has disclosed to the Company in writing pursuant
to this paragraph (b), no employee benefit plan or group of plans maintained by the same employer or employee organization beneficially owns more than 10% of all assets allocated to such pooled separate account or collective investment fund; or

 (iii) the Source constitutes assets of an “investment fund” (within the meaning of Part V of the QPAM Exemption)
managed by a “qualified professional asset manager” or “QPAM” (within the meaning of Part V of the QPAM Exemption), no employee benefit plan’s assets that are included in such investment fund, when combined with the assets
of all other employee benefit plans established or maintained by the same employer or by an affiliate (within the meaning of Section V(c)(1) of the QPAM Exemption) of such employer or by the same employee organization and managed by such QPAM,
exceed 20% of the total client assets managed by such QPAM, the conditions of Part I(c) and (g) of the QPAM Exemption are satisfied, neither the QPAM nor a person controlling or controlled by the QPAM (applying the definition of
“control” in Section V(e) of the QPAM Exemption) owns a 5% or more interest in the Company and (x) the identity of such QPAM and (y) the names of all employee benefit plans whose assets are included in such investment fund have
been disclosed to the Company in writing pursuant to this paragraph (iii); or 
 (iv) the Source is a governmental plan; or

 (v) the Source is one or more employee benefit plans, or a separate account or trust fund comprised of one or more employee
benefit plans, each of which has been identified to the Company in writing pursuant to this paragraph (v); or 
 (vi) the
Source does not include assets of any employee benefit plan, other than a plan exempt from the coverage of ERISA. 
  

 19 

 As used in this Section 6.1, the terms “employee benefit plan,” “governmental
plan,” “party in interest” and “separate account” shall have the respective meanings assigned to such terms in Section 3 of ERISA. 
 Section 6.2 Exculpation of the Purchasers. Each Purchaser acknowledges that it is not relying upon any Person (including the Collateral Agent
or any other Purchaser), other than the Company and its officers (acting in their respective capacities as representatives of the Company), in deciding to invest and in making its investment in the purchase of the Notes and Warrants. Each Purchaser
agrees that none of the Collateral Agent, the other Purchaser or any of their respective controlling Persons, officers, directors, partners, agents or employees shall be liable to such Purchaser for any losses incurred by such Purchaser in
connection with its purchase of the Notes and Warrants. 
 SECTION 7. INFORMATION AS TO THE
COMPANY. 
 Section 7.1 Financial and Business Information. The Borrower and the Company, jointly and severally,
agree to deliver to each holder of Notes: 
 (a) Quarterly Statements. Within 45 days after the end of each quarterly
fiscal period in each fiscal year of the Company (other than the last quarterly fiscal period of each such fiscal year), copies of: 
 (i) a consolidated and consolidating balance sheet of the Company and its Subsidiaries as at the end of such quarter, and 
 (ii) consolidated and consolidating statements of income, changes in stockholders’ equity and cash flows of the Company and its Subsidiaries for such quarter and (in the case of the second and third quarters) for the portion of the
fiscal year ending with such quarter, 
 setting forth in each case in comparative form the figures for the corresponding periods in the
previous fiscal year, all in reasonable detail, prepared in accordance with GAAP applicable to quarterly financial statements generally, and certified by a Senior Financial Officer as fairly presenting, in all material respects, the financial
position of the companies being reported on and their results of operations and cash flows, subject to changes resulting from year-end adjustments. Filing of the Company’s quarterly reports on Form 10-Q under and in satisfaction of the Exchange
Act shall, for purposes of this Section 7.1(a) constitute delivery. 
 (b) Annual Statements. Within 90
days after the end of each fiscal year of the Company, copies of, 
 (i) a consolidated and consolidating balance sheet of the
Company and its Subsidiaries, as at the end of such year, and 
 (ii) consolidated and consolidating statements of income,
changes in stockholders’ equity and cash flows of the Company and its Subsidiaries, for such year, 

  

 20 

 
setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail, prepared in accordance with GAAP, and
accompanied by an opinion thereon of independent certified public accountants of recognized national standing, which opinion shall state that such financial statements present fairly, in all material respects, the financial position of the companies
being reported upon and their results of operations and cash flows and have been prepared in conformity with GAAP, and that the examination of such accountants in connection with such financial statements has been made in accordance with generally
accepted auditing standards, and that such audit provides a reasonable basis for such opinion in the circumstances. The reports in this clause (b) shall be accompanied by any management letter prepared by the above-referenced
accountants. Filing of the Company’s annual reports on Form 10-K under and in satisfaction of the Exchange Act shall, for purposes of this Section 7.1(b), constitute delivery. 
 (c) Notice of Default or Event of Default. Promptly, and in any event within five Business Days after a Responsible Officer becomes
aware of the existence of any Default or Event of Default or that any Person has given any notice or taken any action with respect to a claimed default hereunder or that any Person has given any notice or taken any action with respect to a claimed
default of the type referred to in Section 11(f), a written notice specifying the nature and period of existence thereof and what action the Company is taking or proposes to take with respect thereto; 
 (d) ERISA Matters. Promptly, and in any event within five Business Days after a Responsible Officer becomes aware of any of the
following, a written notice setting forth the nature thereof and the action, if any, that the Company or an ERISA Affiliate proposes to take with respect thereto: 
 (i) with respect to any Plan (other than any Multiemployer Plan), any reportable event, as defined in Section 4043(b) of ERISA and
the regulations thereunder, for which notice thereof has not been waived pursuant to such regulations as in effect on the date hereof; or 
 (ii) the taking by the PBGC of steps to institute, or the threatening by the PBGC of the institution of, proceedings under Section 4042 of ERISA for the termination of, or the appointment of a trustee to
administer, any Plan (other than any Multiemployer Plan), or the receipt by the Company or any ERISA Affiliate of a notice from a Multiemployer Plan that such action has been taken by the PBGC with respect to such Multiemployer Plan; or 

(iii) any event, transaction or condition that could result in the incurrence of any liability by the Company or any ERISA Affiliate
pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate pursuant to
Title I or IV of ERISA or such penalty or excise tax provisions, if such liability or Lien, taken together with any other such liabilities or Liens thereof then existing, could reasonably be expected to have a Material Adverse Effect; 
  

 21 

 (e) Notices of Certain Adverse Events. Promptly, and in any event within five
Business Days after a Responsible Officer becomes aware of any of the following, a written notice regarding: (i) the occurrence of any event or circumstance which has had or will likely have a Material Adverse Effect, (ii) the occurrence
of any event or circumstance which is a matured and un-waived material default under any third party agreement entered into by the Company or any of its Subsidiaries that is Material, (iii) the institution of any action, suit, proceeding,
governmental investigation or arbitration which exposes the Company or any of its Subsidiaries to a liability that is Material, and (iv) the receipt of any communications regarding potential or actual material defaults (whether waived or not)
on any Indebtedness that is Material; and 
 (f) Requested Information. With reasonable promptness, such other
materials, data and information relating to the business, operations, affairs, financial condition, properties or prospects of the Company or any of its Subsidiaries as from time to time may be reasonably requested by any such holder of Notes in
order to enable such holder to monitor the Borrower’s and the Company’s progress in key areas; provided, however, that neither the Borrower nor the Company shall be obligated to provide such information as is comprised of privileged
attorney client communications or that is particularly sensitive confidential business material. In furtherance of the foregoing, the Company hereby agrees to furnish the holders of Notes, promptly upon completion of the top line analysis thereof,
the results of the Phase III data of the Company’s Product known as JZP3, in reasonable detail. 
 (g) Operating Plan
and Budget. As soon as available, and in any event within 30 days after the end of each fiscal year of the Company, a copy of the Company’s consolidated and consolidating budget for the such fiscal year, such budget to show the
Company’s projected consolidated and consolidating revenues, expenses, and balance sheet on a quarterly basis, such budget to be in the form to be provided to the Company’s preferred stockholders. 
 Section 7.2 Officer’s Certificate. Each set of financial statements delivered to a holder of Notes pursuant to
Section 7.1(a) or Section 7.1(b) hereof shall be accompanied by a certificate of a Senior Financial Officer setting forth a statement that such officer has reviewed the relevant terms hereof and has made, or caused to be
made, under his or her supervision, a review of the transactions and conditions of the Company and its Subsidiaries from the beginning of the quarterly or annual period covered by the statements then being furnished to the date of the certificate
and that such review shall not have disclosed the existence of a Default or an Event of Default or, if any such condition or event exists, specifying the nature and period of existence thereof and what action the Company shall have taken or proposes
to take with respect thereto. 
 Section 7.3 Inspection. The Company shall, and shall cause each Subsidiary to, permit the
representatives of each holder of Notes to visit and inspect any of the properties, corporate books and financial records of the Company and each Subsidiary, to examine and make copies (in reasonable quantities) of the books of accounts and other
financial records of the Company and each Subsidiary thereof, and, with the consent of the Company if no Default or Event of Default exists (such consent to not be unreasonably withheld), to discuss the affairs, 

  

 22 

 
finances and accounts of the Company and each Subsidiary with, and to be advised as to the same by the Company’s employees and independent public
accountants (and by this provision the Company authorizes such accountants to discuss with the Purchasers the finances and affairs of the Company and its Subsidiaries so long as consent has been given thereby when required by this
Section 7.3), in each case, at such reasonable times and reasonable intervals during normal business hours upon reasonable prior notice. 
 Section 7.4 Executive Management Access. The Company shall cause the Executive Chairman, the Chief Executive Officer and/or the Chief Financial Officer of the Company to meet with the Purchasers
promptly upon the Purchasers’ reasonable request therefor no less frequently than once per quarter. 
 SECTION 8. PREPAYMENT
OF THE NOTES. 
 Section 8.1 Required Prepayments. In addition to paying the
remaining outstanding principal amount and the interest due on the Notes on the maturity date thereof or upon acceleration of the Notes pursuant to Section 12, all as guaranteed by the Company Guaranty, if a Mandatory Prepayment Event
occurs, the Borrower and the Company each agree as follows: 
 (a) Promptly upon the consummation of such Mandatory Prepayment
Event, the Borrower shall give the holders of the Notes written notice of such Mandatory Prepayment Event with a description in reasonable detail of such Mandatory Prepayment Event including, the calculation of the Net Proceeds received in
connection therewith and, for each holder of a Note, the amount of such holder’s Pro Rata Portion of such Net Proceeds. 
 (b) The Net Proceeds received by the Company or any of its Subsidiaries in connection with such Mandatory Prepayment Event shall be placed upon receipt thereof directly into a deposit or investment account pledged to the Collateral Agent
for the benefit of the holders of the Notes as collateral security for the prompt and full payment of the Notes and shall be applied to the outstanding principal balance of the Notes or released to the Company or its Subsidiaries as follows:

 (i) Each holder of a Note shall have the option, exercised by written notice to the Borrower, prior the end of business on
the date that is 21 days after receiving notice of the Mandatory Prepayment Event or 21 days after the Phase III data on the Company’s Product known as JZP3 is known by the Purchasers, whichever is later (the “End Release
Date”), to require that all or any portion of such holder’s Pro Rata Portion of the Net Proceeds, in such holder’s discretion, be applied as a prepayment in reduction of the outstanding principal balance of the then outstanding
Notes then held by such Holder. 
 (ii) If and to the extent that any holder of a Note declines to require a mandatory
prepayment or otherwise waives the provisions of this Section 8.1 in connection with any Mandatory Prepayment Event, in either case in a writing signed by such holder, or, if such holder fails to give notice prior to the End Release Date
requiring a full or partial prepayment of such holder’s Note or Notes 

  

 23 

 
pursuant to clause (i) above, then an amount equal to such holder’s Pro Rata Portion of the Net Proceeds shall be released from the collateral
account and freely available to the Company and its Subsidiaries for all legal purposes permitted by this Agreement. 
 Section 8.2
Optional Prepayments with Make-Whole Amount. The Borrower may, at its option, upon notice as provided below, prepay at any time all, or from time to time any part of the Notes, in a minimum amount not less than $5,000,000 and in increments of at
least $1,000,000 in excess of such minimum, in the case of a partial prepayment, at 100% of the principal amount so prepaid, together with interest accrued thereon to the date of such prepayment, plus the Make-Whole Amount, if any, determined for
the prepayment date with respect to such principal amount. The Borrower will give each holder of Notes written notice of each optional prepayment under this Section 8.2 not less than 5 days prior to the date fixed for such
prepayment. Each such notice shall specify such date, the aggregate principal amount of the Notes to be prepaid on such date, the principal amount of each Note held by such holder to be prepaid, and the interest and Make-Whole Amount, if any, to be
paid on the prepayment date with respect to such principal amount being prepaid, and shall be accompanied by a certificate of Senior Financial Officer specifying the computation of the Make-Whole Amount due in connection with such prepayment,
setting forth the details of such computation. In the case of each partial prepayment of the Notes made pursuant to this Section 8.2, the principal amount of the Notes to be prepaid shall be allocated among all of the Notes at the time
outstanding in proportion, as nearly as practicable, to the respective unpaid principal amounts thereof not theretofore called for prepayment. 
 Section 8.3 Maturity, Surrender, Etc. In the case of each prepayment of Notes pursuant to this Section 8, the principal amount of each Note to be prepaid shall mature and become due and payable on the date fixed for
such prepayment, together with interest on such principal amount accrued to such date and the applicable Make-Whole Amount, if any. From and after such date, unless the Borrower shall fail to pay such principal amount when so due and payable,
together with the interest and Make-Whole Amount, if any, as aforesaid, interest on such principal amount shall cease to accrue. Any Note paid or prepaid in full shall be surrendered to the Company and cancelled and shall not be reissued, and no
Note shall be issued in lieu of any prepaid principal amount of any Note. 
 SECTION 9. AFFIRMATIVE COVENANTS. 
 Each of the Borrower and the Company covenants, jointly and severally, that so long as any of the Notes are outstanding: 
 Section 9.1 Compliance with Law. The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause each
Subsidiary to, comply with all laws, ordinances or governmental rules or regulations to which each of them is subject, including, without limitation, Environmental Laws, and to obtain and maintain in effect all licenses, certificates, permits,
franchises and other governmental authorizations necessary to the ownership of their respective properties or to the conduct of their respective businesses, in each case to the extent necessary to ensure that non-compliance with such laws,
ordinances or governmental rules or regulations or failures to obtain or maintain in effect such licenses, certificates, permits, franchises and other governmental authorizations could not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. 
  

 24 

 Section 9.2 Insurance. The Borrower will, and will cause each of its Subsidiaries to, and the
Company will, and will cause each Subsidiary to, maintain, with financially sound and reputable insurers, insurance with respect to their respective properties and businesses against such casualties and contingencies, of such types, on such terms
and in such amounts (including deductibles, co-insurance and self insurance, if adequate reserves are maintained with respect thereto) as is customary in the case of entities of established reputations engaged in the same or a similar business and
similarly situated. The Collateral Agent shall be named as “lender’s loss payee” on all insurance policies relating to any Collateral and as “additional insured” under all liability policies (except Directors’ and
Officers’ Insurance, automobile insurance, workers’ compensation, fiduciary liability and employment practices), in each case pursuant to appropriate endorsements in form and substance reasonably satisfactory to the Collateral Agent.

 Section 9.3 Maintenance of Properties. The Borrower will, and will cause each of its Subsidiaries to, and the Company will,
and will cause each Subsidiary to, maintain and keep, or cause to be maintained and kept, their respective properties in good repair, working order and condition (other than ordinary wear and tear), so that the business carried on in connection
therewith may be properly conducted at all times; provided that this Section shall not prevent the Company or any Subsidiary from discontinuing the operation and the maintenance of any of its properties if such discontinuance is desirable in
the conduct of its business and the Company has concluded that such discontinuance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 9.4 Payment of Taxes and Claims. The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause
each Subsidiary to, file all tax returns required to be filed in any jurisdiction and to pay and discharge all taxes shown to be due and payable on such returns and all other taxes, assessments, governmental charges, or levies imposed on them or any
of their properties, assets, income or franchises, to the extent such taxes and assessments have become due and payable and before they have become delinquent and all claims for which sums have become due and payable that have or might become a Lien
(other than Liens permitted by Section 10.3) on properties or assets of the Company or any Subsidiary; provided that neither the Company nor any Subsidiary need pay any such tax or assessment or charge or claim if (a) the
amount, applicability or validity thereof is contested by the Company or such Subsidiary on a timely basis in good faith and in appropriate proceedings, and the Company or a Subsidiary has established adequate reserves therefor in accordance with
GAAP on the books of the Company or such Subsidiary or (b) the nonpayment of all such taxes, assessments, charges and claims in the aggregate could not reasonably be expected to have a Material Adverse Effect. 
 Section 9.5 Corporate Existence, Etc. Subject to Section 10.2, the Borrower will, and will cause each of its Subsidiaries to, and
the Company will, and will cause each Subsidiary to, at all times preserve and keep in full force and effect its corporate existence and the corporate existence of each of such Subsidiary and all rights and franchises of the Borrower, the Company
and such Subsidiaries; provided, that this Section 9.5 shall neither apply to nor operate to prevent the Borrower or the Company from failing to preserve the corporate existence, right or 

  

 25 

 
franchise of any Subsidiary if such failure would not impair the Collateral Agent’s rights in any assets of such Subsidiary pledged as collateral for
the payment of the Obligations and, in the good faith judgment of the Company, such failure would not be reasonably expected to have a Material Adverse Effect. 
 Section 9.6 Minimum Cash Balance. The Borrower will at all times maintain a minimum cash balance equal to 15% of the then outstanding principal amount on the Notes in a deposit or other similar demand
investment account that is pledged to the Collateral Agent for the benefit of the Purchasers as collateral security for the prompt and full payment of the Notes and which such account is subject to a control account agreement, in form and substance
reasonably satisfactory to the Collateral Agent, between the applicable financial intermediary where such account is held and the Collateral Agent. 
 Section 9.7 Subsidiary Documentation. In connection with and within five Business Days of the creation, acquisition and/or capitalization by the Company or any Subsidiary of the Company of a new Subsidiary (a “New
Subsidiary”) on or after the date hereof, the Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to, satisfy the following requirements: 
 (a) In the case of a New Subsidiary which is a Domestic Subsidiary, deliver to the Collateral Agent, the following documentation,
instruments and agreements, in each case, evidencing a first priority perfected security interest and in form and substance reasonably satisfactory to the Collateral Agent: 
 (i) a pledge agreement (substantially in the form of the Pledge Agreement) executed by the Company or the Subsidiary which is the parent
of such New Subsidiary together with the related stock certificates, if any, stock powers and similar documentation reasonably required by the Collateral Agent to attach and perfect a security interest in 100% of the capital stock or similar
ownership interests of the New Subsidiary as collateral security for the prompt and full payment and performance of the Obligations; 
 (ii) a Guaranty executed by the New Subsidiary guaranteeing the prompt and full payment of the Obligations; 
 (iii)
a security agreement, mortgage, deed of trust and/or intellectual property security agreement executed by the New Subsidiary as reasonably required by the Collateral Agent in order to properly attach and perfect (as applicable) a security interest
in all of the property of the New Subsidiary (other than property constituting ownership interests of a Foreign Subsidiary, which shall be subject to the provisions of Section 9.7(b) below) as collateral security for the prompt and full
payment of the Obligations; and 
 (iv) authorization from the new Subsidiary to file any necessary UCC financing statements
and other similar documents or instruments required to perfect any security interests granted pursuant to the clause (iii) above. 
  

 26 

 (b) In the case of a New Subsidiary which is a Foreign Subsidiary, deliver to the
Collateral Agent a pledge agreement or similar instrument or agreement executed by the parent of such New Subsidiary pursuant to which 65% of the outstanding ownership interests of such New Subsidiary is pledged as collateral security for the prompt
and full payment of the Obligations. 
 Section 9.8 Perfection and Maintenance of Security Interests. The Borrower will, and will
cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to, perform any and all steps reasonably requested by the Collateral Agent to perfect, maintain and protect the Collateral Agent’s security interests in and
against the Collateral granted or purported to be granted under this Agreement or any other Related Agreement, including, without limitation, (a) authorizing the Collateral Agent to file financing or continuation statements, or amendments
thereof, (b) delivering to the Collateral Agent all certificates, notes and other instruments representing or evidencing Collateral, which certificates, notes and other instruments have been duly endorsed or are accompanied by duly executed
instruments of transfer or assignment, all in form and substance reasonably satisfactory to the Collateral Agent, (c) at the reasonable direction of the Collateral Agent, delivering to the Collateral Agent warehouse receipts covering that
portion of the Collateral, if any, located in warehouses and for which warehouse receipts are issued, (d) after the occurrence and during the continuance of an Event of Default, and only to the extent permitted by law, transferring Inventory
and Equipment to warehouses designated by the Collateral Agent or taking such other steps as are deemed necessary by the Collateral Agent to maintain its control of the Inventory and Equipment, and (e) executing and delivering all further
instruments and documents, and taking all further action as the Collateral Agent may reasonably request. 
 Section 9.9 Collateral
Locations. The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to, keep the Collateral (other than (a) Inventory delivered, in the ordinary course of any Credit Party’s
business, to clinical research organizations used in clinical research or to physicians as a sample and (b) Equipment being used by employees and consultants of any Credit Party in the ordinary course of its business) at the locations specified
on Schedule 5.20; provided, however, that the Borrower or the Company may amend Schedule 5.20 so long as such amendment occurs by written notice to the Collateral Agent not less than thirty (30) days prior
to the date on which such Collateral is moved. With respect to any new location (which in any event shall be within the continental United States), Borrower and the Company will execute such documents and take such actions as the Collateral Agent
deems reasonably requests to perfect and protect the security interests of the Collateral Agent in the Collateral prior to the transfer or removal of any Collateral to such new location. 
 SECTION 10. NEGATIVE COVENANTS. 
 Each of the Borrower and the Company, jointly
and severally, covenants that so long as any of the Notes are outstanding: 
 Section 10.1 Limitations on Indebtedness.

 (a) The Borrower will not, and will not permit its Subsidiaries to, and the Company will not, and will not permit its
Subsidiaries to, create, issue, assume, guarantee or otherwise incur or in any manner be or become liable in respect of any Indebtedness, except: 
  

 27 

 (i) Indebtedness evidenced by the Notes; 
 (ii) unsecured Indebtedness incurred by the Company or any Domestic Subsidiary of the Company other than the Borrower (or any of the
Borrower’s Subsidiaries) so long as no principal of such Indebtedness is scheduled to mature prior to the stated maturity of the Notes; 
 (iii) (a) secured or unsecured purchase money Indebtedness (including Capital Leases) (such Indebtedness being referred to herein as “Permitted Purchase Money Indebtedness”) incurred by the Company or
any Domestic Subsidiary of the Company other than the Borrower (or any of the Borrower’s Subsidiaries) and (b) secured Indebtedness (such Indebtedness being referred to herein as “Permitted Receivables/Inventory
Indebtedness”) incurred by the Company or any Domestic Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct Subsidiaries) secured by Accounts and Inventory, if all such Permitted Purchase Money
Indebtedness and Permitted Receivables/Inventory Indebtedness does not exceed, in the aggregate at any time outstanding, the greater of (1) $5,000,000 or (2) 8% of Consolidated Net Tangible Assets as determined at such time using the
consolidated balance sheet of the Company and its Subsidiaries for the most recently completed fiscal quarter of the Company; 
 (iv) secured Indebtedness (hereinafter referred to as the “Permitted Other Secured Indebtedness”) created, issued, assumed, guaranteed or otherwise incurred by the Company or any Domestic Subsidiary of the Company other
than the Borrower (or any of the Borrower’s Subsidiaries) so long as no principal of such Indebtedness is scheduled to mature prior to the stated maturity of the Notes; provided that at the time of creation, issuance, assumption,
guarantee or incurrence thereof and after giving effect thereto and to the application of the proceeds thereof, the ratio of (i) Consolidated Secured Indebtedness at such time to (ii) Consolidated EBITDA as measured for the then trailing
six most recently completed fiscal quarters of the Company on an annualized basis or the four most recently completed fiscal quarters of the Company if the date of determination is after the third anniversary of the Closing, shall not be in excess
of 3.0 to 1.0; 
 (v) Indebtedness (hereinafter referred to as the “Permitted Acquisition Indebtedness”)
created, issued, assumed, guaranteed or otherwise incurred by the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s Subsidiaries) used to finance (or assumed in connection with) the acquisition of a
pharmaceutical or biotechnology product (including by way of the acquisition of stock or other similar ownership interests of the Person owning the target product); provided that at the time of creation, issuance, assumption, 

  

 28 

 
guarantee or incurrence thereof and after giving effect thereto and to the application of the proceeds thereof, the aggregate outstanding principal amount of
such Indebtedness permitted by this clause (v) shall not exceed three times the lower of: 
 (1) the annualized EBITDA
of the Person or product being acquired as measured for the then most recent 12 months ended; or 
 (2) the lowest projected
annualized EBITDA for the Person or product being acquired, as the case may be, for any of the three years following the acquisition as determined by the Company in good faith on a pro forma basis and presented to the Company’s board of
directors in connection with the approval of such acquisition; and 
 (vi) Indebtedness represented by currency swaps or
letters of credit entered into or issued, as the case may be, in the ordinary course of business of a Credit Party. 
 (b) The
renewal, extension, increase or refunding of any Indebtedness originally permitted to be issued, incurred or outstanding pursuant to Section 10.1(a) shall constitute the issuance of additional Indebtedness which is, in turn, subject to
the limitations of the applicable provisions of this Section 10.1. 
 (c) Any Person that becomes a Subsidiary
after the date hereof shall for all purposes of this Section 10.1 be deemed to have created, assumed or incurred at the time it becomes a Subsidiary all Indebtedness of such Person existing immediately after it becomes a Subsidiary which
Indebtedness, in turn, shall be subject to the limitations of this Section 10.1 including, for the avoidance of doubt, any exceptions set forth herein. 
 (d) Each Credit Party, the Collateral Agent and each Purchaser acknowledges and agrees that, notwithstanding the incurrence or assumption
of any of the Indebtedness permitted to be incurred or assumed pursuant to Section 10.1(a), the Liens granted to the Collateral Agent for the benefit of the holders of Notes as collateral security for the payment of the Obligations
(including, without limitation, the Liens on the Collateral provided for in Section 3 hereof) shall remain in place as valid and enforceable Liens; provided, however, that the Purchasers and the Collateral Agent hereby
agree that, in the case of the incurrence or assumption of any Permitted Purchase Money Indebtedness, any Permitted Receivables/Inventory Indebtedness or any Permitted Acquisition Indebtedness, if requested by the Company, the Collateral Agent shall
agree, in a writing that is in form and substance reasonably acceptable thereto, with the applicable creditor or creditors holding such Permitted Purchase Money Indebtedness, such Permitted Receivables/Inventory Indebtedness or such Permitted
Acquisition Indebtedness, as the case may be, to subordinate any Liens which the Collateral Agent has or holds on the assets being acquired or financed in favor of the Liens expressly permitted to be incurred under Sections 10.3 (a)(i),
10.3(a)(ii) and 10.3(c), respectively, in connection with such acquisition. 
  

 29 

 Section 10.2 Mergers, Consolidations and Dispositions. The Borrower will not, and will not
permit its Subsidiaries to, and the Company will not, and will not permit its Subsidiaries to, be a party to any merger or consolidation in which more than 50% of the voting power of the Company or such Subsidiary is disposed of, or sell, transfer,
lease or otherwise dispose of any part of its property, including a disposition of property as part of a sale and leaseback transaction; provided, however, that this Section shall neither apply to nor operate to prevent the
Company from being a party to any merger or consolidation so long as such merger or consolidation is not deemed to be a Change in Control, and shall not apply to or prevent the Borrower, the Company or any of its Subsidiaries from: 
 (a) selling Inventory in the ordinary course of its business; 
 (b) selling, transferring or otherwise disposing of worn-out, obsolete or surplus property or property no longer useful or necessary to
the operation of the business of the Company or its Subsidiaries; 
 (c) transferring or licensing rights to property of the
Company or any of its Subsidiaries as part of a co-marketing, co-promotion, out-bound licensing or similar partnering arrangement (which may include product specific financing by such co-marketer, co-promoter, licensor or partner so long as the
Indebtedness represented thereby is otherwise permitted by Section 10.1) of any Product of the Company or any of its Subsidiaries (but, for the avoidance of doubt, not Products of the Borrower or any direct Subsidiary of the Borrower
except in connection with the existing agreement the Borrower has with UCB Pharma concerning the sale of Xyrem® in Europe) so long as, at the time of such sale, transfer or disposition and after giving effect thereto, no Default or Event of Default shall exist (a “Permitted Product
Transfer”); 
 (d) selling, transferring or otherwise disposing of any Product of the Borrower other than Xyrem® so long as, at the time of such sale, transfer or
disposition and after giving effect thereto, no Default or Event of Default shall exist (a “Permitted Product Disposition”); 
 (e) selling, transferring or otherwise disposing of any property from the Company or any Subsidiary of the Company (other than the Borrower) to the Company or any Wholly-owned Subsidiary of the Company (other than the
Borrower) that is a Domestic Subsidiary; 
 (f) selling, transferring or otherwise disposing of any property from the Company
or any Subsidiary of the Company (other than the Borrower or a Subsidiary of the Borrower) to a Foreign Subsidiary of the Company as part of a Permitted Foreign Subsidiary Transfer; or 
 (g) engaging in a transaction whereby any Subsidiary of the Company (other than the Borrower or a direct Subsidiary of the Borrower)
merges or consolidates with or into the Company or any Subsidiary that is a Domestic Subsidiary; provided that in any merger or consolidation involving the Company, the Company shall be the surviving or continuing corporation.

  

 30 

 Section 10.3 Limitation on Liens. The Borrower will not, and will not permit its Subsidiaries
to, and the Company will not, and will not permit its Subsidiaries to, create or incur, or suffer to be incurred or to exist, any Lien (except Permitted Liens) on its or their property, whether now owned or hereafter acquired, or upon any income or
profits therefrom; provided, however, that the foregoing shall neither restrict nor operate to prevent: 
 (a) Liens on
property of the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct Subsidiaries) created solely for the purpose of securing (i) Permitted Purchase Money Indebtedness so long as (x) such
Liens shall not extend to or cover property of the Company or such Subsidiary other than the property so acquired in respect of such Permitted Purchase Money Indebtedness, and (y) the principal amount of the Indebtedness secured by any such
Liens shall at no time exceed the original purchase price of such fixed assets and (ii) Permitted Receivables/Inventory Indebtedness; 
 (b) Liens on property of the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct Subsidiaries) created solely for the purpose of securing Permitted Other Secured
Indebtedness so long as such Liens do not have priority over the Liens granted in favor of the Collateral Agent for the benefit of the Purchasers under this Agreement or any other Related Documents; 
 (c) Liens on property of the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct
Subsidiaries) created solely for the purpose of securing (or assumed in connection with) Permitted Acquisition Indebtedness, so long as such Liens shall not extend to or cover property of the Company or such Subsidiary other than the property being
acquired in connection with such Permitted Acquisition Indebtedness; or 
 (d) Liens on property of the Company or any
Subsidiary of the Company created solely for the purpose of consummating a Permitted Product Transfer permitted by Section 10.2(b), so long as such Liens shall not extend to or cover property of the Company or such Subsidiary other than
the property which is the subject of such Permitted Product Transfer. 
 Section 10.4 Restricted Payments. The Borrower will not,
and will not permit its Subsidiaries to, and the Company will not, and will not permit its Subsidiaries to, except as hereinafter provided: declare or pay any dividends (other than dividends payable solely in capital stock), either in cash or
property, on any shares of its capital stock of any class; directly or indirectly, or through any Subsidiary or through any Affiliate of the Company, purchase, redeem or retire any shares of its capital stock of any class or any warrants, rights or
options to purchase or acquire any shares of its capital stock (other than in connection with the repurchase of common stock by the Company from current or former employees, directors or consultants of the Company upon the termination of their
status as such); voluntarily prepay any unsecured Indebtedness permitted pursuant to Section 10.1(a)(ii) or Permitted Other Secured Indebtedness; or make any other payment or distribution, either directly or indirectly or through any
Subsidiary, in respect of its capital stock; provided, however, that the foregoing shall neither apply to nor operate to prevent any Subsidiary of the Borrower or the Company from making a dividend or similar distribution to the
Borrower, the Company or any Domestic Subsidiary thereof. 
  

 31 

 Section 10.5 Subsidiaries, Acquisitions and Investments. The Borrower will not, and will not
permit its Subsidiaries to, and the Company will not, and will not permit its Subsidiaries to, create or capitalize any Subsidiary after the date hereof, enter into any transaction or series of related transactions in which it acquires all or any
significant portion of the assets or capital stock (or other similar equity interests) of another Person other than in connection with the Merger or make any other Investments other than Permitted Investments; provided, however, that
this Section shall neither apply to nor operate to prevent the Company or any of its Subsidiaries from: 
 (a) creating
and capitalizing a Subsidiary that is a Domestic Subsidiary, acquiring all or a significant portion of the assets of any Person or acquiring all or a significant portion of the capital stock (or other similar equity interests) of another Person if
(i) the Company and its Subsidiaries comply with the requirements set forth in Section 9.7(a) in respect of any New Subsidiary created, (ii) any such assets or stock directly acquired is subject to the continuing security
interests set forth in Section 3 subject to any Liens permitted by Section 10.3, and (iii) no Default or Event of Default otherwise exists as of the time of the creation or capitalization of any such New Subsidiary; or

 (b) creating and capitalizing a Subsidiary that is a Foreign Subsidiary if the Company and its Subsidiaries comply with the
requirements set forth in Section 9.7(b) in respect of any New Subsidiary created and no Default or Event of Default otherwise exists as of the time of the creation or capitalization of such New Subsidiary. 
 For purposes of this Section 10.5, at any time when a Person becomes a Subsidiary, all Investments of such Person at such time shall be
deemed to have been made by such Person, as a Subsidiary, at such time, which Investments, in turn, shall be subject to the limitations of this Section 10.5, including, for the avoidance of doubt, any exceptions set forth herein.

 Section 10.6 Transactions with Affiliates. The Borrower will not, and will not permit its Subsidiaries to, and the Company
will not, and will not permit its Subsidiaries to, enter into or be a party to any Material transaction or arrangement with any Affiliate other than the Company or any Domestic Subsidiary of the Company (including, without limitation, the purchase
from, sale to or exchange of property with, or the rendering of any service by or for, any Affiliate), except upon fair and reasonable terms not materially less favorable to the Company or such Subsidiary than would obtain in a comparable
arm’s-length transaction with a Person other than an Affiliate. 
 Section 10.7 Corporate Documents. Neither the Company nor
the Borrower shall amend, supplement or otherwise modify its respective certificate of incorporation, bylaws or constituent agreements as in effect on the date hereof and after giving effect to the Merger in any manner that is materially adverse to
the interests of the holders of the Notes or the Warrants. 
  

 32 

 SECTION 11. EVENTS OF DEFAULT. 
 An “Event of Default” shall exist if any of the following conditions or events shall occur and be continuing: 
 (a) the Borrower defaults in the payment of any principal on any Note when the same becomes due and payable, whether at maturity or at a
date fixed for prepayment or by declaration or otherwise; or 
 (b) the Borrower defaults in the payment of any interest or
Make-Whole Amount, if any, on any Note for more than one Business Day after the same becomes due and payable; or 
 (c) any
Credit Party defaults in the performance of or compliance with any term contained in Sections 2, 7.1(a), (b) and (c), 7.2 or 10; or 
 (d) any Credit Party defaults in the performance of or compliance with any term contained this Agreement (other than those referred to in paragraphs (a), (b) and (c) of this Section 11) or any
other Related Document and such default is not remedied within 15 days after the earlier of (i) the Company giving timely written notice of such default to the holders of Notes pursuant to Section 7.1(e) or (ii) if the Company
fails to give such timely notice, upon a Responsible Officer obtaining actual knowledge of such default; or 
 (e) any
representation or warranty made in writing by or on behalf of any Credit Party or by any officer of a Credit Party in this Agreement, any other Related Documents or in any writing furnished in connection with the transactions contemplated hereby
proves to have been false or incorrect on the date as of which made or, in the case of any representation or warranty which is not by its terms already qualified by materiality, proves to have been materially false on the date as of which made; or

 (f) (i) the Company or any of its Subsidiaries is in default (as principal or as guarantor or other surety) in the
payment of any principal of or premium or make-whole amount or interest on any Indebtedness that is outstanding in an aggregate principal amount of at least $2,000,000 beyond any period of grace provided with respect thereto, or (ii) the
Company or any Subsidiary is in default in the performance of or compliance with any term of any evidence of any Indebtedness in an aggregate outstanding principal amount of at least $2,000,000 or of any mortgage, indenture or other agreement
relating thereto or any other condition exists, and as a consequence of such default or condition such Indebtedness has become, or has been declared (or one or more Persons are entitled to declare such Indebtedness to be), due and payable before its
stated maturity or before its regularly scheduled dates of payment, or (iii) as a consequence of the occurrence or continuation of any event or condition (other than the passage of time or the right of the holder of Indebtedness to convert such
Indebtedness into equity interests), (1) the Company or any Subsidiary has become obligated to purchase or repay Indebtedness before its regular maturity or before its regularly scheduled dates of payment in an aggregate outstanding principal
amount of at least $2,000,000, or (2) one or more Persons have the right to require the Company or any Subsidiary so to purchase or repay such Indebtedness; or 
  

 33 

 (g) the Company or any Domestic Subsidiary (i) is generally not paying, or admits in
writing its inability to pay, its debts as they become due, (ii) files, or consents by answer or otherwise to the filing against it of, a petition for relief or reorganization or arrangement or any other petition in bankruptcy, for liquidation
or to take advantage of any bankruptcy, insolvency, reorganization, moratorium or other similar law of any jurisdiction, (iii) makes an assignment for the benefit of its creditors, (iv) consents to the appointment of a custodian, receiver,
trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property, (v) is adjudicated as insolvent or to be liquidated, or (vi) takes corporate action for the purpose of any of the
foregoing; or 
 (h) a court or governmental authority of competent jurisdiction enters an order appointing, without consent
by the Company or any of its Domestic Subsidiaries, a custodian, receiver, trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property, or constituting an order for relief or approving a
petition for relief or reorganization or any other petition in bankruptcy or for liquidation or to take advantage of any bankruptcy or insolvency law of any jurisdiction, or ordering the dissolution, winding-up or liquidation of the Company or any
of its Domestic Subsidiaries, or any such petition shall be filed against the Company or any of its Domestic Subsidiaries and such petition shall not be dismissed within 60 days; or 
 (i) a final judgment or judgments for the payment of money aggregating in excess of $2,000,000 are rendered against one or more of the
Company and its Subsidiaries and which judgments are not, within 60 days after entry thereof, bonded, discharged or stayed pending appeal, or are not discharged within 60 days after the expiration of such stay; or 
 (j) a Change in Control shall have occurred; or 
 (k) except as permitted under any Related Document, (i) any material provisions of this Agreement or any other Related Document shall
for any reason cease to be valid, binding and enforceable against the Company or any of its Subsidiaries subject to such agreements for any reason or the Company or any of its Subsidiaries shall so assert, or (ii) due to any action or inaction
of the Company or its Subsidiaries any Lien created by this Agreement or other Related Document on any asset or property having a value, individually or in the aggregate, greater than $100,000 shall at any time fail to constitute a valid and
perfected first priority Lien subject to no prior or equal Lien on any portion of the Collateral purported to be the subject of such Lien; or 
 (l) if (i) any Plan shall fail to satisfy the minimum funding standards of ERISA or the Code for any plan year or part thereof or a waiver of such standards or extension of any amortization period is sought or
granted under Section 412 of the Code, (ii) a notice of intent to terminate any Plan shall have been or is reasonably expected to be filed with the PBGC or the PBGC shall have instituted proceedings under ERISA 

  

 34 

 
Section 4042 to terminate or appoint a trustee to administer any Plan or the PBGC shall have notified the Company or any ERISA Affiliate that a Plan may
become a subject of any such proceedings, (iii) the aggregate “amount of unfunded benefit liabilities” (within the meaning of Section 400l(a)(18) of ERISA) under all Plans, determined in accordance with Title IV of ERISA, shall
exceed $500,000, (iv) the Company or any ERISA Affiliate shall have incurred or is reasonably expected to incur any liability pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit
plans, (v) the Company or any ERISA Affiliate withdraws from any Multiemployer Plan, or (vi) the Company or any Subsidiary establishes or amends any employee welfare benefit plan that provides post-employment welfare benefits in a manner
that would increase the liability of the Company or any Subsidiary thereunder; and any such event or events described in clauses (i) through (vi) above, either individually or together with any other such event or events, could reasonably
be expected to have a Material Adverse Effect. 
 As used in Section 11(j), the terms “employee benefit plan” and
“employee welfare benefit plan” shall have the respective meanings assigned to such terms in Section 3 of ERISA. 
 SECTION 12.
REMEDIES ON DEFAULT, ETC. 
 Section 12.1 Acceleration. 
 (a) If an Event of Default with respect to the Company described in paragraph (g) or (h) of Section 11 (other than
an Event of Default described in clause (i) of paragraph (g) or described in clause (vi) of paragraph (g) by virtue of the fact that such clause encompasses clause (i) of paragraph (g)) has occurred, all the Notes then
outstanding shall automatically become immediately due and payable. 
 (b) If any Event of Default other than those set forth
in Section 12.1(a) has occurred and is continuing, the Minimum Holders may at any time at its or their option, by notice or notices to the Company, declare all the Notes then outstanding to be immediately due and payable. 
 (c) At any time that the Notes become due and payable under this Section 12.1, whether automatically or by declaration, each
Note will forthwith mature and the entire unpaid principal amount of such Note, plus (i) all accrued and unpaid interest thereon and (ii) in the event that the Notes have become due by reason of an Event of Default described in Sections
11(a), (b), (g), (h) or (j), the Make-Whole Amount determined in respect of such principal amount (to the full extent permitted by applicable law), shall all be immediately due and payable, in each and every case without presentment, demand,
protest or further notice, all of which are hereby waived. Each of the Company and the Borrower acknowledges, and the parties hereto agree, that each holder of a Note has the right to maintain its investment in the Notes free from repayment by the
Company (except as herein specifically provided for), and that the provision for payment of a Make-Whole Amount by the Company in the event that the Notes are prepaid or are accelerated as a result of an Event of Default described in Sections 11(a),
(b), (g), (h) or (j), is intended to provide compensation for the deprivation of such right under such circumstances. 
  

 35 

 Section 12.2 Other Remedies. If any Default or Event of Default has occurred and is
continuing, and irrespective of whether any Notes have become or have been declared immediately due and payable under Section 12.1, the holder of any Note at the time outstanding may proceed to protect and enforce the rights of such
holder by an action at law, suit in equity or other appropriate proceeding, whether for the specific performance of any agreement contained herein or in any Note, or for an injunction against a violation of any of the terms hereof or thereof, or in
aid of the exercise of any power granted hereby or thereby or by law or otherwise. 
 Section 12.3 Certain Remedies as to
Collateral. If any Event of Default shall have occurred and be continuing, in addition to and not in limitation of any rights or remedies available to the holders of Notes at law or in equity, the Collateral Agent may (and shall, if so directed
by the Minimum Holders) exercise in respect of the Collateral, in addition to all other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of a secured party on default under the UCC (whether or not the
UCC applies to the affected Collateral) and may also (a) notify any or all obligors on the Accounts to make all payments directly to the Collateral Agent; (b) require the Borrower and the Company to, and the Borrower and the Company hereby
agree that they will, at their expense and upon request of the Collateral Agent forthwith, assemble all or part of the Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place to be designated by the
Collateral Agent which is reasonably convenient to both parties; (c) without notice or demand or legal process, enter upon any premises of the Borrower and the Company and take possession of the Collateral; and (d) without notice except as
specified below, sell the Collateral or any part thereof in one or more parcels at public or private sale, at any of the Collateral Agent’s offices or elsewhere, at such time or times, for cash, on credit or for future delivery, and at such
price or prices and upon such other terms as the Collateral Agent may deem commercially reasonable. The Borrower and the Company agree that, to the extent notice of sale shall be required by law, at least ten (10) days notice to the Borrower
and the Company of the time and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. At any sale of the Collateral, if permitted by law, the Collateral Agent may bid (which bid may
be, in whole or in part, in the form of cancellation of indebtedness) for the purchase of the Collateral or any portion thereof for the account of the Collateral Agent and/or disclaim all warranties. The Collateral Agent shall not be obligated to
make any sale of Collateral regardless of notice of sale having been given. The Borrower and the Company shall remain liable for any deficiency. The Collateral Agent may adjourn any public or private sale from time to time by announcement at the
time and place fixed thereof, and such sale may, without further notice, be made at the time and place to which it was so adjourned. To the extent permitted by law, the Borrower and the Company hereby specifically waive all rights of redemption,
stay or appraisal which they have or may have under any law now existing or hereafter enacted. The Collateral Agent shall not be required to proceed against any Collateral but may proceed against the Borrower and the Company directly. 
 Section 12.4 Appointment of Attorney-in-Fact. Effective upon the occurrence and during the continuation of an Event of Default, the Borrower
and the Company hereby constitute and appoint the Collateral Agent as their attorney-in-fact with full authority in the place and 
  

 36 

 
stead of the Borrower and the Company and in their name, the Collateral Agent or otherwise, from time to time in the Collateral Agent’s discretion to
take any action and to execute any instrument that the Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement, including: (a) to ask, demand, collect, sue for, recover, compound, receive and give
acquittance and receipts for moneys due and to become due under or in respect of any of the Collateral; (b) to adjust, settle or compromise the amount or payment of any Account, or release wholly or partly any customer or obligor thereunder or
allow any credit or discount thereon; (c) to receive, endorse, and collect any drafts or other instruments, documents and chattel paper, in connection with clause (a) above; (d) to file any claims or take any action or institute any
proceedings that the Collateral Agent may deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the Collateral Agent with respect to any of the Collateral; and (e) to sign and endorse any
invoices, freight or express bills, bills of lading, storage or warehouse receipts, assignments, verifications and notices in connection with Accounts and other documents relating to the Collateral. The appointment of the Collateral Agent as the
Borrower’s and the Company’s attorney and the Collateral Agent’s rights and powers are coupled with an interest and are irrevocable until no Event of Default shall exist or payment in full and complete performance of all of the
Obligations. 
 Section 12.5 Limitation on Duty of the Collateral Agent with Respect to Collateral. Beyond the safe custody
thereof, the Collateral Agent shall have no duty with respect to any Collateral in its possession or control (or in the possession or control of any agent or bailee) or with respect to any income thereon or the preservation of rights against prior
parties or any other rights pertaining thereto. The Collateral Agent shall be deemed to have exercised reasonable care in the custody and preservation of the Collateral in its possession if the Collateral is accorded treatment substantially equal to
that which the Collateral Agent accords its own property. The Collateral Agent shall not be liable or responsible for any loss or damage to any of the Collateral, or for any diminution in the value thereof, by reason of the act or omission of any
warehouseman, carrier, forwarding agency, consignee or other agent or bailee selected by the Collateral Agent in good faith. 
 Section 12.6 Application of Proceeds. Upon the occurrence and during the continuance of an Event of Default, (a) the Borrower and the Company irrevocably waive the right to direct the application of any and all payments at
any time or times thereafter received by the Collateral Agent from or on behalf of the Borrower and the Company, and the Borrower and the Company hereby irrevocably agree that the Collateral Agent shall have the continuing exclusive right to apply
and to reapply any and all payments received at any time or times after the occurrence and during the continuance of an Event of Default against the Obligations in such manner as the Collateral Agent may deem advisable notwithstanding any previous
entry by the Collateral Agent upon any books and records and (b) the proceeds of any sale of, or other realization upon, all or any part of the Collateral shall be applied: first, to all fees, costs and expenses incurred by the
Collateral Agent or the Purchasers with respect to this Agreement, the other Related Documents or the Collateral; second, to accrued and unpaid interest and any Make-Whole Amount due on the Notes; and third, to the principal amounts of
the Obligations outstanding. 
 Section 12.7 License of Intellectual Property. To the extent permitted under any relevant
agreement entered into by the Company or the Borrower relating to its Intellectual Property, the Borrower and the Company hereby grant to the Collateral Agent for the benefit of 
  

 37 

 
the holders of Notes, effective only upon the occurrence and during the continuance of any Event of Default hereunder, the non-exclusive limited right and
license to use all Intellectual Property owned or licensed from a third-party by the Borrower or the Company together with any goodwill associated therewith (to the extent owned by the Borrower or the Company), solely to the extent necessary to
enable the Collateral Agent to realize on the Collateral and any successor or assign of the Collateral Agent to enjoy the benefits of the Collateral. This limited right and license shall inure to the benefit of all successors, assigns and
transferees of the Collateral Agent and its successors, assigns and transferees, whether by voluntary conveyance, operation of law, assignment, transfer, foreclosure, deed in lieu of foreclosure or otherwise. Such right and license is granted free
of charge, without requirement that any monetary payment whatsoever be made to the Borrower and the Company by the Collateral Agent. 
 Section 12.8 No Waivers or Election of Remedies, Expenses, Etc. No course of dealing and no delay on the part of the Collateral Agent or any holder of any Note in exercising any right, power or remedy shall operate as a waiver
thereof or otherwise prejudice such holder’s rights, powers or remedies. No right, power or remedy conferred by this Agreement or by any Note upon the Collateral Agent or any holder of a Note shall be exclusive of any other right, power or
remedy referred to herein or therein or now or hereafter available at law, in equity, by statute or otherwise. Without limiting the obligations of the Borrower and the Company under Section 15, the Company will pay to the Collateral
Agent and to the holder of each Note on demand such further amount as shall be sufficient to cover all reasonable costs and expenses of such holder incurred in any enforcement or collection under this Section 12, including, without
limitation, reasonable attorneys’ fees, expenses and disbursements. 
 SECTION 13. REGISTRATION; TRANSFER;
SUBSTITUTION OF NOTES. 
 Section 13.1 Registration of Notes. The Borrower shall keep
at its principal executive office a register for the registration and registration of transfers of Notes. The name and address of each holder of one or more Notes, each transfer thereof and the name and address of each transferee of one or more
Notes shall be registered in such register. Prior to due presentment for registration of transfer, the Person in whose name any Note shall be registered shall be deemed and treated as the owner and holder thereof for all purposes hereof, and the
Borrower shall not be affected by any notice or knowledge to the contrary. 
 Section 13.2 Transfer of Notes. Each Purchaser and
any transferee (as permitted hereby) of a Purchaser may transfer, assign or otherwise negotiate any Note (or any portion thereof) held thereby to (a) any Affiliate of such Purchaser (or permitted transferee) or (b) if such transfer is
acceptable to the Borrower and the Required Holders in their respective discretion, any other Person (each a “Permitted Transfer”). In order to effect a Permitted Transfer, the selling Purchaser (or any selling permitted transferee)
shall surrender the applicable Note at the principal executive office of the Borrower, duly endorsed or accompanied by a written instrument of transfer duly executed by the registered holder of such Note or its attorney duly authorized in writing
and accompanied by the address for notices of each transferee of such Note or part thereof, where upon the Borrower shall execute and deliver, at the Borrower’s expense, one or more new Notes (as requested by the holder thereof) in exchange
therefor, in an aggregate principal amount equal to the unpaid principal amount of the surrendered Note. Each such new Note shall be payable to such Person as such holder may request and shall be substantially in the 

  

 38 

 
form of Exhibit A. Each such new Note shall be dated and bear interest from the date to which interest shall have been paid on the surrendered
Note or dated the date of the surrendered Note if no interest shall have been paid thereon. Notes shall not be transferred in denominations of less than $5,000,000 (or, in the case of any transfer to an existing holder of a Note or an Affiliate
thereof, $1,000,000); provided that if necessary to enable the registration of transfer by a holder of its entire holding of Notes, one Note may be in a denomination of less than $5,000,000. Any transferee, by its acceptance of a Note
registered in its name (or the name of its nominee), shall be deemed to have made the representations set forth in Section 6.6. 
 Section 13.3 Replacement of Notes. Upon receipt by the Borrower of evidence reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note, and 
 (a) in the case of loss, theft or destruction, of indemnity reasonably satisfactory to it, or 
 (b) in the case of mutilation, upon surrender and cancellation thereof, 
 the Borrower at its own expense shall execute and deliver, in lieu thereof, a new Note, dated and bearing interest from the date to which interest shall have been paid on such lost, stolen, destroyed or mutilated Note
or dated the date of such lost, stolen, destroyed or mutilated Note if no interest shall have been paid thereon. 
 Section 13.4
Securitization. The Borrower hereby acknowledges that the holders of Notes and their permitted transferees may sell or securitize the Obligations (a “Securitization”) owing thereto through the pledge of the Obligations as
collateral security for loans to such holders or their permitted transferees or through the sale of the right to payment on the Obligations or the issuance of direct or indirect undivided interests in the Obligations. The Borrower shall cooperate
with the holders of Notes to effect any proposed Securitization including, without limitation, by providing such information as may be reasonably requested by the holders in connection with the rating of the Obligations by a nationally recognized
ratings agency in connection with the Securitization. 
 SECTION 14. PAYMENTS ON NOTES. 
 Section 14.1 Place of Payment. Subject to Section 14.2, payments of principal, Make-Whole Amount, if any, and interest becoming
due and payable on the Notes shall be made to the account or accounts designated in writing by each holder of a Note. 
 Section 14.2
Home Office Payment. So long as a Purchaser or its nominee shall be the holder of any Note, and notwithstanding anything contained in Section 14.1 or in such Note to the contrary, the Borrower will pay all sums becoming due on such
Note for principal, Make-Whole Amount, if any, and interest by the method and at the address specified for such purpose below the Purchaser’s name on Schedule A, or by such other method or at such other address as such Purchaser
shall have from time to time specified to the Borrower in writing for such purpose, without the presentation or surrender of such Note or the making of any notation thereon, except that upon written request of the Borrower made concurrently with or
reasonably promptly after payment or prepayment in full of any Note, any holder of the Note shall surrender 
  

 39 

 
such Note for cancellation, reasonably promptly after any such request, to the Borrower at its principal executive office or at the place of payment most
recently designated by the Borrower pursuant to Section 14.1. Prior to any sale or other disposition of any Note held by a Purchaser or its nominee such Purchaser will, at its election, either endorse thereon the amount of principal paid
thereon and the last date to which interest has been paid thereon or surrender such Note to the Borrower in exchange for a new Note or Notes pursuant to Section 13.2. The Borrower will afford the benefits of this Section 14.2
to any Purchaser that is the direct or indirect transferee of any Note purchased by such Purchaser under this Agreement and that has made the same agreement relating to such Note as such Purchaser has made in this Section 14.2.

 SECTION 15. EXPENSES, ETC. 
 Section 15.1 Fees; Transaction Expenses. The Borrower and the Company will pay (a) all fees due upon Closing under the Commitment Letter; (b) all reasonable costs and expenses (including
reasonable attorneys’ fees of Pillsbury Winthrop Shaw Pittman LLP, special counsel to certain of the Purchasers) incurred by the Purchasers or holder of a Note in connection with the transactions contemplated hereby (subject to a maximum of
$300,000 in the aggregate with respect to such transactions), (c) all reasonable costs and expenses (including reasonable attorneys’ fees of a single law firm) incurred by the Collateral Agent or any holder of a Note in connection with any
amendments, waivers or consents under or in respect of this Agreement, any other Related Document including the Notes (whether or not such amendment, waiver or consent becomes effective), (d) the reasonable costs and expenses incurred by the
Collateral Agent or any holder of a Note in enforcing or defending (or determining whether or how to enforce or defend) any rights under this Agreement or the Notes or in responding to any subpoena or other legal process or informal investigative
demand issued in connection with this Agreement or the Notes, or by reason of being a holder of any Note (including reasonable attorneys’ fees for all such holders), and (e) the reasonable costs and expenses incurred by the Collateral
Agent or any holder of a Note, including financial advisors’ fees, incurred in connection with the insolvency or bankruptcy of the Company or any Subsidiary. The Borrower will pay, and will save each Purchaser and each other holder of a Note
harmless from, all claims in respect of any fees, costs or expenses, if any, of brokers and finders (other than those retained by a Purchaser). 
 Section 15.2 Survival. The obligations of the Company and the Borrower under this Section 15 will survive the payment or transfer of any Note, the enforcement, amendment or waiver of any provision of this Agreement
or the Notes, and the termination of this Agreement. 
 SECTION 16. SURVIVAL OF REPRESENTATIONS
AND WARRANTIES; ENTIRE AGREEMENT. 
 All representations and warranties contained
herein shall survive the execution and delivery of this Agreement and the other Related Documents, the purchase or transfer by a holder of any Note or Warrant of such Note or Warrant or portion thereof or interest therein and the payment of any Note
or the exercise of any Warrant, and may be relied upon by any subsequent holder of a Note, regardless of any investigation made at any time by or on behalf of any holder of a Note. All statements contained in any certificate or other instrument
delivered by or on behalf of the Borrower or the Company pursuant to this Agreement shall be deemed representations and warranties of the Borrower or the Company under this Agreement. Subject to the preceding sentence, this Agreement and the other
Related Documents embody the entire agreement and understanding between the Purchasers and the Company and supersede all prior agreements and understandings relating to the subject matter hereof. 
  

 40 

 SECTION 17. AMENDMENT AND WAIVER. 
 Section 17.1 Requirements. This Agreement and the Notes may be amended, and the observance of any term hereof or of the Notes may be waived
(either retroactively or prospectively), with (and only with) the written consent of the Company, the Borrower and the Required Holders, except that no such amendment or waiver may, without the written consent of the holder of each Note at the time
outstanding affected thereby, (a) change the amount or time of any prepayment or payment of principal of, or reduce the rate or change the time of payment or method of computation of interest or of the Make-Whole Amount on, the Notes,
(b) change the percentage of the principal amount of the Notes the holders of which are required to consent to any such amendment or waiver, or (c) amend any of Sections 8.1, 11(a), 12.1(a) and (b), 17.1 or 20 or the
definitions of Required Holders or Minimum Holders set forth on Schedule B. 
 Section 17.2 Solicitation of Holders of
Notes. 
 (a) Solicitation. The Borrower will provide each holder of the Notes (irrespective of the amount of Notes
then owned by it) with sufficient information, sufficiently far in advance of the date a decision is required, to enable such holder to make an informed and considered decision with respect to any proposed amendment, waiver or consent in respect of
any of the provisions hereof or of the Notes. The Borrower and the Company will deliver executed or true and correct copies of each amendment, waiver or consent effected pursuant to the provisions of this Section 17 to each holder of
outstanding Notes promptly following the date on which it is executed and delivered by, or receives the consent or approval of, the requisite holders of Notes. 
 (b) Payment. Neither the Borrower nor the Company will directly or indirectly pay or cause to be paid any remuneration, whether by
way of supplemental or additional interest, fee or otherwise, or grant any security, to any holder of Notes as consideration for or as an inducement to the entering into by any holder of Notes of any waiver or amendment of any of the terms and
provisions hereof unless such remuneration is concurrently paid, or security is concurrently granted, on the same terms, ratably to each holder of Notes then outstanding even if such holder did not consent to such waiver or amendment. 
 Section 17.3 Binding Effect, Etc. Any amendment or waiver consented to as provided in this Section 17 applies equally to all
holders of Notes and is binding upon them and upon each future holder of any Note and upon the Borrower without regard to whether such Note has been marked to indicate such amendment or waiver. No such amendment or waiver will extend to or affect
any obligation, covenant, agreement, Default or Event of Default not expressly amended or waived or impair any right consequent thereon. No course of dealing between the Borrower and the holder of any Note nor any delay in exercising any rights
hereunder or under any Note shall operate as a waiver of any rights of any holder of such Note. As used herein, the term “this Agreement” and references thereto shall mean this Agreement as it may from time to time be amended or
supplemented. 
  

 41 

 Section 17.4 Notes Held by Company, Etc. Solely for the purpose of determining whether the
holders of the requisite percentage of the aggregate principal amount of Notes then outstanding approved or consented to any amendment, waiver or consent to be given under this Agreement or the Notes, or have directed the taking of any action
provided herein or in the Notes to be taken upon the direction of the holders of a specified percentage of the aggregate principal amount of Notes then outstanding, Notes directly or indirectly owned by the Company or any of its Subsidiaries shall
be deemed not to be outstanding. 
 SECTION 18. NOTICES. 
 All notices and communications provided for hereunder shall be in writing and sent (a) by telefacsimile if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery
service (charges prepaid), or (b) by registered or certified mail with return receipt requested (postage prepaid), or (c) by a recognized overnight delivery service (with charges prepaid). Any such notice must be sent: 
 (i) if to a Purchaser or its nominee, to such Purchaser or its nominee at the address specified for such communications in
Schedule A, or at such other address as any holder of a Note or it shall have specified to the Company in writing, 
 (ii) if to any other holder of any Note, to such holder at such address as such other holder shall have specified to the Company in writing, or 
 (iii) if to the Borrower or the Company, to the Company at 3180 Porter Drive, Palo Alto, CA 94304, to the attention of Matthew K. Fust, Chief Financial Officer, with a copy to General Counsel, fax:
(650) 496-3781, or at such other address as the Company shall have specified to the holder of each Note in writing. 
 Notices under
this Section 18 will be deemed given only when actually received. 
 SECTION 19. REPRODUCTION OF
DOCUMENTS. 
 This Agreement and all documents relating hereto, including, without limitation, (a) consents, waivers and
modifications that may hereafter be executed, (b) documents received by the Purchasers at the Closing (except the Notes and Warrants themselves), and (c) financial statements, certificates and other information previously or hereafter
furnished to the Purchasers, may be reproduced by the Purchasers by any photographic, photostatic, microfilm, microcard, miniature photographic or other similar process and any holder of a Note may destroy any original document so reproduced. Each
of the Company and the Borrower agrees and stipulates that, to the extent permitted by applicable law, any such reproduction shall be admissible in evidence as the original itself in any judicial or administrative proceeding (whether or not the
original is in existence and whether or not such reproduction was made by a holder of any Note in the regular course of business) and any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible in evidence.
This Section 19 shall not prohibit the Company and the Borrower or any other holder of Notes from contesting any such reproduction to the same extent that it could contest the original, or from introducing evidence to demonstrate the
inaccuracy of any such reproduction. 
  

 42 

 SECTION 20. CONFIDENTIAL INFORMATION. 
 For the purposes of this Section 20, “Confidential Information” means information delivered to a Purchaser by or on behalf of
the Company or any Subsidiary in connection with the transactions contemplated by or otherwise pursuant to this Agreement that is proprietary in nature; provided that such term does not include information that (a) was publicly known or
otherwise known to such Purchaser without restriction prior to the time of such disclosure as evidenced by its written records, (b) subsequently becomes publicly known through no act or omission by such Purchaser or any Person acting on its
behalf, (c) otherwise becomes known to such Purchaser other than through disclosure by the Company or any Subsidiary or (d) constitutes financial statements delivered to a holder of a Note under Section 7.1 that are otherwise
publicly available, except in the case of clause (a), (b), or (c), to the extent such information came from a source known to such Purchaser to be bound by an obligation of confidentiality to the Company as any of its Subsidiaries. Each Purchaser
agrees to maintain the confidentiality of such Confidential Information for a period of at least 7 years in accordance with procedures adopted by such Purchaser in good faith to protect confidential information of third parties delivered thereto,
which procedures shall be at least as stringent as those used by such Purchaser with respect to its own important confidential information; provided that a Purchaser may deliver or disclose Confidential Information to (i) its directors,
trustees, officers, employees, agents, attorneys and affiliates (to the extent such disclosure reasonably relates to the administration of the investment represented by such Purchaser’s Notes) who are bound to the terms of this
Section 20 or are otherwise bound by a duty of confidentiality at least as restrictive as the terms of this Section 20, (ii) such Purchaser’s financial advisors and other professional advisors who agree to hold
confidential the Confidential Information substantially in accordance with the terms of this Section 20, (iii) any other holder of any Note, (iv) any Person who is permitted to purchase a Note or Warrant from such Purchaser
pursuant to the terms hereof or of the Notes or Warrants, as the case may be (but only if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section 20),
(v) any Person from which a Purchaser offers to purchase any Note or Warrant of the Company (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this
Section 20), (vi) any federal or state regulatory authority having jurisdiction over such Purchaser, (vii) any other Person to which such delivery or disclosure may be necessary or appropriate (w) to effect compliance with
any law, rule, regulation or order applicable to a Purchaser, (x) in response to any subpoena or other legal process, (y) in connection with any litigation to which such Purchaser is a party or (z) if an Event of Default has occurred
and is continuing, to the extent such Purchaser may reasonably determine such delivery and disclosure to be necessary or appropriate in the enforcement or for the protection of the rights and remedies under any Notes and this Agreement. Each holder
of a Note, by its acceptance of a Note, will be deemed to have agreed to be bound by and to be entitled to the benefits of this Section 20 as though it were a party to this Agreement. On reasonable request by the Company in connection
with the delivery to any holder of a Note of information required to be delivered to such holder under this Agreement or requested by such holder (other than a holder that is a party to this Agreement or its nominee), such holder will enter into an
agreement with the Company embodying the provisions of this Section 20. 
  

 43 

 SECTION 21. THE COLLATERAL AGENT. 
 Section 21.1 Appointment; Nature of Relationship. LB I Group Inc. is appointed by the Purchasers as the Collateral Agent hereunder and under
each of the other Related Documents, and each of the Purchasers irrevocably authorizes the Collateral Agent (for so long as the Collateral Agent remains in such capacity under this Agreement) to act as the contractual representative of such
Purchaser with only the rights and duties expressly set forth herein and in the other Related Documents. The Collateral Agent agrees to act as such contractual representative upon the express conditions contained in this Section 21.
Notwithstanding the use of the defined term “Collateral Agent” it is expressly understood and agreed that the Collateral Agent shall not have any fiduciary responsibilities to any Purchaser by reason of this Agreement and that the
Collateral Agent is merely acting as the representative of the Purchasers with only those duties as are expressly set forth in this Agreement and the other Related Documents. In its capacity as the Purchasers’ contractual representative, the
Collateral Agent (i) does not assume any fiduciary duties to any of the Purchasers, (ii) is a “representative” of the Purchasers within the meaning of Section 9-511 of the UCC and (iii) is acting as an independent
contractor, the rights and duties of which are limited to those expressly set forth in this Agreement and the other Related Documents. Each of the Purchasers agrees to assert no claim against the Collateral Agent on any agency theory or any other
theory of liability for breach of fiduciary duty, all of which claims each Purchaser waives. 
 Section 21.2 Powers. The
Collateral Agent shall have and may exercise such powers under the Related Documents as are specifically delegated to the Collateral Agent by the terms of each thereof, together with such powers as are reasonably incidental thereto. The Collateral
Agent shall have no implied duties or fiduciary duties to the Purchasers, or any obligation to the Purchasers to take any action hereunder or under any of the other Related Documents except any action specifically provided by the Related Documents
required to be taken by the Collateral Agent. 
 Section 21.3 General Immunity. Neither the Collateral Agent nor any of its
directors, officers, agents or employees shall be liable to the Company, the Borrower, any Subsidiary or Affiliate of the Company or the Borrower, or any Purchaser for any action taken or omitted to be taken by it or them hereunder or under any
other Related Documents or in connection herewith or therewith except to the extent such action or inaction is found in a final judgment by a court of competent jurisdiction to have arisen solely from (i) the gross negligence or willful
misconduct of such Person or (ii) breach of contract by such Person with respect to the Related Documents. 
 Section 21.4 No
Responsibility for Loans, Creditworthiness, Collateral, Recitals, Etc. Neither the Collateral Agent nor any of its directors, officers, Collateral Agents or employees shall be responsible for or have any duty to ascertain, inquire into, or
verify (i) any statement, warranty or representation made in connection with any Related Document or any borrowing hereunder; (ii) the performance or observance of any of the covenants or agreements of any obligor under any Related
Document; (iii) the satisfaction of any condition specified in Section 4, except receipt of items required to be delivered solely to the Collateral Agent; (iv) the existence or possible existence of any Default or Event of
Default or (v) the validity, effectiveness or genuineness of any Related Document or any other instrument or writing furnished in connection therewith. The Collateral Agent shall not be responsible to any 

  

 44 

 
Purchaser for any recitals, statements, representations or warranties herein or in any of the other Related Documents, for the perfection or priority of any
of the Liens on any of the Collateral, or for the execution, effectiveness, genuineness, validity, legality, enforceability, collectibility, or sufficiency of this Agreement or any of the other Related Documents or the transactions contemplated
thereby, or for the financial condition of any guarantor of any or all of the Obligations, the Company or any of its Subsidiaries. 
 Section 21.5 Action on Instructions of Purchasers. The Collateral Agent shall in all cases be fully protected in acting, or in refraining from acting, hereunder and under any other Related Document in accordance with written
instructions signed by the Required Purchasers (or any other percentage of Purchasers specified to be the applicable percentage in this Agreement or any other Related Document to act on specified matters), and such instructions and any action taken
or failure to act pursuant thereto shall be binding on all of the Purchasers and on all holders of Notes. The Collateral Agent shall be fully justified in failing or refusing to take any action hereunder and under any other Related Document unless
it shall first be indemnified to its satisfaction by the Purchasers pro rata against any and all liability, cost and expense that it may incur by reason of taking or continuing to take any such action. 
 Section 21.6 Employment of Collateral Agents and Counsel. The Collateral Agent may execute any of its duties as the Collateral Agent
hereunder and under any other Related Document by or through employees, agents, and attorney-in-fact and shall not be answerable to the Purchasers, except as to money or securities received by it or its authorized agents. The Collateral Agent shall
be entitled to advice of counsel concerning the contractual arrangement between the Collateral Agent and the Purchasers and all matters pertaining to the Collateral Agent’s duties hereunder and under any other Related Document. 
 Section 21.7 Reliance on Documents; Counsel. The Collateral Agent shall be entitled to rely upon any Note, notice, consent, certificate,
affidavit, letter, telegram, statement, paper or document believed by it to be genuine and correct and to have been signed or sent by the proper person or persons, and, in respect to legal matters, upon the opinion of counsel selected by the
Collateral Agent, which counsel may be employees of the Collateral Agent. 
 Section 21.8 The Collateral Agent’s Reimbursement
and Indemnification. The Purchasers agree to reimburse and indemnify the Collateral Agent ratably in proportion to the principal amount of their respective Notes outstanding from time to time (i) for any amounts not reimbursed by the
Borrower or the Company for which the Collateral Agent is entitled to reimbursement under the Related Documents, (ii) for any other expenses incurred by the Collateral Agent on behalf of the Purchasers, in connection with the preparation,
execution, delivery, administration and enforcement of the Related Documents and (iii) for any liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind and nature whatsoever
which may be imposed on, incurred by or asserted against the Collateral Agent in any way relating to or arising out of the Related Documents or any other document delivered in connection therewith or the transactions contemplated thereby, or the
enforcement of any of the terms thereof or of any such other documents, provided that no Purchaser shall be liable for any of the foregoing to the extent any of the foregoing is found in a final non-appealable judgment by a court of competent
jurisdiction to have arisen solely from the gross negligence or willful misconduct of the Collateral Agent. 
  

 45 

 Section 21.9 Rights as a Purchaser. With respect to its Notes, the Collateral Agent shall
have the same rights and powers hereunder and under any other Related Document as any Purchaser and may exercise the same as though it were not the Collateral Agent, and the term “Purchaser” or “Purchasers” shall, unless the
context otherwise indicates, include the Collateral Agent in its individual capacity. 
 Section 21.10 Successor Collateral
Agent. The Collateral Agent may resign at any time by written notice to the Purchasers and the Credit Parties, and the Collateral Agent may be removed at any time with or without cause by written notice received by the Collateral Agent from the
Required Purchasers. Upon any such resignation or removal, the Required Purchasers shall have the right to appoint, on behalf of the Credit Parties and the Purchasers, a successor Collateral Agent. If no successor Collateral Agent shall have been so
appointed by the Required Purchasers and shall have accepted such appointment within thirty days after the retiring Collateral Agent’s giving notice of resignation, then the retiring Collateral Agent may appoint, on behalf of the Credit Parties
and the Purchasers, a successor Collateral Agent. Notwithstanding anything herein to the contrary, so long as no Default has occurred and is continuing, each such successor Collateral Agent shall be subject to approval by the Credit Parties, which
approval shall not be unreasonably withheld. Upon the acceptance of any appointment as the Collateral Agent hereunder by a successor Collateral Agent, such successor Collateral Agent shall thereupon succeed to and become vested with all the rights,
powers, privileges and duties of the retiring Collateral Agent, and the retiring Collateral Agent shall be discharged from its duties and obligations hereunder and under the other Related Documents. After any retiring Collateral Agent’s
resignation hereunder as Collateral Agent, the provisions of this Section 21 shall continue in effect for its benefit in respect of any actions taken or omitted to be taken by it while it was acting as the Collateral Agent hereunder and
under the other Related Documents. 
 Section 21.11 Collateral Documents. 
 (a) Each Purchaser authorizes the Collateral Agent to enter into the Collateral Documents to which it is a party and to take all action
contemplated by such documents. Each Purchaser agrees that no holder of the Notes (other than the Collateral Agent) shall have the right individually to seek to realize upon the security granted by any Collateral Document, it being understood and
agreed that such rights and remedies may be exercised solely by the Collateral Agent for the benefit of the holders of the Notes upon the terms of the Collateral Documents. 
 (b) In the event that any Collateral is hereafter pledged by any Person as collateral security for the Obligations, the Collateral Agent
is hereby authorized to execute and deliver on behalf of the holders of the Notes any Related Documents necessary or appropriate to grant and perfect a Lien on such Collateral in favor of the Collateral Agent on behalf of the holders of the Notes.

 (c) The Purchasers hereby authorize the Collateral Agent, at its option and in its discretion, to (y) release any Lien
granted to or held by the Collateral Agent upon any Collateral and/or (z) release any guarantor from its obligations under any Guaranty (i) upon the satisfaction of all of the Obligations at any time arising under or in respect of this
Agreement or the Related Documents or the transactions contemplated hereby or 

  

 46 

 
thereby; (ii) in connection with any transaction permitted by, but only in accordance with, the terms of the applicable Related Document; or
(iii) in connection with any transaction approved, authorized or ratified in writing by the Required Purchasers, unless such release is required to be approved by all of the Purchasers hereunder. Upon request by the Collateral Agent at any
time, the Purchasers will confirm in writing the Collateral Agent’s authority to release particular types or items of Collateral pursuant to this Section 21.11. 
 (d) Upon any sale or transfer of assets constituting Collateral which is permitted pursuant to the terms of any Related Document, or
consented to in writing by the Required Purchasers, the Collateral Agent shall (and is hereby irrevocably authorized by the Purchasers to) execute such documents as may be necessary to evidence the release of the Liens granted to the Collateral
Agent for the benefit of the holders of the Notes herein or pursuant hereto upon the Collateral that was sold or transferred; provided, however, that (i) the Collateral Agent shall not be required to execute any such document on
terms which, in the Collateral Agent’s reasonable opinion, would expose the Collateral Agent to liability or create any obligation or entail any consequence other than the release of such Liens without recourse or warranty, and (ii) such
release shall not in any manner discharge, affect or impair the Obligations or any Liens upon (or obligations of the Company or any of its Subsidiaries in respect of) all interests retained by the Company or any of its Subsidiaries, including
(without limitation) the proceeds of the sale, all of which shall continue to constitute part of the Collateral. 
 SECTION 22. MISCELLANEOUS.

 Section 22.1 Successors and Assigns. All covenants and other agreements contained in this Agreement by or on behalf of any of
the parties hereto bind and inure to the benefit of their respective successors and assigns (including, without limitation, any subsequent holder of a Note) whether so expressed or not. Neither the Borrower nor the Company shall be entitled to
assign its rights hereunder without the written consent of each Purchaser and the Collateral Agent. 
 Section 22.2 Payments Due on
Non-Business Days. Anything in this Agreement or the Notes to the contrary notwithstanding, any payment of principal of or Make-Whole Amount or interest on any Note that is due on a date other than a Business Day shall be made on the next
succeeding Business Day without including the additional days elapsed in the computation of the interest payable on such next succeeding Business Day. 
 Section 22.3 Headings. Section headings used in this Agreement are for convenience of reference only and are not a part of this Agreement for any other purpose. 
 Section 22.4 Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall (to the full extent permitted by law) not
invalidate or render unenforceable such provision in any other jurisdiction. 
  

 47 

 Section 22.5 Construction. Each covenant contained herein shall be construed (absent express
provision to the contrary) as being independent of each other covenant contained herein, so that compliance with any one covenant shall not (absent such an express contrary provision) be deemed to excuse compliance with any other covenant. Where any
provision herein refers to action to be taken by any Person, or which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or indirectly by such Person. 
 Section 22.6 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which
together shall constitute one instrument. Each counterpart may consist of a number of copies hereof, each signed by less than all, but together signed by all, of the parties hereto. 
 Section 22.7 Governing Law. This Agreement shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the State of New York, including Section 5-1401 of the General Obligations Law of said State. 
 Section 22.8 Waiver of Jury Trial. Each of the Borrower and the Company irrevocably waives, to the fullest extent permitted by law, any and all right to trial by jury in any legal proceeding arising out of
or relating to this Agreement or any other Related Document or the transactions contemplated thereby. 
 Section 22.9 Indemnity.
The Borrower and the Company further agree, jointly and severally, to defend, protect, indemnify, and hold harmless the Collateral Agent and each and all of the holders of Notes, each of their respective Affiliates and their respective officers,
directors, employees, attorneys and agents (collectively, the “Indemnitees”) from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses of any kind or nature
whatsoever (including, without limitation, the reasonable fees and disbursements of counsel for such Indemnitees in connection with any investigative, administrative or judicial proceeding, whether or not such Indemnitees shall be designated a party
thereto), imposed on, incurred by, or asserted against such Indemnitees in any manner relating to or arising out of this Agreement, any other Related Documents or the Merger Agreement (collectively, the “Indemnified Matters”);
provided, however, that neither the Borrower nor the Company shall have any obligation to an Indemnitee hereunder with respect to Indemnified Matters caused by or resulting from (a) a dispute among the Purchasers or
a dispute between any Purchaser and the Collateral Agent, or (b) the willful misconduct or gross negligence of such Indemnitee. If the undertaking to indemnify, pay and hold harmless set forth in the preceding sentence may be unenforceable
because it is violative of any law or public policy, the Borrower and the Company shall contribute the maximum portion which it is permitted to pay and satisfy under applicable law, to the payment and satisfaction of all Indemnified Matters incurred
by the Indemnitees. This Section 22.9 shall survive the full payment of the Obligations and the termination of this Agreement or any other Related Document. 
 *    *    *    *    * 
  

 48 

 If you are in agreement with the foregoing, please sign the form of agreement on the accompanying
counterpart of this Agreement and return it to the Company, whereupon the foregoing shall become a binding agreement between you and the Company and the Borrower. 
  

			
	 Very truly yours,

	
	TWIST MERGER SUB, INC.
		
	By:	 	 /s/ Matthew K. Fust

		 	Matthew K. Fust, Vice President and
		 	Chief Financial Officer

  

			
	 JAZZ PHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ Samuel R. Saks

		 	 Samuel R. Saks, Chief Executive Officer

  

			
	 LBI I GROUP INC.

		
	 By:
	 	 /s/ Jeffrey A. Ferrell

	 Name:
	 	 Jeffrey A. Ferrell

	 Title:
	 	 Vice President

  

			
	 KKR TRS HOLDINGS, INC.

		
	 By:
	 	 /s/ Barbara J.S. McKee

	 Name:
	 	 Barbara J.S. McKee

	 Title:
	 	 Authorized Signatory

  

 49 

			
	DEEP COVE MEZZANINE, LLC
		
	By:	 	 /s/ Reeve B. Waud

	Name:	 	Reeve B. Waud
	Its:	 	Manager

  

			
	CARDINAL FUND I, L.P.
		
	By:	 	Cardinal Management I, L.P., General Partner
		
	By:	 	Cardinal MGP, L.L.C., General Partner
		
	By:	 	 /s/ Ray Pinson

	Name:	 	Ray Pinson
	Title:	 	Vice President

  

			
	FW JAZZ PHARMA INVESTORS, L.P.
		
	By:	 	Group VI, 31, L.L.C., General Partner
		
	By:	 	 /s/ Ray Pinson

	Name:	 	Ray Pinson
	Title:	 	Vice President

  

			
	OAK HILL CREDIT ALPHA FUND, LP
		
	By:	 	Oak Hill Credit Alpha GenPar, L.P., Its General Partner
		
	By:	 	Oak Hill Credit Alpha MGP, LLC, Its General Partner
		
	By:	 	 /s/ Glenn R. August

	Name:	 	Glenn R. August
	Title:	 	Managing Member

  

 50 

			
	 LERNER ENTERPRISES, L.P.

		
	 By:
	 	 Oak Hill Advisors, L.P. as advisor and attorney-in-fact to Lerner Enterprises, L.P. (OHP account)

		
	 By:
	 	 /s/ Glenn R. August

	 Name:
	 	 Glenn R. August

	 Title:
	 	 President

  

			
	 GENERAL ELECTRIC PENSION TRUST

		
	 By:
	 	 GE Asset Management Incorporated

		 	 Its Investment Manager

  

			
	By:	 	 /s/ Michael M. Pastore

	Name:	 	Michael M. Pastore
	Title:	 	Vice President

  

 51 

 SCHEDULE A 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 INFORMATION RELATING TO PURCHASERS

  

					
	 NAME AND ADDRESS OF
 PURCHASER
	 	 PRINCIPAL AMOUNT
 OF NOTES TO BE
 PURCHASED
	 	 NUMBER OF SHARES
 OF BB PREFERRED
 WARRANT
SHARES

	 LB I Group Inc.
 c/o Lehman Brothers
 399 Park Avenue, 9th Floor
 New York, NY 10022
 Attn: Jeffrey A. Ferrell
	 	$30,000,000	 	3,260,870
			
	 KKR TRS Holdings, Inc.
 c/o KKR Financial
Corp.
 4 Embarcadero Center, Suite 2050
 San Francisco, CA
94111
 Attn: Barbara J.S. McKee
	 	$25,000,000	 	2,717,391

  

 52 

					
	 NAME AND ADDRESS OF
 PURCHASER
	 	 PRINCIPAL AMOUNT
 OF NOTES TO BE
 PURCHASED
	 	 NUMBER OF SHARES
 OF BB PREFERRED
 WARRANT
SHARES

	 Deep Cove Mezzanine, LLC
 560 Oakwood Avenue, Suite 203
 Lake Forest, IL 60045
 Attn: Mark Flower
  
	 	$ 5,000,000	 	543,478
			
	 Cardinal Fund I, L.P.
 201 Main Street, Suite 2415
 Fort Worth, TX 76102
 Attn: Ray Pinson
  
	 	$ 800,000	 	86,957
			
	 FW Jazz Pharma Investors, L.P.
 201 Main Street, Suite 3100
 Fort Worth, TX 76102
 Attn: John H. Fant
	 	$ 400,000	 	43,478

  

 53 

					
	 NAME AND ADDRESS OF
 PURCHASER
	 	 PRINCIPAL AMOUNT
 OF NOTES TO BE
 PURCHASED
	 	 NUMBER OF SHARES
 OF BB PREFERRED
 WARRANT
SHARES

	 Oak Hill Credit Alpha Fund, LP
 c/o Oak Hill
Advisors, LP
 65 East 55th Street - 32nd Floor
 New York, NY 10022
 Attn: Jennifer Cohen/Shilpa Wani
	 	$ 7,000,000	 	760,870
			
	 Lerner Enterprises, L.P.
 c/o Oak Hill
Advisors
 65 East 55th
Street
 New York, NY 10022
 Attn: Jennifer Cohen/Shilpa
Wani
	 	$ 3,800,000	 	413,043

  

 54 

					
	 NAME AND ADDRESS OF
 PURCHASER
	 	 PRINCIPAL AMOUNT
 OF NOTES TO BE
 PURCHASED
	 	 NUMBER OF SHARES
 OF BB PREFERRED
 WARRANT
SHARES

	 General Electric Pension Trust
 c/o GE Asset Management Incorporated
 3001 Summer Street
 P.O. Box 7900
 Stamford, CT 06904-7900
 Attn: Daniel L. Furman
  
	 	$ 8,000,000	 	869,565

  

 55 

 SCHEDULE B 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 DEFINED TERMS 
 As used herein, the following terms have the respective meanings set forth below or set forth in the Section hereof following such term: 

“Accounts” means, with respect to any Person, all of such Person’s now existing and future: (a) accounts (as defined in the
UCC), and any and all other receivables, including, without limitation, all accounts created by, or arising from, all of such Person’s sales, leases, rentals of goods or renditions of services to its customers (whether or not they have been
earned by performance), including but not limited to, those accounts arising under any of such Person’s trade names, logos or styles, or through any of such Person’s divisions; (b) any and all instruments, documents, chattel paper
(including electronic chattel paper), contracts and contract rights (all as defined in the UCC); (c) unpaid seller’s or lessor’s rights (including rescission, replevin, reclamation, repossession and stoppage in transit) relating to
the foregoing or arising therefrom; (d) rights to any goods represented by any of the foregoing, including rights to returned, reclaimed or repossessed goods; (e) reserves and credit balances arising in connection with or pursuant to any
of the foregoing; (f) guaranties, supporting obligations, payment intangibles and letter of credit rights (all as defined in the UCC); (g) insurance policies or rights relating to any of the foregoing; (h) general intangibles
pertaining to any and all of the foregoing (including all rights to payment, including those arising in connection with bank and non-bank credit cards), and including books and records and any electronic media and software thereto; (i) notes,
deposits or property of account debtors securing the obligations of any such account debtors to such Person; and (j) cash and non-cash proceeds (as defined in the UCC) of any and all of the foregoing. 
 “Affiliate” means, at any time, and with respect to any Person, any other Person that at such time directly or indirectly through one or
more intermediaries Controls, or is Controlled by, or is under common Control with, such first Person. As used in this definition, “Control” means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. Unless the context otherwise clearly requires, any reference to an “Affiliate” is a reference to an Affiliate
of the Company. 
 “Asset Disposition” means any transaction, or series of related transactions, pursuant to which the
Company or any of its Subsidiaries sells, assigns, transfers or otherwise disposes of any property (whether now owned or hereafter acquired) yielding proceeds to any Credit Party in excess of $500,000 for any such transaction or series of related
transactions to any other Person (other than the Company or any Domestic Subsidiary), in each case, whether or not the consideration therefor consists of cash, securities or other assets, excluding any sales of Inventory in the ordinary course of
business on ordinary business terms; provided, however, that, notwithstanding the foregoing, any sale, assignment, transfer or other disposal of any property by the Company or any Subsidiary of the Company permitted by
Section 10.2 (a), (b) or (c) shall not be deemed to be an Asset Disposition. 

 “Bankruptcy Code” is defined in Section 2.4. 
 “Business Day” means any day other than a Saturday, a Sunday or a day on which commercial banks in New York City are required or
authorized to be closed. 
 “Capital Lease” means, at any time, a lease with respect to which the lessee is required
concurrently to recognize the acquisition of an asset and the incurrence of a liability in accordance with GAAP. 
 “Capitalized
Rentals” of any Person means as of the date of any determination thereof the amount at which the aggregate Rentals due and to become due under all Capital Leases under which such Person is a lessee would be reflected as a liability on a
consolidated balance sheet of such Person. 
 “Closing” is defined in Section 1.3. 
 “Change in Control” means (i) a sale of all or substantially all of the assets of the Company to a Person that is neither a Person
who holds any shares of Series B/P Preferred Stock of the Company as of the date the first share of Series B/P Preferred Stock was issued (an “Initial B/P Holder”) nor an Affiliate of an Initial B/P Holder, or to two or more Persons
acting together as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of or voting securities of the Company (a “Group”) that does not include an Initial B/P Holder or an
Affiliate of an Initial B/P Holder, or a sale of all or substantially all of the assets of the Company to a Person in which the stockholders of the Company immediately prior to such transaction do not control more than 50% of the voting power
immediately following the transaction; (ii) a transaction or series of related transactions by the Company (other than transaction(s) determined by the Board of Directors to be primarily for cash financing purposes) or by any stockholder or
stockholders of the Company resulting in more than 50% of the voting power of the Company being held by a Person that is neither an Initial B/P Holder nor an Affiliate of an Initial B/P Holder, or by a Group that does not include an Initial B/P
Holder or an Affiliate of an Initial B/P Holder; (iii) a merger or consolidation of the Company with or into a Person that is neither an Initial B/P Holder nor an Affiliate of an Initial B/P Holder, or with or into a Group that does not include
an Initial B/P Holder or an Affiliate of an Initial B/P Holder, if and only if, after such merger or consolidation, directors of the Company immediately prior to such merger or consolidation do not constitute a majority of the directors of the
surviving entity or its parent. 
 “Code” means the Internal Revenue Code of 1986, as amended from time to time, and the
rules and regulations promulgated thereunder from time to time. 
 “Collateral” is defined in Section 3.1.

 “Collateral Agent” means LB I Group Inc. in its capacity as contractual representative for itself and the Purchasers
pursuant to Section 21 hereof and any successor Collateral Agent appointed pursuant Section 21. 
  

 2 

 “Collateral Documents” means the Pledge Agreement and all other mortgages, deeds of
trust, security agreements, assignments, control account agreements, financing statements and other documents or instruments as shall from time to time secure the Obligations. 
 “Commitment Letter” is defined in Section 4.5. 
 “Company Guaranty” is defined in Section 2.3. 
 “Confidential Information” is defined in Section 20. 
 “Consolidated
EBITDA” means, with reference to any period, the EBITDA of the Company and its Subsidiaries determined on a consolidated basis for such period. 
 “Consolidated Net Tangible Assets” means as of the date of any determination thereof the total amount of all Tangible Assets of the Company and its Subsidiaries determined on a consolidated basis (and
without duplication) in accordance with GAAP. 
 “Consolidated Secured Indebtedness” means as of the date of any
determination thereof all secured Indebtedness of the Company and its Subsidiaries determined on a consolidated basis (and without duplication but after eliminating intercompany items) in accordance with GAAP. 
 “Credit Party” means the Borrower, the Company and any Domestic Subsidiary. 
 “Default” means an event or condition the occurrence or existence of which would, with the lapse of time or the giving of notice or
both, become an Event of Default. 
 “Documents of Title” shall mean all present and future documents (as defined in the
UCC), and any and all warehouse receipts, bills of lading, shipping documents, chattel paper, instruments and similar documents, all whether negotiable or not. 
 “Domestic Subsidiary” means a Subsidiary of the Company formed under the laws of any state of the United States or the District of Columbia. 
 “Environmental Laws” means any and all Federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments,
orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including but not limited
to those related to hazardous substances or wastes, air emissions and discharges to waste or public systems. 
 “Equipment”
means all equipment (as defined in the UCC), including, without limitation (whether or not included in the UCC definition of “equipment”), all furniture, furnishings, fixtures and machinery, and all parts thereof and all additions and
accessions thereto and replacements therefor and all cash and non-cash proceeds (as defined in the UCC) of any and all of the foregoing. 
 “EBITDA” for any Person during any period means Net Income of such Person for such period plus all amounts deducted in arriving at such Net Income amount in respect of (a) Interest 

  

 3 

 
Expense for such period, plus (b) Federal, state and local income taxes for such period, plus (c) all amounts charged for
depreciation of fixed assets and amortization of intangible assets during such period, plus (d) all non-cash, non-recurring or extraordinary charges, expenses or losses for such period, minus (e) non-cash gains, non-recurring
gains, and extraordinary gains, all determined in accordance with GAAP. 
 “ERISA” means the Employee Retirement Income
Security Act of 1974, as amended from time to time, and the rules and regulations promulgated thereunder from time to time in effect. 
 “ERISA Affiliate” means any trade or business (whether or not incorporated) that is treated as a single employer together with the Company under Section 414 of the Code. 
 “Event of Default” is defined in Section 11. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Foreign
Subsidiary” means a Subsidiary of the Company that is not a Domestic Subsidiary. 
 “Fraudulent Conveyance” is
defined in Section 2.3. 
 “GAAP” means generally accepted accounting principles as in effect from time to time
in the United States of America. 
 “General Intangibles” means, as to any Person, all “general intangibles” as
defined in the UCC, now owned or hereafter acquired, including, without limitation (whether or not included in the UCC definition of “general intangibles”), all of such Person’s then owned or existing and future acquired or arising
general intangibles, causes in action and causes of action and all other intangible personal property of such Person of every kind and nature, including, without limitation, Intellectual Property, franchises, tax refund claims, reversions or any
rights thereto and any other amounts payable to such Person from any rights and claims against carriers and shippers, rights to indemnification, and business interruption, property, casualty or any similar type of insurance and any proceeds thereof,
and all cash and non-cash proceeds (as defined in the UCC) of any and all of the foregoing. 
 “Governmental Authority”
means 
 (a) the government of 
 (i) the United States of America or any State or other political subdivision thereof, or 
 (ii) any jurisdiction in which the
Company or any Subsidiary conducts all or any part of its business, or which asserts jurisdiction over any properties of the Company or any Subsidiary, or 
 (b) any entity exercising executive, legislative, judicial, regulatory or administrative functions of, or pertaining to, any such government. 
  

 4 

 “Guaranty” means, with respect to any Person, any obligation (except the endorsement in
the ordinary course of business of negotiable instruments for deposit or collection) of such Person guaranteeing or in effect guaranteeing any Indebtedness, dividend or other obligation of any other Person in any manner, whether directly or
indirectly, including (without limitation) obligations incurred through an agreement, contingent or otherwise, by such Person: 
 (a) to
purchase such Indebtedness or obligation or any property constituting security therefor; 
 (b) to advance or supply funds (i) for the
purchase or payment of such Indebtedness or obligation, or (ii) to maintain any working capital or other balance sheet condition or any income statement condition of any other Person or otherwise to advance or make available funds for the
purchase or payment of such Indebtedness or obligation; 
 (c) to lease properties or to purchase properties or services primarily for the
purpose of assuring the owner of such Indebtedness or obligation of the ability of any other Person to make payment of the Indebtedness or obligation; or 
 (d) otherwise to assure the owner of such Indebtedness or obligation against loss in respect thereof. 
 In
any computation of the Indebtedness or other liabilities of the obligor under any Guaranty, the Indebtedness or other obligations that are the subject of such Guaranty shall be assumed to be direct obligations of such obligor. 
 “Hazardous Material” means any and all pollutants, toxic or hazardous wastes or any other substances that pose a hazard to health or
safety, the removal of which may be required or the generation, manufacture, refining, production, processing, treatment, storage, handling, transportation, transfer, use, disposal, release, discharge, spillage, seepage, or filtration of which is
restricted, prohibited or penalized by any applicable Environmental Law (including, without limitation, asbestos, urea formaldehyde foam insulation and polychlorinated biphenyls). 
 “holder” means, with respect to any Note, the Person in whose name such Note is registered in the register maintained by the Company
pursuant to Section 13.1. 
 “Indebtedness” with respect to any Person means, at any time, without duplication,

 (a) its liabilities for borrowed money and its redemption obligations in respect of mandatorily redeemable preferred stock; 
 (b) its liabilities for the deferred purchase price of property acquired by such Person (excluding accounts payable arising in the ordinary course of
business but including all liabilities created or arising under any conditional sale or other title retention agreement with respect to any such property); 
 (c) all liabilities appearing on its balance sheet in accordance with GAAP in respect of Capital Leases; 
  

 5 

 (d) all liabilities for borrowed money secured by any Lien with respect to any property owned by such
Person (whether or not it has assumed or otherwise become liable for such liabilities); 
 (e) all its liabilities in respect of letters of
credit or instruments serving a similar function issued or accepted for its account by banks and other financial institutions (whether or not representing obligations for borrowed money); 
 (f) all payment obligations of such Person with respect to interest rate swaps, currency swaps and similar obligations; and 
 (g) any Guaranty of such Person with respect to liabilities of a type described in any of clauses (a) through (f) hereof. 
 Indebtedness of any Person shall include all obligations of such Person of the character described in clauses (a) through (g) to the extent
such Person remains legally liable in respect thereof notwithstanding that any such obligation is deemed to be extinguished under GAAP. 
 “Intellectual Property” means all present and future designs, patents, patent rights and applications therefor, trademarks and registrations or applications therefor, trade names, inventions, copyrights and all applications
and registrations therefor, software or computer programs, in-bound licensed rights, trade secrets, methods, processes, know-how, drawings, specifications, descriptions, and all memoranda, notes and records with respect to any research and
development, whether now owned or hereafter acquired, and all goodwill associated with any of the foregoing. 
 “Interest
Expense” of the Company and its Subsidiaries for any period means all interest (including the interest component of Rentals on Capital Leases) and all amortization of debt discount and expense on any particular Indebtedness (including,
without limitation, payment-in-kind, zero coupon and other like securities) for which such calculations are being made. Computations of Interest Expense on a pro forma basis for Indebtedness having a variable interest rate shall be calculated
at the rate in effect on the date of any determination. 
 “Inventory” means, as to any Person, all “inventory” of
such Person as defined in the UCC including, without limitation (whether or not included in the UCC definition of “inventory”), all of such Person’s then owned or existing and future acquired or arising: (a) inventory,
merchandise, goods and other personal property intended for sale or lease or for display or demonstration; (b) work in process; (c) raw materials and other materials and supplies of every nature and description used or which might be used
in connection with the manufacture, packing, shipping, advertising, selling, leasing or furnishing of the foregoing or otherwise used or consumed in the conduct of business; (d) documents evidencing, and General Intangibles relating to, any of
the foregoing; and (e) all cash and non-cash proceeds (as defined in the UCC) of any and all of the foregoing. 
 “Investment
Property” means a security, whether certificated or uncertificated, security entitlement, securities account, commodity contract or commodity account. 
  

 6 

 “Investments” means all investments, in cash or by delivery of property, made directly
or indirectly in any property or assets of any Person or in any Person, whether by acquisition of shares of capital stock, Indebtedness or other obligations or Securities or by loan, advance, capital contribution or otherwise. 
 “Knowledge” means, as to the Company, the actual knowledge of any officer, director or employee of the Company or any Subsidiary of the
Company after reasonable investigation. 
 “Lien” means, with respect to any Person, any mortgage, lien, pledge, charge,
security interest or other encumbrance, or any interest or title of any vendor, lessor, lender or other secured party to or of such Person under any conditional sale or other title retention agreement or Capital Lease, upon or with respect to any
property or asset of such Person (including in the case of stock, stockholder agreements, voting trust agreements and all similar arrangements). 
 “Make- Whole Amount” means, with respect to any principal prepayment for which the Make-Whole Amount is applicable, an amount determined with reference to the following formula: 
 Make-Whole Amount = pmt x (.40 – (qtr x .0167)) 
 where: 
  

					
	pmt	  	=	  	the amount of the applicable principal prepayment; and
			
	qtr	  	=	  	the number which is the quotient of: (x) the fewer of the number of months elapsed subsequent to the date of the Closing and the date upon which (i) an Event of Default
occurs and continues for more than 30 days notwithstanding the fact that such Event of Default is cured thereafter, or (ii) the applicable prepayment is made; divided by (y) three.

 Notwithstanding the foregoing to the contrary, so long as no Event of Default shall have occurred and be
continuing, the Make-Whole Amount for any voluntary principal prepayment on the Notes of up to $40,000,000 in the aggregate at any time after the second anniversary of the Closing shall be equal to 10% of such principal prepayment if the Company
shall have, prior to or at such time, closed one or more equity financings (other than in connection with the issuance of the Series B Preferred Stock of the Company) in an aggregate gross amount of at least $40,000,000; provided,
however, that the $40,000,000 maximum amount described in this proviso for the alternate Make-Whole Amount shall be reduced dollar for dollar by the amount of any mandatory prepayments made pursuant to Section 8.1. 
 “Mandatory Prepayment Event” means, with respect to any Credit Party, the occurrence of an Asset Disposition in connection with such
Credit Party, the receipt by such Credit Party of any cash insurance proceeds for damaged or destroyed property that yields gross proceeds to such Credit Party in excess of $500,000, or the receipt by such Credit Party of any cash proceeds from any
judgment awards or settlements that yield gross proceeds to such Credit Party in excess of $500,000. 
 “Material” means
material in relation to the business, operations, affairs, financial condition, assets or properties of the Company and its Subsidiaries taken as a whole. 
  

 7 

 “Material Adverse Effect” means a material adverse effect on (a) the business,
operations, affairs, financial condition, assets or properties of the Company and its Subsidiaries taken as a whole, or (b) the ability of the Company or the Borrower to perform its obligations under this Agreement and the Notes and Warrants,
or (c) the validity or enforceability of this Agreement or the Notes or the Warrants. 
 “Merger” is defined in the
opening recitals to this Agreement. 
 “Merger Agreement” is defined in the opening recitals to this Agreement. 

“Minimum Holders” means, at any time, the holders of at least 31% in principal amount of the Notes at the time outstanding (exclusive
of Notes then owned by the Company). 
 “Minority Interests” means, with respect to any Person, any shares of stock of any
class of a Subsidiary of such Person (other than directors’ qualifying shares as required by law) that are not owned by such Person and/or one or more of its Subsidiaries. Minority Interests shall be valued by valuing Minority Interests
constituting preferred stock at the voluntary or involuntary liquidating value of such preferred stock, whichever is greater, and by valuing Minority Interests constituting common stock at the book value of capital and surplus applicable thereto
adjusted, if necessary, to reflect any changes from the book value of such common stock required by the foregoing method of valuing Minority Interests in preferred stock. 
 “Multiemployer Plan” means any Plan that is a “multiemployer plan” (as such term is defined in Section 400 l(a)(3) of ERISA). 
 “Net Income” for any Person during any period means the gross revenues of such Person and its Subsidiaries for such period less all
expenses and other proper charges (including taxes on income), determined on a consolidated basis after eliminating earnings or losses attributable to outstanding Minority Interests, but excluding in any event: 
 (a) any gains or losses on the sale or other disposition of Investments or fixed or capital assets, and any taxes on such excluded gains and any tax
deductions or credits on account of any such excluded losses; 
 (b) the proceeds of any life insurance policy; 
 (c) net earnings and losses of any Subsidiary accrued prior to the date it became a Subsidiary; 
 (d) net earnings and losses of any corporation (other than a Subsidiary), substantially all the assets of which have been acquired in any manner by such
Person or any Subsidiary thereof, realized by such corporation prior to the date of such acquisition; 
 (e) net earnings and losses of any
corporation (other than a Subsidiary) with which such Person or any Subsidiary thereof shall have consolidated or which shall have merged into or with such Person or any Subsidiary thereof prior to the date of such consolidation or merger;

  

 8 

 (f) net earnings of any business entity (other than a Subsidiary) in which such Person or any Subsidiary
thereof has an ownership interest unless such net earnings shall have actually been received by such Person or any Subsidiary thereof in the form of cash distributions; 
 (g) any portion of the net earnings of any Subsidiary which for any reason is unavailable for payment of dividends to such Person or any Subsidiary thereof; 
 (h) earnings resulting from any reappraisal, revaluation or write-up of assets; 
 (i) any deferred or other credit representing any excess of the equity in any Subsidiary of such Person at the date of acquisition thereof over the
amount invested in such Subsidiary; 
 (j) any gain arising from the acquisition of any securities of such Person or any Subsidiary thereof;

 (k) any reversal of any contingency reserve, except to the extent that provision for such contingency reserve shall have been made from
income arising during such period; and 
 (l) any other extraordinary gain. 
 “Net Proceeds” means: 
 (a)
with respect to any Asset Disposition by any Person, the amount of cash received (directly or indirectly) from time to time (whether as initial consideration or through the payment or disposition of deferred consideration) by or on behalf of such
Person in connection therewith after deducting therefrom only (i) the amount of any Indebtedness secured by any Lien which is permitted by Section 10.3 on any property (other than any Indebtedness assumed by the purchaser of such
property and Indebtedness evidenced by the Notes) which is required to be, and is, repaid in connection with such Asset Disposition, (ii) reasonable expenses related thereto incurred by such Person in connection with the Asset Disposition,
(iii) transfer taxes paid or due to be paid by such Person to any taxing authorities in connection with such Asset Disposition, and (iv) any amount of reserves properly taken on the balance sheet of the Person making the Asset Disposition,
as reasonably determined by the Board of Directors of such Person in its good faith judgment; provided that such reserves shall be deemed part of Net Proceeds if and to the extent such reserves are not actually paid by the applicable Person
and are removed from such Person’s balance sheet; 
 (b) with respect to any insurance proceeds received by any Person in connection
with the damage or destruction of any property or asset, the amount of cash received (directly or indirectly) by or on behalf of such Person in connection therewith after deducting therefrom only (i) the amount of any Indebtedness secured by
any Lien which is permitted by Section 10.3 on the damaged or destroyed property or asset (other than any Indebtedness evidenced by the Notes) and (ii) reasonable expenses related thereto incurred by such Person in connection with
the collection of such insurance proceeds; 
 (c) with respect to any judgment awards or settlements received by any Person, the amount of
cash received (directly or indirectly) by or on behalf of such Person in 

  

 9 

 
connection therewith after deducting therefrom only reasonable expenses related thereto incurred by such Person in connection with the obtaining of such
award or the negotiation of such settlement; and 
 (d) cash received by any Person from the conversion of any non-cash proceeds received in
connection with an Asset Disposition, insurance awards or any judgments or settlements, subject to any applicable reductions noted in clauses (a), (b) and (c) above. 
 “New Subsidiary” is defined in Section 9.7. 
 “Notes” is defined in Section 1. 
 “Obligations” is defined in
Section 2.2. 
 “Officer’s Certificate” means a certificate of a Senior Financial Officer or of any other
officer of the Company whose responsibilities extend to the subject matter of such certificate. 
 “Orphan Medical” is
defined in the opening recitals of this Agreement. 
 “Orphan Sub” is defined in Section 8.4(b). 
 “Other Collateral” means: 
 (a) all other goods and property, whether or not delivered, including, without limitation, such other goods and property: (i) the sale or lease of which gives or purports to give rise to any Account or other
Collateral, including, but not limited to, all Inventory and other merchandise returned or rejected by or repossessed from customers; (ii) securing any Account or other Collateral, including, without limitation, all rights as a consignor, a
consignee, an unpaid vendor or lienor (including, without limitation, stoppage in transit, replevin and reclamation) with respect to such other goods and properties; or (iii) warranty claims relating to goods; 
 (b) all substitutes and replacements for, accessories, attachments, and other additions to, any of the above and any and all products or
masses into which any goods are physically united such that their identity is lost; 
 (c) all policies and certificates of
insurance relating to any of the foregoing, now owned or hereafter acquired, evidencing or pertaining to any and all items of Collateral; 
 (d) all files, correspondence, computer programs, tapes, discs and related data processing software which contain information identifying or pertaining to any of the Collateral or any account debtor, or showing the
amounts thereof or payments thereon or otherwise necessary or helpful in the realization thereon or the collection thereof; and 
 (e) any and all products and proceeds of the foregoing (including, but not limited to, any claim to any item of Collateral and any claim against any third party for loss of, damage to or destruction of any or all of, the Collateral or for
proceeds payable 

  

 10 

 
under, or unearned premiums with respect to, policies of insurance) in whatever form, including, but not limited to, cash, instruments, chattel paper,
security agreements and other documents. 
 “PBGC” means the Pension Benefit Guaranty Corporation referred to and defined in
ERISA or any successor thereto. 
 “Permitted Acquisition Indebtedness” is defined in Section 10.1(a)(v).

 “Permitted Foreign Subsidiary Transfer” means the transfer by the Company or a Subsidiary of the Company other than the
Borrower (or a Subsidiary of the Borrower) of the international rights to a Product candidate to a Foreign Subsidiary, all pursuant to documentation and on terms reasonably acceptable to the Purchasers. 
 “Permitted Investments” means: 
 (a) Investments by the Company and its Subsidiaries in and to the Company or a: 
 (i)
Domestic Subsidiary, including any Investment in a corporation which, after giving effect to such Investment, will become a Domestic Subsidiary as permitted by Section 10.5(a); or 
 (ii) Foreign Subsidiary permitted to be created and capitalized by Section 10.5(b) so long as: 
 (1) such Foreign Subsidiary is established solely to carry out the Company’s or any of its Subsidiaries’ business operations in
a particular foreign jurisdictions where it is necessary or prudent, in the good faith determination of the Board of Directors of the Company, to establish a separate legal entity under local law; 
 (2) such Investment is comprised of only that amount of capital and other property as is determined to be necessary from time to time, in
the good faith discretion of the Board of Directors of the Company, to conduct the ordinary and intended business operations of such Foreign Subsidiary; and 
 (3) such Investment would not be reasonably expected to have a Material Adverse Effect or otherwise materially adversely effect the value
or priority of the Collateral, taken as a whole, for the prompt and full payment of the Obligations; 
 (b) Investments
representing loans or advances in the usual and ordinary course of business to officers, directors and employees for expenses (including moving expenses related to a transfer) incidental to carrying on the business of the Company or any Domestic
Subsidiary; 
  

 11 

 (c) Investments in property or assets to be used in the ordinary course of the business
of the Company and its Subsidiaries as described in Section 9.6 of this Agreement; 
 (d) Investments representing
travel advances in the usual and ordinary course of business to officers and employees of the Company and its Subsidiaries incidental to carrying-on the business of the Company or any Subsidiaries; 
 (e) receivables arising from the sale of goods and services in the ordinary course of business of the Company and its Subsidiaries;

 (f) Investments in commercial paper or corporate debt obligation of corporations organized under the laws of the United
States or any state thereof maturing in 270 days or less from the date of issuance which, at the time of acquisition by the Company or any Subsidiary, is accorded the highest rating by Standard & Poor’s Ratings Group, a division of
McGraw-Hill, Inc., a New York corporation, or by Moody’s Investors Service, Inc.; 
 (g) Investments in direct
obligations of the United States of America or any agency or instrumentality of the United States of America, the payment or guarantee of which constitutes a full faith and credit obligation of the United States of America, in either case, maturing
within twelve months from the date of acquisition thereof; 
 (h) Investments in certificates of deposit and time deposits
maturing within one year from the date of issuance thereof, issued by a bank or trust company organized under the laws of the United States or any State thereof; provided that at the time of acquisition thereof by the Company or a Subsidiary,
(i) the senior unsecured long-term debt of such bank or trust company or of the holding company of such bank or trust company is rated AA or better by Standard & Poor’s Ratings Group, a division of McGraw-Hill, Inc., a New York
corporation, or “Aa2” or better by Moody’s Investors Service, Inc. or (ii) such Investments are fully insured by the Federal Depository Insurance Corporation; and 
 (i) Investments in any money market fund which invests substantially all of its assets in obligations described in clauses (g) and
(h) above. 
 “Permitted Liens” means: 
 (a) Liens in favor of the Collateral Agent for the benefit of the Purchasers pursuant to this Agreement or any other Related Document;

 (b) Liens for property taxes and assessments or governmental charges or levies and Liens securing claims or demands of
mechanics and materialmen so long as the payment thereof is not at the time required by Section 9.4; 
 (c) Liens
of or resulting from any judgment or award, the time for the appeal or petition for rehearing of which shall not have expired, or in respect of which the Company or a Subsidiary thereof shall at any time in good faith be prosecuting an appeal or
proceeding for a review and in respect of which a stay of execution pending such appeal or proceeding for review shall have been secured; 
  

 12 

 (d) Liens incidental to the conduct of business or the ownership of properties and assets
(including Liens in connection with worker’s compensation, unemployment insurance and other like laws, warehousemen’s and attorneys’ liens and statutory landlords’ liens); provided in each case, the obligation secured is
not overdue or, if overdue, is being contested in good faith by appropriate actions or proceedings; and 
 (e) minor survey
exceptions or minor encumbrances, easements or reservations, or rights of others for rights-of-way, utilities and other similar purposes, or zoning or other restrictions as to the use of real properties, which are necessary for the conduct of the
activities of the Company and its Subsidiaries or which customarily exist on properties of corporations engaged in similar activities and similarly situated and which do not in any event materially impair their use in the operation of the business
of the Company and its Subsidiaries. 
 “Permitted Other Secured Indebtedness” is defined in
Section 10.1(a)(iv). 
 “Permitted Purchase Money Indebtedness” is defined in Section 10.1(a)(iii).

 “Permitted Receivables/Inventory Indebtedness” is defined in Section 10.1(a)(iii). 
 “Person” means an individual, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a
government or agency or political subdivision thereof. 
 “Plan” means an “employee benefit plan” (as defined in
Section 3(3) of ERISA) that is or, within the preceding five years, has been established or maintained, or to which contributions are or, within the preceding five years, have been made or required to be made, by the Company or any ERISA
Affiliate or with respect to which the Company or any ERISA Affiliate may have any liability. 
 “Pledge Agreement” means
the Stock Pledge Agreement, dated as of the date of the Closing, executed by the Company in favor of the Collateral Agent for the benefit of the Purchasers, pursuant to which the Company shall have pledged and collaterally assigned 100% of the
capital stock of the Borrower as security for the prompt and full payment and performance of the Obligations. 
 “Product”
means a pharmaceutical product, drug or medication. 
 “property” or “properties” means, unless otherwise
specifically limited, real or personal property of any kind, tangible or intangible, choate or inchoate. 
 “Pro Rata
Portion” means, with respect to any holder of a Note upon the occurrence of a Mandatory Prepayment Event, the amount determined by multiplying the Net Proceeds received in connection with such Mandatory Prepayment Event by a fraction the
numerator of which is the aggregate outstanding principal amount of all Notes held by such holder at such time and the denominator of which is the aggregate outstanding principal amount of all outstanding Notes at such time. 
  

 13 

 “QPAM Exemption” means the Prohibited Transaction Class Exemption 84-14 issued by the
United States Department of Labor. 
 “Related Documents” means this Agreement, the Notes, the Warrants, the Collateral
Documents and each other instrument or document to be delivered hereunder or thereunder or otherwise in connection therewith. 
 “Rentals” means and includes as of the date of any determination thereof all fixed payments (including as such all payments which the lessee is obligated to make to the lessor on termination of the lease or surrender of the
property) payable by the Company or a Subsidiary, as lessee or sublessee under a lease of real or personal property, but shall be exclusive of any amounts required to be paid by the Company or a Subsidiary (whether or not designated as rents or
additional rents) on account of maintenance, repairs, insurance, taxes and similar charges. Fixed rents under any so-called “percentage leases” shall be computed solely on the basis of the minimum rents, if any, required to be paid by the
lessee regardless of sales volume or gross revenues. 
 “Required Holders” means, at any time, the holders of at least 65%
in principal amount of the Notes at the time outstanding (exclusive of Notes then owned by the Company). 
 “Responsible
Officer” means any Senior Financial Officer and any other officer of the Company with responsibility for the administration of the relevant portion of this Agreement. 
 “Securities” is defined in Section 5.13. 
 “Securities Act” means the Securities Act of 1933, as amended from time to time. 
 “Senior Financial Officer” means the chief financial officer, principal accounting officer, treasurer or controller of the Company. 
 “Subsidiary” means, as to any Person, any corporation, association or other business entity in which such Person or one or more of its Subsidiaries or such Person and one or more of its Subsidiaries
owns sufficient equity or voting interests to enable it or them (as a group) ordinarily, in the absence of contingencies, to elect a majority of the directors (or Persons performing similar functions) of such entity, and any partnership or joint
venture if more than a 50% interest in the profits or capital thereof is owned by such Person or one or more of its Subsidiaries or such Person and one or more of its Subsidiaries (unless such partnership can and does ordinarily take major business
actions without the prior approval of such Person or one or more of its Subsidiaries). Unless the context otherwise clearly requires, any reference to a “Subsidiary” is a reference to a Subsidiary of the Company. For the avoidance of
doubt, any reference to a Subsidiary of the Company in this Agreement shall mean and include the Borrower and each Subsidiary of the Borrower. 
 “Tangible Assets” means as of the date of any determination thereof for any Person, the total amount of all assets of such Person and its Subsidiaries (less depreciation, depletion and 

  

 14 

 
other properly deductible valuation reserves) after deducting, without duplication, good will, patents, trade names, trade marks, copyrights, franchises,
experimental expense, organization expense, unamortized debt discount and expense, deferred assets other than prepaid insurance and prepaid taxes, the excess of cost of shares acquired over book value of related assets and such other assets as are
properly classified as “intangible assets” in accordance with GAAP. 
 “UCC” means the Uniform Commercial Code as
in effect on the date hereof in the State of New York, as amended from time to time, and any successor statute. 
 “Voting
Stock” means Securities of any class or classes, the holders of which are ordinarily, in the absence of contingencies, entitled to elect a majority of the corporate directors (or Persons performing similar functions). 
 “Wholly-owned Subsidiary” means, at any time, any Subsidiary one hundred percent (100%) of all of the equity interests (except
directors’ qualifying shares) and voting interests of which are owned by any one or more of the Company and the Company’s other Wholly-owned Subsidiaries at such time. 
  

 15 

 Exhibit A 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 FORM OF
NOTE 
 THIS NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT UNDER SECTIONS 1272 AND 1273 OF THE INTERNAL REVENUE CODE
OF 1986, AS AMENDED. FOR INFORMATION REGARDING THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE AND THE YIELD TO MATURITY OF THE NOTE, PLEASE CONTACT [NAME AND TITLE OF CONTACT PERSON] OF THE BORROWER AT [CONTACT PERSON’S
PHONE NUMBER] OR [CONTACT PERSON’S ADDRESS]. 
 THIS SENIOR SECURED PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933 AND, ACCORDINGLY, MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT. COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THIS SENIOR SECURED PROMISSORY NOTE AND RESTRICTING ITS TRANSFER OR
SALE MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD HEREOF TO THE SECRETARY OF THE BORROWER AT ITS PRINCIPAL EXECUTIVE OFFICES. 
 TWIST MERGER SUB, INC. 
 15% Senior Secured Note
due                     , 2011 
  

			
	No.                     	    	Date
	$                     	    	

 FOR VALUE RECEIVED, the undersigned,
TWIST MERGER SUB, INC. (herein called the “Borrower”), a corporation organized and existing under the laws of the State of Delaware, hereby promises to pay to
                    , or registered assigns, the principal sum of
                     DOLLARS on
                    , 2011, with interest (computed on the basis of a 360-day year of twelve 30-day months) on the unpaid balance thereof at
the rate of 15% per annum from the date hereof, payable quarterly in arrears, on the last day of March, June, September and December in each year, commencing with September 30, 2005, until the principal hereof shall have become due and
payable; provided, however, interest on such unpaid balance shall accrue at the rate of 17% per annum during the continuance of any Event of Default. 
 Payments of principal of, interest on and any Make-Whole Amount with respect to this Note are to be made in lawful money of the United States of America at such place as the holder of this Note shall have designated
by written notice to the Borrower as provided in the Note Purchase Agreement referred to below. 
 This Note is one of a series of Senior
Notes (herein called the “Notes”) issued pursuant to that certain Senior Secured Note and Warrant Purchase Agreement, dated as of June 24, 2005 (as from time to time amended, the “Note Purchase Agreement”),
among the Borrower, Jazz Pharmaceuticals, Inc., LB I Group Inc., as Collateral Agent and a Purchaser, and the other 

 
Purchasers named therein and is entitled to the benefits thereof. This Note is secured pursuant to the provisions of the Note Purchase Agreement and other
Related Documents (defined in the Note Purchase Agreement) and is entitled to the benefit of the rights and security provided thereby. Each holder of this Note will be deemed, by its acceptance hereof, (i) to have agreed to the confidentiality
provisions set forth in Section 20 of the Note Purchase Agreement and (ii) to have made the representations set forth in Section 6 of the Note Purchase Agreement. 
 As provided in the Note Purchase Agreement, upon surrender of this Note for registration of transfer, duly endorsed, or accompanied by a written
instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, a new Note for a like principal amount will be issued to, and registered in the name of, the transferee. Prior to due
presentment for registration of transfer, the Borrower may treat the person in whose name this Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Borrower will not be affected by any
notice to the contrary. 
 The Borrower will make required prepayments of principal on the dates and in the amounts specified in the Note
Purchase Agreement. This Note is also subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreement, but not otherwise. 
 If an Event of Default, as defined in the Note Purchase Agreement, occurs and is continuing, the principal of this Note may be declared or otherwise
become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreement. 
 To the fullest extent permitted by applicable law, the Borrower waives: (a) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default, nonpayment,
maturity, release, compromise, settlement, extension or renewal of any or all of the obligations or liabilities under the Note Purchase Agreement or evidenced hereby, (b) all rights to notice and hearing prior to the taking of possession or
control of any collateral (including by way of attachment or replevy), and (c) the benefit of all valuation, appraisal and exemption laws. 
  

 2 

 This Note shall be construed and enforced in accordance with, and the rights of the parties shall be
governed by, the laws of the State of New York, including Section 5-1401 of the General Obligations Law of said State. 
 BORROWER ACKNOWLEDGES THAT THE BORROWER HAS WAIVED THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING ON THIS NOTE. 
  

			
	 TWIST MERGER SUB, INC.

		
	 By
	 	  

		 	 [Title]

  

 3 

 EXHIBIT B 
 FORM OF WARRANT 
 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF
COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 THE SECURITIES
REPRESENTED BY THIS WARRANT, AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT, ARE SUBJECT TO CERTAIN VOTING RESTRICTIONS PURSUANT TO A VOTING AGREEMENT RELATING TO SUCH SECURITIES, AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN
COMPLIANCE WITH THE TERMS OF SUCH AGREEMENT. A COPY OF SUCH VOTING AGREEMENT WILL BE FURNISHED TO THE REGISTERED HOLDER OF THIS WARRANT WITHOUT CHARGE UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THIS WARRANT OR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE HOLDER HEREOF, THE COMPANY AND CERTAIN HOLDERS OF SECURITIES OF THE COMPANY. A COPY OF SUCH AGREEMENT WILL BE FURNISHED TO THE REGISTERED HOLDER OF THIS WARRANT WITHOUT CHARGE UPON
WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 
  

  

			
	 Warrant No.: BB-«warrantno»
	 	Number of Shares: «shares»
	 Date of Issuance: June 24, 2005
	 	(subject to adjustment)

 JAZZ PHARMACEUTICALS, INC. WARRANT NO. BB-«warrantno» 
 Series BB Preferred Stock Warrant 
 This Warrant No. BB-«warrantno» (this “Warrant”) of Jazz Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that «holder», the
initial holder of this Warrant, or its registered assigns (the “Registered Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at any time after the date hereof and on or before the Expiration
Date (as defined in Section 6 below), up to «shares» shares of Series BB Preferred Stock of the Company (“Series BB Preferred Stock”), at a purchase price of $1.84 per share. This Warrant is one of a series of
warrants to purchase in the aggregate 8,695,652 shares of Series BB Preferred Stock (collectively, the “Series BB Warrants”) issued pursuant to that certain Senior Secured Note and Warrant Purchase Agreement, dated June 24,
2005, by and among the Company and the initial holders of the Series BB Warrants (the 

 
“Purchase Agreement”). The shares purchasable upon exercise of this Warrant and the purchase price per share, as adjusted from time to time
pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Stock” and the “Purchase Price,” respectively. 
 1. Exercise. 
 (a) Manner of Exercise. This Warrant may be exercised by the
Registered Holder, in whole or in part, by surrendering this Warrant, with the exercise form appended hereto as Exhibit A duly executed by such Registered Holder, at the principal office of the Company, or at such other office or agency
as the Company may designate, accompanied by payment in full of the Purchase Price payable in respect of the number of shares of Warrant Stock purchased upon such exercise unless exercised pursuant to the Net Issue Exercise provisions of
Section 1(c) below. The Purchase Price may be paid by cash, check, or wire transfer. 
 (b) Effective Time of Exercise.
Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 1(a) above. At such time, the
person or persons in whose name or names any certificates for Warrant Stock shall be issuable upon such exercise as provided in Section 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Stock represented
by such certificates. 
 (c) Net Issue Exercise. 
 (i) In lieu of exercising this Warrant in the manner provided above in Section 1(a), the Registered Holder may elect to receive shares equal to the value of this Warrant (or the portion of this Warrant being
canceled) by surrender of this Warrant at the principal office of the Company together with notice of such election on the exercise form appended hereto as Exhibit A duly executed by such Registered Holder, in which event the Company shall
issue to such Registered Holder a number of shares of Warrant Stock computed using the following formula: 
 X = Y (A—B)

 A 
  

			
		
	Where X =	  	The number of shares of Warrant Stock to be issued to the Registered Holder.
		
	Y =	  	The number of shares of Warrant Stock purchasable under this Warrant (at the date of such calculation).
		
	A =	  	The fair market value of one share of Warrant Stock (at the date of such calculation).
		
	B =	  	The Purchase Price (as adjusted through the date of such calculation).

  

 -2- 

 (ii) For purposes of this Section 1(c), the fair market value of Warrant Stock on the date of
calculation shall mean with respect to each share of Warrant Stock: 
 (A) if the Common Stock of the Company (“Common
Stock”) is traded on a securities exchange or The Nasdaq Stock Market, the fair market value shall be deemed to be the product of (x) the closing price on the date of calculation (or, if there are no sales for such date, then on the
last date on which there were sales) and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible on such date; or 
 (B) if the Common Stock is actively traded over the counter, the fair market value shall be deemed to be the product of (x) the closing bid or sales price (whichever is applicable) on the date of calculation (or,
if the date of calculation is not a trading day, the last trading day prior to the date of calculation) and (y) the number of shares of Common Stock into which each share of Warrant Stock is convertible on such date; or 
 (C) if neither (A) nor (B) is applicable, the fair market value of Warrant Stock shall be determined in good faith by the Company’s Board
of Directors. 
 (d) Delivery to Registered Holder. As soon as practicable after the exercise of this Warrant in whole or in
part, and in any event within ten (10) days thereafter, the Company at its expense will cause to be issued in the name of, and delivered to, the Registered Holder, or as such Registered Holder (upon payment by such Registered Holder of any
applicable transfer taxes) may direct: 
 (i) a certificate or certificates for the number of shares of Warrant Stock to which such
Registered Holder shall be entitled, and 
 (ii) in case such exercise is in part only, a new warrant or warrants (dated the date hereof) of
like tenor, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the face of this Warrant minus the number
of such shares purchased by the Registered Holder upon such exercise as provided in Section 1(a) or 1(c) above. 
 2.
Adjustments. 
 (a) Redemption or Conversion of Preferred Stock. If all of the Series BB Preferred Stock is
redeemed or converted into shares of Common Stock (including without limitation pursuant to the automatic conversion provisions of the Company’s certificate of incorporation providing for the conversion of the Series BB Preferred Stock into
Common Stock in connection with a qualified initial public offering of the Company’s securities), then this Warrant shall automatically become exercisable for that number of shares of Common Stock equal to the number of shares of Common Stock
that would have been received if this Warrant had been exercised in full and the shares of Series BB Preferred Stock received thereupon had been simultaneously converted into shares of Common Stock immediately prior to such event, and the Purchase
Price shall be automatically adjusted to equal the amount obtained by multiplying the then existing Purchase Price by a fraction, (i) the numerator of which shall be the 

  

 -3- 

 
aggregate Purchase Price of the shares of Series BB Preferred Stock for which this Warrant was exercisable immediately prior to such redemption or
conversion, and (ii) the denominator of which shall be the number of shares of Common Stock for which this Warrant is exercisable immediately after such redemption or conversion. 
 (b) Stock Splits and Dividends. If the outstanding shares of Warrant Stock shall be subdivided into a greater number of shares or a dividend
in Warrant Stock shall be paid in respect of Warrant Stock, the Purchase Price in effect immediately prior to such subdivision or at the record date of such dividend shall simultaneously with the effectiveness of such subdivision or immediately
after the record date of such dividend be proportionately reduced. If outstanding shares of Warrant Stock shall be combined into a smaller number of shares, the Purchase Price in effect immediately prior to such combination shall, simultaneously
with the effectiveness of such combination, be proportionately increased. When any adjustment is required to be made in the Purchase Price, the number of shares of Warrant Stock purchasable upon the exercise of this Warrant shall be changed to the
number determined by dividing (i) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by
(ii) the Purchase Price in effect immediately after such adjustment. 
 (c) Reclassification, Etc. In case there occurs any
reclassification or change of the outstanding securities of the Company or of any reorganization of the Company (or any other corporation the stock or securities of which are at the time receivable upon the exercise of this Warrant) or any similar
corporate reorganization on or after the date hereof, then and in each such case the Registered Holder, upon the exercise hereof at any time after the consummation of such reclassification, change, or reorganization, shall be entitled to receive, in
lieu of the stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock or other securities or property to which such Registered Holder would have been entitled upon such consummation if such
Registered Holder had exercised this Warrant immediately prior thereto, all subject to further adjustment pursuant to the provisions of this Section 2. 
 (d) Adjustment Certificate. When any adjustment is required to be made in the Warrant Stock or the Purchase Price pursuant to this Section 2, the Company shall promptly mail to the Registered Holder
a certificate setting forth (i) a brief statement of the facts requiring such adjustment, (ii) the Purchase Price after such adjustment and (iii) the kind and amount of stock or other securities or property into which this Warrant
shall be exercisable after such adjustment. 
 3. Transfers. 
 (a) Unregistered Security. Each holder of this Warrant acknowledges that this Warrant, the Warrant Stock and the Common Stock issuable upon
conversion of the Warrant Stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and agrees that in no event will it dispose of all or any portion of this Warrant, the Warrant Stock or
the Common Stock issuable upon conversion of the Warrant Stock unless and until (a) it has complied with the provisions of Section 3(b) below, and (b) if reasonably requested by the Company, the Registered Holder shall have furnished
the Company with an opinion of counsel 

  

 -4- 

 
reasonably satisfactory in form and substance to the Company and the Company’s counsel to the effect that (x) such disposition will not require
registration under the Securities Act and (y) appropriate action necessary for compliance with the Securities Act and any applicable state, local, or foreign law has been taken. Without limiting the foregoing, the Registered Holder, by
accepting this Warrant, agrees that it may transfer this Warrant (or any portion hereof) only to one of its Affiliates (as defined in the Purchase Agreement) or to any other person or entity that is acceptable to the Company, provided that, in the
case of any transfer, the applicable transferee must agree in writing to be subject to the terms of this Warrant, the Investor Rights Agreement, the First Refusal and Co-Sale Agreement and the Voting Agreement (as such terms are defined below);
provided, however, that, except with respect to transfers to its Affiliates, the Registered Holder hereby covenants not to effect such transfer if such transfer either would invalidate the securities laws exemptions pursuant to which
this Warrant was originally offered and sold or would itself require registration and/or qualification under the Securities Act or applicable state securities laws. Each certificate evidencing this Warrant transferred as provided above shall bear an
appropriate restrictive legend substantially to the foregoing effect. 
 For purposes of this Warrant, (i) “Investor Rights
Agreement” means that certain Second Amended and Restated Investor Rights Agreement, dated as of June 24, 2005, by and among the Company, the investors in the Company’s Series A Preferred Stock, Series B Preferred Stock and Series
B Prime Preferred Stock, the holders of warrants to purchase Series BB Preferred Stock (and any shares issued upon exercise of such warrants) and certain holders of the Common Stock, (ii) “First Refusal and Co-Sale Agreement”
means that certain Second Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of June 24, 2005, by and among the Company, the investors in the Company’s Series A Preferred Stock, Series B Preferred Stock and Series
B Prime Preferred Stock, the holders of Series BB Preferred Stock and the holders of warrants to purchase Series BB Preferred Stock (and any shares issued upon exercise of such warrants) and the persons identified as “Executives” therein
and (iii) “Voting Agreement” means that certain Second Amended and Restated Voting Agreement, dated as of June 24, 2005, by and among the Company, the investors in the Company’s Series A Preferred Stock, Series B
Preferred Stock and Series B Prime Preferred Stock, the holders of Series BB Preferred Stock and the holders of warrants to purchase Series BB Preferred Stock (and any shares issued upon exercise of such warrants) and certain holders of the Common
Stock. 
 (b) Transferability. Subject to the provisions of this Section 3 and the provisions of Section 5, this
Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of the Warrant with a properly executed assignment in the form of Exhibit B hereto at the principal office of the Company. Any purported transfer of
all or any portion of this Warrant in violation of the provisions of this Warrant shall be null and void. 
 (c) Warrant Register.
The Company will maintain a register containing the names and addresses of the Registered Holders of this Warrant and all other warrants to purchase Series BB Preferred Stock. Until any transfer of this Warrant is made in the warrant register,
the Company may treat the Registered Holder of this Warrant as the absolute owner hereof for all purposes; provided, however, that if this Warrant is properly assigned in blank, the Company may (but shall not be required to) treat the
bearer hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. Any Registered Holder may change such Registered Holder’s address as shown on the warrant register by written notice to the Company
requesting such change. 
  

 -5- 

 4. Representations and Warranties of the Registered Holder. The Registered Holder hereby
represents and warrants to the Company that: 
 (a) Authorization. The Registered Holder has full power and authority to enter
into, and perform its obligations under, this Warrant. This Warrant, when executed and delivered by the Registered Holder, will constitute a valid and legally binding obligation of the Registered Holder, enforceable in accordance with its terms,
except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the
availability of specific performance, injunctive relief, or other equitable remedies. 
 (b) Purchase Entirely for Own Account.
This Warrant is issued to the Registered Holder in reliance upon the Registered Holder’s representation to the Company, which by the Registered Holder’s acceptance of this Warrant, the Registered Holder hereby confirms, that the Warrant to
be acquired by the Registered Holder, the Warrant Stock and the Common Stock to be issued upon the conversion of the Warrant Stock (collectively, the “Securities”) will be acquired for investment for the Registered Holder’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Registered Holder has no present intention of selling, granting any participation in, or otherwise distributing the same. By
accepting this Warrant, the Registered Holder further represents that the Registered Holder does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to
any third person, with respect to any of the Securities. The Registered Holder has not been formed for the specific purpose of acquiring the Securities. 
 (c) Disclosure of Information. The Registered Holder has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the
Securities with the Company’s management and has had an opportunity to review the Company’s facilities. The Registered Holder understands that such discussions, as well as any written information delivered by the Company to the Registered
Holder, were intended to describe the aspects of the Company’s business which it believes to be material. 
 (d) Restricted
Securities. The Registered Holder understands that the Securities have not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends
upon, among other things, the bona fide nature of the investment intent and the accuracy of the Registered Holder’s representations as expressed herein. The Registered Holder understands that the Securities are “restricted securities”
under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Registered Holder must hold the Securities indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state
authorities, or an exemption from such registration and qualification requirements is available. The Registered Holder acknowledges that the Company has no obligation to register or qualify 

  

 -6- 

 
the Securities for resale. The Registered Holder further acknowledges that if an exemption from registration or qualification is available, it may be
conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Registered Holder’s control, and which
the Company is under no obligation and may not be able to satisfy. 
 (e) No Public Market. The Registered Holder understands
that no public market now exists for any of the securities issued by the Company, and that the Company has made no assurances that a public market will ever exist for the Securities. 
 (f) Accredited Investor. The Registered Holder is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act. 
 5. Market Standoff. 
 (a) Market Standoff. The Registered Holder hereby agrees that, if so requested by the Company and the Underwriter’s Representative (as defined below), if any, the Registered Holder shall not sell,
make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of this Warrant or other securities of the Company (“Market Standoff”) without the prior written consent of the Company and the
Underwriter’s Representative for such period of time (a) not to exceed one hundred eighty (180) days following the effective date of a Registration Statement of the Company filed under the Securities Act in the case of the
Company’s initial public offering or (b) commencing with the date the Company provides notice to the Registered Holder of a proposed follow-on offering and ending 90 days after the effective date of the Registration Statement or, in the
event of a shelf registration, the date of the prospectus for such follow-on offering, as may be requested by the Underwriter’s Representative; provided, however, that the Registered Holder shall not be required to agree to a Market Standoff
for a period of time that commences less than thirty (30) days after the expiration of another period of time during which the Registered Holder has agreed to a Market Standoff. The obligations of the Registered Holder under this Section 5
shall be conditioned upon similar agreements being in effect with each other stockholder of the Company who is an officer, or director or, with respect only to the Company’s initial public offering, greater than 1% stockholder of the Company
prior to such initial public offering. For purposes of this Warrant, the “Underwriter’s Representative” is the representative the underwriter or underwriters selected for the underwriting of a public offering of the
Company’s securities. 
 (b) Stop-Transfer Instructions. In order to enforce the covenants set forth in Section 3 and
Section 5(a), the Company may impose stop-transfer instructions with respect to the securities of the Registered Holder (and the securities of every other person subject to the restrictions in Section 3 and Section 5(a)). 

 

 -7- 

 6. Termination. This Warrant (and the right to purchase securities upon exercise hereof)
shall terminate on June 24, 2012 (the “Expiration Date”). 
 7. Notices of Certain Transactions. In the
event that the Company shall propose at any time to: 
 (a) declare any dividend or distribution upon the Common Stock, whether in cash,
property, stock, or other securities, whether or not a regular cash dividend and whether or not out of earnings or earned surplus; 
 (b)
offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; 
 (c) effect any reclassification or recapitalization of the Common Stock or Preferred Stock outstanding involving a change in the Common Stock or Preferred Stock; 
 (d) merge or consolidate with or into any other partnership, corporation, business trust, joint stock company, trust, unincorporated association, joint
venture, governmental authority or other entity of whatever nature; or 
 (e) sell, lease, or convey all or substantially all its assets,
property or business, or to liquidate, dissolve, or wind up or otherwise consummate a Liquidation Event (as defined in the Company’s Second Amended and Restated Certificate of Incorporation); then, in connection with each such event, the
Company shall send to the Registered Holder (in accordance with the provisions of Section 23): 
 (i) at least twenty
(20) days’ prior written notice of the date on which a record shall be taken for such dividend, distribution or subscription rights (and specifying the date on which the holders of Common Stock and/or Preferred Stock shall be entitled
thereto) or for determining rights to vote in respect of the matters referred to in (c), (d) and (e) above; and 
 (ii) in the case
of the matters referred to in (c), (d) and (e) above, at least 20 days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Common Stock shall be entitled to exchange their
Common Stock and/or Preferred Stock for securities or other property deliverable upon the occurrence of such event or the record date for the determination of such holders if such record date is earlier). 
 8. Reservation of Stock. The Company will at all times reserve and keep available, solely for the issuance and delivery upon the exercise
of this Warrant, such shares of Warrant Stock (and Common Stock issuable upon conversion of the Warrant Stock) and other stock, securities and property, as from time to time shall be issuable upon the exercise of this Warrant. 
 9. Exchange of Warrants. Upon the surrender by the Registered Holder of any Warrant or Warrants, properly endorsed, to the Company at the
principal office of the Company, the Company will, subject to the provisions of Section 3 hereof, issue and deliver to or upon the order of such Registered Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the
name of such Registered Holder, calling in the aggregate on the face or faces thereof for the number of shares of Series BB Preferred Stock called for on the face or faces of the Warrant or Warrants so surrendered. 
  

 -8- 

 10. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company,
or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
 11. No Rights as Stockholder. Until the exercise of this Warrant, the Registered Holder of this Warrant shall not have or exercise any rights by virtue hereof as a stockholder of the Company. 

12. Additional Rights. Upon exercise of this Warrant, the Registered Holder shall have and be entitled to exercise the rights granted to
the signatories who are holders of Series BB Preferred Stock under each of (a) the Voting Agreement, (b) the First Refusal and Co-Sale Agreement and (c) the Investor Rights Agreement. By its receipt of this Warrant, the Registered
Holder agrees to be bound by the Voting Agreement, the First Refusal and Co-Sale Agreement and the Investor Rights Agreement. 
 13. No
Fractional Shares. No fractional shares of Series BB Preferred Stock will be issued in connection with any exercise hereunder. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the
product of such fraction multiplied by the fair market value of one share of Series BB Preferred Stock on the date of exercise, as determined in good faith by the Company’s Board of Directors. 
 14. Amendment or Waiver. Any term of the Series BB Warrants may be amended or waived only by an instrument in writing signed by the Company
and the holders of Series BB Warrants covering at least sixty-five percent (65%) of the number of shares of Series BB Preferred Stock subject to Series BB Warrants outstanding at the time of such amendment or waiver. 
 15. Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any
provision of this Warrant. 
 16. Governing Law. This Warrant shall be governed, construed and interpreted in accordance with
the laws of the State of California, without giving effect to principles of conflicts of law. 
 17. Survival of
Representations. Unless otherwise set forth in this Warrant, the warranties, representations and covenants of the Company and the Purchasers contained in or made pursuant to this Warrant shall survive the execution and delivery of this
Warrant. 
 18. Transfer; Successors and Assigns. The terms and conditions of this Warrant shall inure to the benefit of and be
binding upon the respective successors and permitted assigns of the 

  

 -9- 

 
parties provided that they have complied with the terms and conditions herein. Nothing in this Warrant, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Warrant, except as expressly provided in this Warrant. 
 19. Counterparts. This Warrant may be executed in two or more counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument. 
 20. Attorney’s Fees. If any action at law or in equity (including
arbitration) is necessary to enforce or interpret the terms of any of this Warrant, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may
be entitled. 
 21. Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law,
the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this Warrant,
(b) the balance of this Warrant shall be interpreted as if such provision were so excluded and (c) the balance of this Warrant shall be enforceable in accordance with its terms. 
 22. Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Warrant, upon any
breach or default of any other party under this Warrant, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein,
or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of
any kind or character on the part of any party of any breach or default under this Warrant, or any waiver on the part of any party of any provisions or conditions of this Warrant, must be in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this Warrant or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 23. Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by
confirmed facsimile if sent during normal business hours of the recipient, or if not, then on the next business day; (iii) one day after deposit with a nationally (or internationally) recognized overnight courier, specifying next day delivery,
with written verification of receipt. All notices to the Company shall be sent to the Company’s principal place of business. All notices to the Registered Holder shall be sent to the address as set forth on the signature page of this Warrant or
at such other address as the Registered Holder may designate pursuant to Section 3(c) by ten (10) days’ advance notice to the Company. 
 24. Entire Agreement. This Warrant and the documents and agreements referred to herein (including the Company’s Second Amended and Restated Certificate of Incorporation, Investor Rights Agreement,
the First Refusal and Co-Sale Agreement and the Voting Agreement) constitute the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter
hereof existing between the parties hereto are expressly canceled. 
  

 -10- 

			
	JAZZ PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	Address:	 	3180 Porter Drive
		 	Palo Alto, CA 94304
	
	Fax Number: (650) 496-3781

 Accepted and Agreed: 
  

			
	REGISTERED HOLDER
	
	«HOLDER»
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	
	Address:
	«address»

 [Signature Page to Series BB Preferred Stock Warrant] 
  

 -11- 

 EXHIBIT A 
 EXERCISE FORM 
  

					
	To: Jazz Pharmaceuticals, Inc.	  	Dated:	 	  

 The undersigned, pursuant to the provisions set forth in the attached Warrant No.
BB-«warrantno», hereby irrevocably elects to (a) purchase              shares of Series BB Preferred Stock covered by such Warrant and herewith makes payment of
$            , representing the full purchase price for such shares at the price per share provided for in such Warrant, or (b) exercise such Warrant for
             shares purchasable under the Warrant pursuant to the Net Issue Exercise provisions of Section 1(c) of the Warrant. 
 The undersigned acknowledges that it has reviewed the representations and warranties contained in Section 4 of the Warrant and by its signature
below hereby makes such representations and warranties to the Company as of the date hereof. 
  

			
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	Name of Entity:	 	  

 EXHIBIT B 
 ASSIGNMENT FORM 
 FOR VALUE RECEIVED,
                                        
hereby sells, assigns and transfers all of the rights of the undersigned transferor under the attached Warrant with respect to the number of shares of Series BB Preferred Stock covered thereby set forth below, unto: 
  

					
	 Name of Assignee
	 	 Address/Fax Number
	 	 No. of Shares

 The undersigned transferor represents that it has complied with all of the provisions of the
attached Warrant governing the transfer of such Warrant, including without limitation the provisions of Section 3 thereof, and acknowledges that any purported transfer of all or any part of such Warrant in violation of the terms of the attached
Warrant shall be null and void. 
  

							
	Dated:	 	  
	  	By:	 	  

		 		  	Name:	 	  

		 		  	Title:	 	  

 The undersigned transferee of the attached Warrant acknowledges the limitations on transfer of the
attached Warrant, including without limitation those contained in Section 3 thereof, agrees to be bound by the terms of the attached Warrant and the Investor Rights Agreement, the Right of First Refusal and Co-Sale Agreement and the Voting
Agreement (each as defined in the attached Warrant) to the same extent as if the undersigned transferee were the initial holder of the attached Warrant, and shall deliver to the Company together with this assignment form counterpart signature pages
to the Investor Rights Agreement, the Right of First Refusal and Co-Sale Agreement and the Voting Agreement. 
  

							
	Dated:	 	  
	  	By:	 	  

		 		  	Name:	 	  

		 		  	Title:	 	  

 EXHIBIT 4.2 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 Closing: June 24, 20051  
 List of Closing Deliveries 
 Principal Note
and Warrant Documents 
  

	 	 1.
	 Senior Secured Note and Warrant Purchase Agreement dated as of June 24, 2005 by and among Twist Merger Sub, Inc.,
as the Borrower, Jazz Pharmaceuticals, Inc., as the Company, LB I Group Inc, as the Collateral Agent and a Purchaser, and the other Purchasers party thereto (the “Purchase Agreement”).2 

  

					
	Schedule A	  	-	    	Information Relating to Purchasers
	Schedule B	  	-	    	Defined Terms
	Schedule 5.4	  	-	    	Subsidiaries
	Schedule 5.5	  	-	    	Financials
	Schedule 5.7	  	-	    	Filings
	Schedule 5.8	  	-	    	Litigation
	Schedule 5.11	  	-	    	Intellectual Property
	Schedule 5.18	  	-	    	Environmental
	Schedule 5.19	  	-	    	Names
	Schedule 5.20	  	-	    	Locations; FEIN
	Exhibit A	  	-	    	Form of Note
	Exhibit B	  	-	    	Form of Warrant
	Exhibit 4.2	  	-	    	List of Closing Deliveries

  

	 	2.	Original Notes issued to each Purchaser in the principal amount as indicated below: 

  

				
	 Purchaser
	  	Principal Amount
	 LB I Group Inc.
	  	$	30,000,000
	 KKR TRS Holdings, Inc.
	  	$	25,000,000
	 Deep Cove Mezzanine, LLC
	  	$	5,000,000
	 Cardinal Fund I, L.P.
	  	$	800,000
	 FW Jazz Pharma Investors, L.P.
	  	$	400,000
	 Oak Hill Credit Alpha Fund, LP
	  	$	7,000,000
	 Lerner Enterprises, L.P.
	  	$	3,800,000
	 General Electric Pension Trust
	  	$	8,000,000
	 Total
	  	$	80,000,000
		  	 	 

	1	All documents dated as of June 24, 2005 unless otherwise stated. 

	2	Each capitalized term used in this Exhibit 4.2 without definition shall have the meaning ascribed thereto under the Purchase Agreement. 

	 	3.	Original Warrants issued to each Purchaser for the number of shares of Series BB Preferred Stock as indicated below: 

  

			
	 Purchaser
	  	Warrant Shares
	 LB I Group Inc.
	  	3,260,870
	 KKR TRS Holdings, Inc.
	  	2,717,391
	 Deep Cove Mezzanine, LLC
	  	543,478
	 Cardinal Fund I, L.P.
	  	86,957
	 FW Jazz Pharma Investors, L.P.
	  	43,478
	 Oak Hill Credit Alpha Fund, LP
	  	760,870
	 Lerner Enterprises, L.P.
	  	413,043
	 General Electric Pension Trust
	  	869,565
	 Total
	  	8,695,652
		  	 

 Collateral Documents 
  

	 	4.	Stock Pledge Agreement executed by the Company in favor of the Collateral Agent for the benefit of the holders of Notes whereby the Company pledges 100% of the issued and
outstanding stock of the Borrower. 

  

	 	5.	Original Stock Certificate(s) evidencing the pledged shares under the Pledge Agreement noted in item 4 together with an executed stock powers certificate. 

 

	 	6.	Intellectual Property Security Agreement executed by the Company in favor of the Collateral Agent for the benefit of the holders of Notes and suitable for filing with the United
States Patent and Trademark Office. 

  

	 	7.	Intellectual Property Security Agreement of the Borrower in favor of the Collateral Agent for the benefit of the holders of Notes and suitable for filing with the United States
Patent and Trademark Office. 

  

	 	8.	Control Account Agreement executed by the Borrower, the Collateral Agent and the financial intermediary holding the pledged account pursuant to Section 9.7 of the
Purchase Agreement. 

  

	 	9.	UCC Financing Statement naming the Borrower as the debtor and the Collateral Agent as the representative of the secured party and filed with the Secretary of State of Delaware.

  

	 	10.	UCC Financing Statement naming the Company as the debtor and the Collateral Agent as the representative of the secured party and filed with the Secretary of State of Delaware.

  

	 	11.	UCC Financing Statement naming Orphan Medical, Inc., the surviving corporation to the Merger, as the debtor and the Collateral Agent as the representative of the secured party and
filed with the Secretary of State of Delaware. 

  

 2 

 Certificates and Opinions 
  

	 	 12.
	 Certificate of the Secretary of the Company certifying as to the incumbency and signatures of the officers executing the
principal documents and that attached thereto are true and complete copies of: (a) the Company’s Certificate of Incorporation3, (b) the Company’s bylaws, (c) resolutions of the board of directors of the Company approving the transactions contemplated by the Purchase Agreement, (d) written consent of the stockholders of the
Company approving the transactions contemplated by the Purchase Agreement and (e) the Merger Agreement. 

  

	 	13.	Certificate of the Secretary of the Borrower certifying as to the incumbency and signatures of the officers executing the principal documents and that attached thereto are true and
complete copies of: (a) the Borrower’s Certificate of Incorporation, (b) the Borrower’s bylaws, and (c) resolutions of the board of directors of the Borrower approving the transactions contemplated by the Purchase Agreement.

  

	 	14.	Certificate of Compliance executed by the Chief Executive Officer of the Company and certifying that, as of the date of the Closing and both before and after taking into account the
effect of the Merger and the issuance and sale of the Notes and Warrants: (a) all of the conditions to closing have been satisfied, (b) all of the representations and warranties of the Company and the Borrower in the Purchase Agreement are
true and correct or true and correct in all material respects with respect to representations and warranties that are not qualified as to materiality, (c) the Company and the Borrower have performed and complied with all of the agreements and
conditions contained in the Purchase Agreement to be complied with thereby and (d) no Default or Event of Default exists. 

  

	 	15.	Solvency Certificate executed by the Credit Parties’ Chief Financial Officer certifying as to the solvency of each of the Credit Parties both before and after giving effect to
the Merger and the sale and issuance of the Notes. 

  

	 	16.	Legal opinion rendered by Simpson Thacher & Bartlett LLP, special counsel to the Company and the Borrower, in form and substance reasonably satisfactory to the Purchasers,
relating to, among other things, the due authorization of Notes and the security interests granted under the Note Purchase Agreement. 

  

	 	17.	Legal opinion rendered by Heller Ehrman LLP, special counsel to the Company, in form and substance reasonably satisfactory to the Purchasers, relating to, among other things, the
due authorization of the Warrants. 

  

	 	18.	Legal opinion rendered by the General Counsel to the Company, in form and substance reasonably satisfactory to the Purchasers, as to certain matters relating to the Purchase
Agreement. 

  

	 3
	 Amendment necessary to provide for new designated Series BB Preferred Stock to be issued upon exercise
of the warrants and to increase the number of shares. 

  

 3 

 Other Documents and Deliveries 
  

	 	19.	Post Closing Matters Agreement between the Borrower and the Collateral Agent. 

  

	 	20.	Copy of Second Amended and Restated Investors’ Rights Agreement. 

  

	 	21.	Copy of Second Amended and Restated Right of First Refusal and Co-Sale Agreement. 

  

	 	22.	Copy of Second Amended and Restated Voting Agreement. 

  

	 	23.	Payoff and release letter executed by Silicon Valley Bank in respect of the outstanding Liens in favor thereof against the properties of the Borrower together with UCC III
termination statement. 

  

	 	24.	Financials of the Company for FYE 2004 (audited) and Ql of 2005 (unaudited) and also including pro forma for the Company on a consolidated basis after taking into account the
closing of the Merger. 

  

	 	25.	Copies of insurance certificates for the Credit Parties indicating that the collateral Agent is named as the loss payee and additional insured. 

  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]